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ABSTRACT 
 
Recent genome wide analysis has estimated that >95% of human genes are alternatively 
spliced, allowing for the production of many protein isoforms from a single gene. Splicing is 
controlled by SR proteins, factors which bind to exonic splicing enhancers (ESEs) through RNA 
binding domains and recruit the splicosome via protein-protein interactions mediated by their RS 
domains, protein domains rich in highly charged arginine-serine dipeptides. Defects in 
alternative splicing have been linked to several diseases, including Cystic Fibrosis, breast cancer, 
and Spinal Muscular Atrophy (SMA). SMA is a neurodegenerative disorder caused by the loss of 
survival of motor neuron 1 (SMN1) gene. A nearly identical copy of the gene, SMN2, encodes an 
identical protein but contains a CT transition on the ESE of exon 7, disrupting SR protein 
binding and resulting in substantial exon 7 skipping.  
Significant research efforts have focused on redirecting the splicing pattern of SMN2 to 
produce a full-length SMN protein normally generated by SMN1. Splicing modulators have 
ranged from small molecule activators such as sodium phenylbutyrate and valproic acid, to viral 
vectors encoding antisense oligonucleotides. In particular, a synthetic peptide-oligonucleotide 
conjugate containing a short chain of arginine-serine dipeptides to mimic the RS domain has 
been shown to redirect splicing patterns. However, little work has been done to explore the 
potential flexibility of the design of this synthetic RS domain.  This dissertation reports efforts 
toward the design and synthesis of several synthetic SR protein mimics and the experimental 
design to determine their ability to increase inclusion of exon 7 in SMN2. The synthetic RS 
domains consist of three motifs – α-peptide, β-peptide, and peptide dendrimer – attached to 
antisense oligonucleotides targeted to SMN2 exon 7. The synthesis and conjugation of these 
mimics is straightforward, allowing for easy derivatization.  The efficacy of these molecules was 
examined using an in vitro splicing assay.  Analysis of these molecules using in vitro splicing 
assays indicates that neither synthetic RS domains nor antisense oligonucleotides alone affect 
splicing patterns, but conjugated molecules may play a beneficial role.   
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CHAPTER 1:  
ALTERNATIVE SPLICING AND DISEASE 
1.1 Alternative Splicing 
Alternative splicing is a process by which non-coding regions are removed from 
messenger RNA (mRNA) to produce a variety of protein products.  The frequency of alternative 
splicing is high in the human genome, with recent estimates indicating that greater than 95% of 
human genes are spliced in some fashion.
1-3
  The study of alternative splicing and its 
mechanisms has produced a number of insights into the required components that are used to 
process mRNA.  These components are separated into two categories based on their proximity to 
the mRNA.  Cis-acting elements are sequence motifs located within the mRNA that can direct 
splicing proteins to the correct gene encoding regions.
4,5
  Trans-acting elements, on the other 
hand, are the protein components that bind to the mRNA and control the splicing mechanism by 
assisting in the recognition of exons.
6,7
  When combined, these elements control the choice of 
gene-encoding sequences that will be included in the mature mRNA, and direct the reactions to 
produce the final product. 
The mechanism of alternative 
splicing involves a series of steps that 
remove the non-coding introns from the 
exons, producing a mature mRNA that 
can be used as a template for translation.  
It involves recognition of the RNA 
sequence elements involved in splicing by 
a number of proteins that constitute the 
spliceosome, assembly of different 
protein elements onto the pre-mRNA, and consecutive trans-esterification reactions that remove 
the introns and connect the exons together.  This series of reactions is highly complex, requiring 
a number of splicing proteins and RNA molecules that must attach and detach from the core 
splicing proteins on the mRNA.  The outcome of the splicing reaction can lead to multiple 
mRNA products through differential exon choices.  Possible outcomes include removal or 
Figure 1.1. Possible outcomes of alternative splicing 
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inclusion of a particular exon, choice of alternative splice sites that may or may not lead to 
inclusion of a particular exon, or use of mutually exclusive exons that can lead to two very 
different mRNA products (Figure 1.1).   
Unlike constitutive splicing, alternative splicing relies on additional sequence elements in 
order to strengthen recognition of the pre-mRNA by the spliceosome and ensure that the correct 
exon is inserted into the mature mRNA.  The relative strength of these elements can be regulated, 
so that certain exons can be included or excluded depending on the conditions of the splicing 
event.  Weaker splicing sequences are flanked by additional sequence elements to ensure that 
they are recognized by the spliceosome.  These elements are called splicing enhancer sequences, 
and they can be located either within the exon (exonic splicing enhancer – ESE) or in the intron 
(intronic splicing enhancer – ISE).  In contrast, additional sequences called splicing silencers 
(ESS or ISS) are present within the pre-mRNA, acting as negative regulators of splicing and 
preventing exon inclusion.  These sequence elements are particularly useful if an exon is not 
included in the mature mRNA under normal circumstances.   
In addition to cis-acting elements, trans-acting elements play an important role in 
alternative splicing.  A family of proteins called the SR proteins, named for their intrinsically 
disordered RS domains rich in arginine-serine dipeptides, act as positive regulators of alternative 
splicing by binding to enhancer sequences on the pre-mRNA and recruiting the spliceosome to 
that sequence (Figure 1.2a).
7,8
  These proteins are modular, containing the RS domain and an 
RNA binding domain that targets the enhancer sequences.  Research into the structure and 
function of the SR proteins indicates that the RS domain is very general, and can be exchanged 
with different RS domains of other SR proteins and retain the activity of the original protein.
9
  In 
contrast, a class of proteins called the heterogenous nuclear ribonucleoproteins (hnRNPs) act as 
negative regulators of alternative splicing by targeting the silencing elements on the pre-mRNA 
and preventing interaction of the particular exon with the splicing machinery (Figure 1.2a).
10
  
Although some interactions of hnRNPs with pre-mRNA may be promote splicing, including the 
promotion of exon 7 inclusion in SMN2 mRNA through interaction of hnRNP-G with SR-like 
protein Htra2β1,11 in general the main function of the hnRNPs is to block binding of pre-mRNA 
by the spliceosome.   
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1.2 SR Proteins 
SR proteins play an important role in splicing, and their properties can be utilized to 
develop splicing modifiers.  The structure of SR proteins is modular, consisting of one or two N-
terminal RNA binding domains (RBD) and a C-terminal intrinsically disordered RS (arginine-
serine rich) domain that functions primarily as a protein-protein interaction domain, but has also 
been proposed to interact with RNA.
12-15
  In alternative splicing, an SR protein binds to an ESE 
via its RBD (Figure 1.2b).  It then interacts with the small subunit of SR-like protein U2AF 
(U2AF
35
), resulting in recruitment of the large subunit, U2AF
65
, to the polypyrimidine tract of 
the adjacent intron.  This complex then recruits the remainder of the spliceosome to the 
mRNA.
6,16
 
 
 
The determinants of RS domain strength, defined as the ability of the domain to activate 
splicing, were systematically studied by Graveley and co-workers in 1998.
17
  The strength of 5 
different RS domains was found to be directly correlated with RS content, specifically the 
number of RS tetrapeptides, although other factors may be involved.  Despite this correlation, the 
sequence requirements to activate alternative splicing are not clear, although they are less 
stringent than for constitutive splicing.  For example, non-charged amino acids, such as glycine, 
can be substituted for charged residues in SR proteins without affecting activation.
18,19
  In small 
peptide models, however, the charged residues are essential for activity.
20
  Some of the 
Figure 1.2. Structure and roles of SR proteins. a) SR proteins bind to ESE motifs on pre-mRNA and recruit 
spliceosomal proteins while inhibiting binding of hnRNP molecules. b) SR proteins consist of two domains.  
a) b) 
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variability of the effects of alternative splicing modulators may arise from differences in the 
strength of the splicing signals present in the pre-mRNA. 
The serine residues in the RS domain are reversibly phosphorylated.
6,21
  The negative 
charges are proposed to serve three functions: assistance in protein-protein interactions, 
prevention of non-specific RNA binding, and nuclear transport.
6,22,23
  Manley and co-workers 
demonstrated in 1998 that dephosphorylation of serine is not required for the SR protein 
SF2/ASF in the activation of alternative splicing.
23,24
  Phosphorylation was shown to enhance 
binding of SF2/ASF to both the U1snRNP complex and U2AF
35
.
24
  Increasing the salt 
concentration in binding studies led to a decrease in binding, demonstrating that the binding is 
largely ionic in nature.  Phosphorylation also aids in preventing non-specific RNA binding 
through charge repulsion with the RNA backbone.
23
  In addition, phosphorylation of serine is 
essential for the transport of SR proteins to the nucleus.  Tarn and co-workers demonstrated that 
a nuclear transport protein, transportin-SR2, specifically interacts with phosphorylated RS 
domains and facilitates their nuclear import.
25
 
In 2003, Krainer and co-workers demonstrated that a minimal RS domain composed of 
10 RS (phosphorylated), RD, or RE dipeptide repeats could enhance exon 7 inclusion in SMN2 
mRNA.  Synthetic RS domains without phosphorylated serine (or a negatively charged 
equivalent) could not activate SMN2 splicing.
20
  Caputi and co-workers demonstrated similarly 
that a minimal RS domain comprised of 8 dipeptide repeats was functional as a modulator of 
splicing in the Bcl-x gene both in vitro and in vivo.
26
  Together, this work provides two important 
insights about the requirements for synthetic SR proteins.  First, a synthetic RS domain can be 
permanently and fully “phosphorylated”.  Second, synthetic RS domains can be smaller than the 
natural counterpart (SF2/ASF, for example, contains 15 RS dipeptide repeats) and still activate 
splicing in vitro and, importantly, in vivo.   
1.3 Alternative Splicing and Disease 
The high prevalence of alternative splicing in the human genome increases the potential 
for errors in the splicing mechanism that can lead to a disease phenotype.  Malfunction of the 
splicing mechanism can lead to gain or loss of particular sequence elements that can affect the 
processing of mRNA or production of dysfunctional protein, which can have profoundly 
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negative effects on human health.
27-29
  Recent estimates indicate that as high as 50% of human 
genetic disease can be directly linked so aberrant splicing patterns by defining splicing-related as 
any disease state in which some part of the splicing mechanism is malfunctioning.
30,31
  There are 
many possible ways in which alternative splicing can malfunction.  Mutations in cis-acting 
elements on the pre-mRNA can lead to loss of enhancer sequences, gain of silencing sequences, 
activation of cryptic (rarely used) splicing sequences, or changes in secondary structure, leading 
to undesired splicing patterns.
32,33
  In addition, mutations to genes encoding trans-acting 
elements can have more global effects on alternative splicing.
7
   
Table 1.1 Examples of Splicing-Related Diseases
28
 
Disease Gene/Splicing  
Factors Affected 
Genetic Effect of Mutation 
Duchenne Muscular Dystrophy Dystrophin Mutation of dystrophin protein 
Myotonic Dystrophy DMPK, MBNL-1 CUG-repeat expansion; 
sequestration of MBNL-1 
Cystic Fibrosis CFTR Loss of CFTR protein 
Spinal Muscular Atrophy SMN1 Loss of SMN protein 
 
Many examples exist of diseases that are directly related to changes in alternative 
splicing (Table 1.1).
28
 Each disease has its own set of mechanisms that researchers are 
attempting to address, with the hope of developing effective molecular therapies.  Diseases such 
Duchenne Muscular Dystrophy contain mutations that affect the inclusion of exons, leading to 
loss of functional protein. Researchers have developed treatments utilizing molecules that lead to 
skipping of exon 23 of dystrophin, redirecting the splicing of mRNA and producing more 
truncated, yet functional, protein, leading to the milder form of the disease.
34
  Antisense 
molecules that cause exon skipping are currently being utilized in clinical trials for DMD.
35
  
Other diseases such as Myotonic Dystrophy are caused by sequestration of the muscleblind-like-
1 (MBNL1) splicing factor by a repeat-expansion in the 3’-untranslated region of a different 
RNA, and researchers developing molecules to free MBNL by binding the RNA secondary 
structure, allowing it to function as a splicing factor in other systems.
36,37
  Spinal Muscular 
6 
 
Atrophy (SMA) is a well-characterized splicing-related disease that is also amenable to therapies 
that aim to change alternative splicing and protein production. 
1.4 Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) is a pediatric, autosomal recessive neurodegenerative 
disorder that is characterized by degeneration of alpha motor neurons in the anterior horn of the 
spinal cord.  This motor degeneration leads to proximal muscle weakness, pulmonary issues, and 
inability to sit, stand, or walk.  SMA is separated into three clinical subtypes based on disease 
severity.
38
  Type I (Werdnig–Hoffmann disease) is the most severe subtype.  Patients are 
diagnosed within the few months of life and show many of the characteristic symptoms of the 
disease, usually dying before the age of 2.  Type II (Dubowitz disease), the intermediate subtype, 
is usually diagnosed after the age of 2 and presents fewer, less severe variants of the symptoms.  
Patients are generally able to sit unassisted, but are unable to stand or walk and must be confined 
to a wheelchair, and generally survive into adulthood.  Type III (Kugelberg–Welander disease), 
the least severe subtype, has a much later onset and is characterized by mild symptoms and a 
relatively normal lifespan.  The disease rate is 1 in 6000 live births, with a carrier rate of 1 in 40.  
It is currently the most common genetic cause of infant mortality in the United States.   
SMA is caused by the deletion or mutation of the telomeric survival-of-motor-neuron-1 
(SMN1) gene on chromosome 5q13.
39
  A nearly identical gene, SMN2, is present as an inverted 
repeat in the centromere.  The two genes are 99% homologous, containing 11 translationally 
silent nucleotide transitions.  Both genes encode for the survival-of-motor-neuron (SMN) 
protein, a 294-amino acid containing protein that serves several functions including snRNP 
biogenesis and assembly of these proteins into aggregates called gems.
40,41
  The key nucleotide 
difference is a CT nucleotide transition at position +6 of exon 7 of SMN2.  This difference 
causes substantial skipping of exon 7 during splicing (Figure 1.3).
42,43
  As a result, the protein 
that is predominantly produced by SMN2 is truncated and quickly degraded.  It has been 
estimated that the SMN2 gene produces roughly 10-20% of the protein that is produced normally 
by a functional SMN1 gene.  Although the SMN protein is ubiquitously expressed and thus 
deficient in all patient tissues, only the motor neurons of the spinal cord are degraded as a result 
of this disease.  It has been hypothesized that the small amount of functional protein produced by 
SMN2 is adequate for all cell types except motor neurons, or that the SMN protein may play an 
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additional, unknown role in motor neurons.  In 
particular, studies indicate that SMN protein may 
play an important role in axon biogenesis, which 
is reduced substantially in the absence of SMN1.
44  
The effect of the CT transition has been 
debated in the literature.  In 2002, it was proposed 
that the transition disrupts the consensus 
sequence of an SF2/ASF dependent ESE.
45
  
SF2/ASF is an SR protein that assists in splicing 
regulation.  At the same time, a second model 
was proposed in which the transition instead 
creates an ESS at the same position, leading to 
increased binding of hnRNP A1, a splicing 
inhibitor.
46
  Later work by Krainer and co-
workers further explored these changes, finding 
that the loss of the ESE is followed by an 
increased ability for hnRNP A1 to non-specifically bind to SMN2 mRNA.
47
  This work indicates 
that a balance exists between positive and negative regulatory factors, and that the CT 
transition shifts the balance toward exon exclusion. 
Differences in disease severity between different SMA subtypes have led researchers to 
examine what causes these differences on the genetic level.  Examination of patient tissues has 
indicated that there is variation in the number of SMN2 gene copies that inversely correlates with 
disease severity – an increased number of SMN2 copies correlates to a decrease in the severity of 
SMA.  Type I patients generally have 1-2 copies of the SMN2 gene, whereas type III patients 
may have 4 or more copies.
48,49
  It has been hypothesized that, although the SMN2 gene only 
produces 20% of the full length protein produced by SMN1, having an increased number of 
SMN2 gene copies leads to production of a sufficient amount of SMN protein to make up for the 
production lost from the deletion or mutation of SMN1.  This hypothesis, suggested by clinical 
data, was further verified in mouse models using human SMN2 as a means of alleviating the 
symptoms of SMA-like mice lacking copies of the murine Smn gene.  In 2000, two studies 
Figure 1.3. SMN1 contains an ESE that binds 
SF2/ASF, leading to exon 7 inclusion.  SMN2 has 
a CU transition, which disrupts this ESE, 
causing exon 7 exclusion. 
SMN1 
SMN2 
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showed that Smn-/- knockout mice that have no functional mouse Smn gene could be rescued 
from the disease phenotype by the addition of 8 copies of the human SMN2 gene.
50,51
  It is clear 
that SMN2, because of its ability to produce full length protein and modify the disease 
phenotype, represents a potential target for therapeutic intervention. 
1.5 Therapeutic Approaches to Treat Spinal Muscular Atrophy 
Treatment of alternative splicing-related diseases continues to be addressed and 
developed using a number of methods.  Currently, most clinical treatments for diseases such as 
SMA are palliative, focusing on increasing the comfort of patients and helping to alleviate the 
symptoms associated with the disease.
52,53
  Palliative treatments for SMA patients include 
physiotherapy to improve mobility and muscle strength, respiratory support to assist in routine 
breathing, and nutritional assistance via feeding tubes to circumvent difficulties in the 
consumption of food.  For diseases such as cystic fibrosis, which have the potential for bacterial 
infections, routine antibiotic treatment is necessary to prevent additional complications.  
Although these treatments are beneficial to patients and can increase patient comfort, the 
underlying cause of the disease is often not addressed.   
While there is currently no cure for SMA, a number of research groups have proposed 
treatments that address the underlying cause of the disease.  These treatments target different 
processes associated with the transcription, splicing, and translation of the SMN2 gene, so that 
more full length protein can be produced in the absence of SMN1.  Although many have yet to 
reach the clinic, great potential has been shown for a number of different strategies, and further 
development will hopefully be able to make these strategies clinically feasible.   
1.5.1 Small Molecule Therapeutics 
Small molecule therapeutics for SMA have been examined in a number of contexts, from 
cellular assays to clinical trials, with moderate success (Figure 1.4).  In 2001, Burghes and co-
workers identified aclarubicin (1.1), an anthracycline antibiotic, which increases exon 7 inclusion 
in SMN2 transcripts.
54
  Aclarubicin has been shown to interact with DNA topoisomerase II, but 
how this increases exon 7 inclusion is unknown.  The major disadvantage of this treatment is that 
it is non-specific and highly toxic, reducing the possibility of its development as a clinical 
treatment substantially.  Sodium butyrate (1.2) and valproic acid (1.3), both histone deacetylase 
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inhibitors (HDACi), cause an increase in the 
level of SR protein transcript and SMN2 
transcript, respectively.
55,56
  HDACi act by 
inhibiting the removal of acetyl groups from 
the lysine residues of histones, causing 
chromatin to remain unwound and able to 
interact with RNA polymerase, increasing 
expression of various genes.  These 
molecules are non-specific, and exploration 
of the effects of using a non-specific 
transcription enhancer is ongoing.  Several 
small molecules, including sodium butyrate, valproic acid, and hydroxyurea (1.4), are currently 
being utilized in human clinical trials.
57,58
  These trials have only produced mild therapeutic 
effects in patients with less severe forms of the disease, indicating that further small molecule 
screening, as well as other strategies, must be utilized.  Identification of novel compounds that 
affect SMN2 transcription, splicing, and translation continues, and hopefully additional clinically 
relevant molecules will be identified.
59
 
1.5.2. Gene Therapy 
As SMA results from a lack of SMN1 gene expression, several research groups have 
worked toward the development of a gene therapy method that would reconstitute the SMN1 
gene using a viral vector encoding the gene.
60
  This method is one of the more direct means of 
replacing the absent SMN protein.  However, possible issues associated with the use of a viral 
vector, as well as stable delivery and expression of the vector, have slowed its translation from 
the laboratory to the clinic.  In mouse models, the vector has shown promise, helping to increase 
the levels of SMN1 transcript and SMN protein as well as showing the best life expectancy 
outcome to date, suggesting that it is a viable method that should continue to be explored, despite 
possible issues associated with human use.
61
  Further work on this treatment is ongoing. 
 
 
Figure 1.4. Small molecule treatments for SMA 
1.1 
1.2 
1.3 
1.4 
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1.5.3 Antisense Oligonucleotides 
Antisense oligonucleotides have been widely utilized in a number of contexts, including 
the down-regulation and silencing of gene expression using RNA interference (RNAi) and to 
alter the splicing of RNA by blocking of splicing sequences in diseases like cystic fibrosis.
62
  In 
the context of SMA, it was initially unknown if this strategy would be amenable to development 
as a therapy, as the goal of the antisense oligonucleotide was not to down-regulate or exclude a 
particular sequence element, but rather to include a sequence element.  Several research groups 
explored the sequences within and surrounding exon 7 of SMN2 in order to identify sequence 
elements that could be blocked in order to increase inclusion of exon 7 (Figure 1.5).  
 
In 2007, Krainer and co-workers conducted an antisense walk across exon 7 using 
antisense oligonucleotides of 15-16 bases to bind to different sequence elements of the exon and 
see what effect the oligonucleotides would have on splicing.
63
  They identified a number of 
sequences that had positive effects (leading to exon 7 inclusion), as well as several sites that had 
the opposite effect, leading to exon 7 exclusion.  These sites corresponded to the binding of other 
splicing proteins, including enhancers (such as SR-like protein Htra2β1) and inhibitors (hnRNP 
A1).  Since that time, additional antisense walks have been conducted by Krainer and others, 
identifying additional sites on which antisense oligonucleotides can bind and increase inclusion 
of exon 7.
64,65
  In general, these oligonucleotides block inhibitory factors such as hnRNPs from 
Figure 1.5. Possible targets for antisense oligonucleotides on SMN2 pre-mRNA 
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binding SMN2 pre-mRNA or redirect the splicing machinery away from exon 8 and toward exon 
7.  With their laboratory successes, antisense oligonucleotides have been further explored as 
possible clinically relevant molecules by commercial laboratories, and several are currently 
recruiting for phase I human clinical trials as potential treatments for SMA.  Time will tell if they 
can continue to be a viable method for increasing exon 7 inclusion in SMN2 and production of 
full length protein in humans, after showing great promise in cellular and mouse models. 
1.5.4 Trans-Splicing 
A novel strategy developed by 
Lorson and co-workers takes advantage 
of a normal but rarely used form of 
alternative splicing called “trans-
splicing”.66,67  This process takes 
advantage of the multi-step process of 
mRNA splicing by allowing for the 
attachment of two different, non-linear 
mRNA pieces in the second step of the 
splicing reaction, instead of the normal 
attachment of the linear mRNA in two pieces separated by the intron.  The resulting molecule is 
a hybrid of the two mRNAs, containing sequence elements from two different mRNA molecules.  
Lorson and co-workers recognized that this process can be enhanced if the second mRNA piece 
is connected to the target RNA branch point sequence via antisense oligonucleotide binding, 
increasing the effective concentration of the trans-splicing mRNA.  Combining these traits, they 
developed a trans-splicing antisense oligonucleotide targeted to SMN2 pre-mRNA via an RNA 
binding domain with a second region that contained the correct SMN2 mRNA protein-encoding 
sequence (Figure 1.6).  Attachment to and splicing of the trans-splicing antisense SMN2 mRNA 
produced a trans-spliced mRNA product that was able to produce the correct SMN protein under 
cellular conditions, as measured by immunofluorescence.   
Later work to further develop these molecules led to the incorporation of several 
additional features.  First, an antisense walk across the SMN2 gene indicated that exon 3 
contained the most beneficial site for binding of their trans-splicing antisense oligonucleotide.
68
  
Figure 1.6. Trans-splicing mRNA strategy 
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Second, Lorson and co-workers found that inclusion of an antisense oligonucleotide targeted to 
the junction of exon 8 downstream of exon 7 increased the ability of the trans-splicing reaction to 
occur, leading to further SMN protein production.
69
  Third, and most importantly, they were able 
to encode these molecules into viral vectors and stably express them in mouse models.
70,71
  The 
vector contains both the trans-splicing oligonucleotide and the antisense oligonucleotide, 
creating a powerful method for altering mRNA splicing and increasing production of SMN 
protein.  As mentioned, these vectors have been successful in mouse models, and it is only a 
matter of time before they end up in clinical trials. 
1.5.5 Bifunctional Molecules 
Antisense oligonucleotides can also be 
used in novel ways to mimic proteins or 
RNA binding sites, leading to changes in 
alternative splicing patterns.  As with the 
oligonucleotides mentioned above, the 
goal of these strategies is to increase 
inclusion of an exon, but in this case the 
method is to reconstitute some binding 
event or molecular interaction that is lost 
under disease conditions.  Two particular 
strategies have been used to increase 
inclusion of SMN2 exon 7 and treat 
SMA.  Mutoni and co-workers 
developed a bifunctional antisense oligonucleotide containing a sequence targeted to SMN2 pre-
mRNA and a second sequence containing multiple repeats of the exon 7 ESE sequence motif that 
is interrupted by the CT transition in SMN2 pre-mRNA (Figure 1.7).72-74  The binding of this 
bifunctional oligonucleotide to the target pre-mRNA provides a location for SF2/ASF to bind, 
assisting in the recruitment of the remaining spliceosomal proteins as described previously.  
Lorson and co-workers were able to increase the inclusion of exon 7 and expression of the full 
length SMN protein under cellular conditions, and this method was amenable to encoding the 
Figure 1.7. Bifunctional mRNA strategy 
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antisense oligonucleotide into a viral vector, making it a possible therapeutic option for SMA 
patients.
72
   
A second novel strategy utilizing antisense oligonucleotides by Krainer and co-workers 
involved the development of SR protein mimics that could bind to the SMN2 pre-mRNA and 
recruit the spliceosomal machinery via interaction with synthetic RS domains.
20
  These 
molecules consisted of peptide nucleic acid (PNA) RNA binding domains and peptide regions 
consisting of 10 RS, RD, or RE dipeptide repeats.  These molecules were all effective at 
increasing inclusion of exon 7 in SMN2 mRNA, as well as BRCA mRNA.  Further work by 
Caputi and co-workers demonstrated that a minimal RS domain of 8 dipeptide repeats was able 
to modulate the splicing of Bcl-x mRNA.
26
  Bcl-x is a gene that encodes two proteins, Bcl-xL and 
Bcl-xS, that both act as regulators of cancer cell proliferation.  They demonstrated that these 
molecules were effective at switching the splicing isoform from Bcl-xL, an anti-apoptotic form, 
to Bcl-xS, the pro-apoptotic form both in vitro and, importantly, in vivo.  In both studies, a small 
number of minimal RS domains were utilized, but little was done to explore the structural space 
occupied by the synthetic RS domain and see if changes in the structure can affect activity.  SR 
protein RS domains are intrinsically disordered, suggesting that addition of structural elements 
may change activity, but little work had been done previously to explore this area. 
1.6 Project Design 
The goal of this project is to develop specific synthetic alternative splicing activators that 
will be used to increase the knowledge of the splicing reaction and could ultimately be used as 
lead molecules for molecular therapeutics.  These molecules would be most useful if they could 
be readily redesigned to address different types of splicing-related diseases.  Taking this into 
consideration, our current design of alternative splicing activators focuses on bifunctional 
molecules containing a portion that specifically binds to the pre-mRNA and a portion that 
activates splicing.  The overall approach that are using is shown in Figure 1.8.   
14 
 
 
We are focused in this project only on the understanding and development of the splicing 
activation domain of the bifunctional molecules, not the RNA binding domain.  Therefore, we 
have used previously developed antisense oligonucleotides to specifically target the splicing 
activator to the SMN2 pre-mRNA.  The activation domain is modeled on a class of splicing 
activators, called the SR proteins, which contain phosphorylated RS dipeptide repeat sequences.  
These highly charged molecules recruit a collection of proteins (the spliceosome) to the pre-
mRNA for correct splicing.  We are exploring the sequence, charge, and structural requirements 
of the splicing activator using α-peptide, β-peptide, and dendrimer scaffolds.  The efficacy of 
these molecules is examined using an in vitro splicing assay.   
1.7 Importance and Relevance 
Alternative splicing is an important process to understand, and the control of splicing has 
great potential as a therapeutic strategy.  Spinal muscular atrophy is a common genetic disease 
that is currently without effective therapeutic treatment, but which could be treated by molecules 
that modulate alternative splicing of SMN2 pre-mRNA.  Increased levels of full-length SMN2 
mRNA containing exon 7 have been shown to ameliorate the disease in mouse models, and an 
increased copy number of SMN2 in humans has been inversely correlated with disease severity, 
indicating that SMN2 is an important target for therapeutic intervention.  There has been 
significant exploration of small molecules to treat SMA, including molecules in clinical trials, 
but these treatments suffer from low efficacy and lack of specificity.  Genetic approaches, such 
as antisense oligonucleotides and gene therapy, are promising, but are limited by delivery to and 
stability in the cellular environment.  Minimal synthetic splicing activators could act specifically, 
Figure 1.8. General approach for splicing activation by synthetic activators 
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similar to other genetic approaches, and mimic the SR proteins that are unable to bind to SMN2 
pre-mRNA.  The scope of possible RS domain mimics has not been explored in great detail 
previously, and the proposed synthetic activators introduce variations in sequence, structure, 
charge, and scaffold, representing the first time that non-peptide conjugates have been explored 
as splicing activators.  These molecules will help to increase the knowledge of the requirements 
of minimal RS domains and provide a platform for the development of splicing activators that 
have strong potential to be therapeutic lead molecules. 
1.8 References 
(1) Johnson, J. M.; Castle, J.; Garrett-Engele, P.; Kan, Z.; Loerch, P. M.; Armour, C. D.; 
Santos, R.; Schadt, E. E.; Stoughton, R.; Shoemaker, D. D. Science 2003, 302, 2141. 
(2) Pan, Q.; Shai, O.; Lee, L. J.; Frey, B. J.; Blencowe, B. J. Nat. Genet. 2008, 40, 1413-5. 
(3) Wang, E. T.; Sandberg, R.; Luo, S.; Khrebtukova, I.; Zhang, L.; Mayr, C.; Kingsmore, S. 
F.; Schroth, G. P.; Burge, C. B. Nature 2008, 456, 470-6. 
(4) Liu, H. X.; Chew, S. L.; Cartegni, L.; Zhang, M. Q.; Krainer, A. R. Mol. Cell. Biol. 2000, 
20, 1063. 
(5) Smith, C. W.; Valcarcel, J. Trends Biochem. Sci. 2000, 25, 381. 
(6) Graveley, B. R. RNA 2000, 6, 1197. 
(7) Manley, J. L.; Tacke, R. Genes Dev. 1996, 10, 1569. 
(8) Sanford, J. R.; Ellis, J.; Caceres, J. F. Biochem. Soc. Trans. 2005, 33, 443. 
(9) Chandler, S. D.; Mayeda, A.; Yeakley, J. M.; Krainer, A. R.; Fu, X. D. Proc. Nat. Acad. 
Sci. U. S. A. 1997, 94, 3596. 
(10) Kashima, T.; Rao, N.; David, C. J.; Manley, J. L. Hum. Mol. Genet. 2007, 16, 3149. 
(11) Hofmann, Y.; Wirth, B. Hum. Mol. Genet. 2002, 11, 2037. 
(12) Haynes, C.; Iakoucheva, L. M. Nucleic Acids Res. 2006, 34, 305. 
(13) Shen, H.; Green, M. R. Mol. Cell. 2004, 16, 363. 
(14) Shen, H.; Kan, J. L.; Green, M. R. Mol. Cell. 2004, 13, 367. 
(15) Singh, R.; Valcarcel, J. Nat. Struct. Mol. Biol. 2005, 12, 645. 
(16) Fu, X. D. RNA 1995, 1, 663. 
(17) Graveley, B. R.; Hertel, K. J.; Maniatis, T. EMBO J. 1998, 17, 6747. 
16 
 
(18) Allemand, E.; Gattoni, R.; Bourbon, H. M.; Stevenin, J.; Caceres, J. F.; Soret, J.; Tazi, J. 
Mol. Cell. Biol. 2001, 21, 1345. 
(19) Caceres, J. F.; Krainer, A. R. EMBO J. 1993, 12, 4715. 
(20) Cartegni, L.; Krainer, A. R. Nat. Struct. Biol. 2003, 10, 120. 
(21) Stamm, S. J. Biol. Chem. 2008, 283, 1223. 
(22) Nikolakaki, E.; Drosou, V.; Sanidas, I.; Peidis, P.; Papamarcaki, T.; Iakoucheva, L. M.; 
Giannakouros, T. Biochim. Biophys. Acta 2008, 1780, 214. 
(23) Xiao, S. H.; Manley, J. L. EMBO J. 1998, 17, 6359. 
(24) Wu, J. Y.; Maniatis, T. Cell 1993, 75, 1061. 
(25) Lai, M. C.; Lin, R. I.; Tarn, W. Y. Proc. Nat. Acad. Sci. U. S. A. 2001, 98, 10154. 
(26) Wilusz, J. E.; Devanney, S. C.; Caputi, M. Nucleic Acids Res. 2005, 33, 6547. 
(27) Cartegni, L.; Chew, S. L.; Krainer, A. R. Nat. Rev. Genet. 2002, 3, 285. 
(28) Garcia-Blanco, M. A.; Baraniak, A. P.; Lasda, E. L. Nat. Biotechnol. 2004, 22, 535. 
(29) Wang, G. S.; Cooper, T. A. Nat. Rev. Genet. 2007, 8, 749. 
(30) Cooper, T. A.; Wan, L.; Dreyfuss, G. Cell 2009, 136, 777. 
(31) Poulos, M. G.; Batra, R.; Charizanis, K.; Swanson, M. S. Cold Spring Harbor Perspect. 
Biol. 2011, 3, a000778. 
(32) Buratti, E.; Chivers, M.; Kralovicova, J.; Romano, M.; Baralle, M.; Krainer, A. R.; 
Vorechovsky, I. Nucleic Acids Res. 2007, 35, 4250. 
(33) Roca, X.; Olson, A. J.; Rao, A. R.; Enerly, E.; Kristensen, V. N.; Borresen-Dale, A. L.; 
Andresen, B. S.; Krainer, A. R.; Sachidanandam, R. Genome Res. 2008, 18, 77. 
(34) Gebski, B. L.; Mann, C. J.; Fletcher, S.; Wilton, S. D. Hum. Mol. Genet. 2003, 12, 1801. 
(35) Goemans, N. M.; Tulinius, M.; van den Akker, J. T.; Burm, B. E.; Ekhart, P. F.; 
Heuvelmans, N.; Holling, T.; Janson, A. A.; Platenburg, G. J.; Sipkens, J. A.; Sitsen, J. 
M.; Aartsma-Rus, A.; van Ommen, G. J.; Buyse, G.; Darin, N.; Verschuuren, J. J.; 
Campion, G. V.; de Kimpe, S. J.; van Deutekom, J. C. N. Engl. J. Med. 2011, 364, 1513. 
(36) Arambula, J. F.; Ramisetty, S. R.; Baranger, A. M.; Zimmerman, S. C. Proc. Nat. Acad. 
Sci. U. S. A. 2009, 106, 16068. 
(37) Wong, C. H.; Fu, Y.; Ramisetty, S. R.; Baranger, A. M.; Zimmerman, S. C. Nucleic Acids 
Res. 2011, 39, 8881. 
(38) Munsat, T. L.; Davies, K. E. Neuromuscul. Disord. 1992, 2, 423. 
17 
 
(39) Lefebvre, S.; Burglen, L.; Reboullet, S.; Clermont, O.; Burlet, P.; Viollet, L.; Benichou, 
B.; Cruaud, C.; Millasseau, P.; Zeviani, M.; et al. Cell 1995, 80, 155. 
(40) Eggert, C.; Chari, A.; Laggerbauer, B.; Fischer, U. Trends Mol. Med. 2006, 12, 113. 
(41) Meister, G.; Eggert, C.; Fischer, U. Trends Cell. Biol. 2002, 12, 472. 
(42) Lorson, C. L.; Hahnen, E.; Androphy, E. J.; Wirth, B. Proc. Nat. Acad. Sci. U. S. A.  
1999, 96, 6307. 
(43) Monani, U. R.; Lorson, C. L.; Parsons, D. W.; Prior, T. W.; Androphy, E. J.; Burghes, A. 
H.; McPherson, J. D. Hum. Mol. Genet. 1999, 8, 1177. 
(44) Setola, V.; Terao, M.; Locatelli, D.; Bassanini, S.; Garattini, E.; Battaglia, G. Proc. Nat. 
Acad. Sci. U. S. A. 2007, 104, 1959. 
(45) Cartegni, L.; Krainer, A. R. Nat. Genet. 2002, 30, 377. 
(46) Kashima, T.; Manley, J. L. Nat. Genet. 2003, 34, 460. 
(47) Cartegni, L.; Hastings, M. L.; Calarco, J. A.; de Stanchina, E.; Krainer, A. R. Am. J. 
Hum. Genet. 2006, 78, 63. 
(48) Brahe, C. Neuromuscul. Disord. 2000, 10, 274. 
(49) Feldkotter, M.; Schwarzer, V.; Wirth, R.; Wienker, T. F.; Wirth, B. Am. J. Hum. Genet. 
2002, 70, 358. 
(50) Hsieh-Li, H. M.; Chang, J. G.; Jong, Y. J.; Wu, M. H.; Wang, N. M.; Tsai, C. H.; Li, H. 
Nat. Genet. 2000, 24, 66. 
(51) Monani, U. R.; Sendtner, M.; Coovert, D. D.; Parsons, D. W.; Andreassi, C.; Le, T. T.; 
Jablonka, S.; Schrank, B.; Rossoll, W.; Prior, T. W.; Morris, G. E.; Burghes, A. H. Hum. 
Mol. Genet. 2000, 9, 333. 
(52) Mercuri, E.; Bertini, E.; Iannaccone, S. T. Lancet Neurol. 2012, 11, 443. 
(53) Wang, C. H.; Finkel, R. S.; Bertini, E. S.; Schroth, M.; Simonds, A.; Wong, B.; Aloysius, 
A.; Morrison, L.; Main, M.; Crawford, T. O.; Trela, A.; Participants of the International 
Conference on, S. M. A. S. o. C. J. Child Neurol. 2007, 22, 1027. 
(54) Andreassi, C.; Jarecki, J.; Zhou, J.; Coovert, D. D.; Monani, U. R.; Chen, X.; Whitney, 
M.; Pollok, B.; Zhang, M.; Androphy, E.; Burghes, A. H. Hum. Mol. Genet. 2001, 10, 
2841. 
(55) Brichta, L.; Hofmann, Y.; Hahnen, E.; Siebzehnrubl, F. A.; Raschke, H.; Blumcke, I.; 
Eyupoglu, I. Y.; Wirth, B. Hum. Mol. Genet. 2003, 12, 2481. 
18 
 
(56) Chang, J. G.; Hsieh-Li, H. M.; Jong, Y. J.; Wang, N. M.; Tsai, C. H.; Li, H. Proc. Nat. 
Acad. Sci. U. S. A.  2001, 98, 9808. 
(57) Swoboda, K. J.; Kissel, J. T.; Crawford, T. O.; Bromberg, M. B.; Acsadi, G.; D'Anjou, 
G.; Krosschell, K. J.; Reyna, S. P.; Schroth, M. K.; Scott, C. B.; Simard, L. R. J. Child 
Neurol. 2007, 22, 957. 
(58) Tsai, L. K.; Yang, C. C.; Hwu, W. L.; Li, H. Eur. J. Neurol. 2007, 14, e8. 
(59) Xiao, J.; Marugan, J. J.; Zheng, W.; Titus, S.; Southall, N.; Cherry, J. J.; Evans, M.; 
Androphy, E. J.; Austin, C. P. J. Med. Chem. 54, 6215. 
(60) Passini, M. A.; Cheng, S. H. Trends Mol. Med. 2011, 17, 259. 
(61) Glascock, J. J.; Osman, E. Y.; Wetz, M. J.; Krogman, M. M.; Shababi, M.; Lorson, C. L. 
Hum. Gene. Ther. 23, 330. 
(62) Kole, R.; Krainer, A. R.; Altman, S. Nat. Rev. Drug Discovery 2012, 11, 125. 
(63) Hua, Y.; Vickers, T. A.; Baker, B. F.; Bennett, C. F.; Krainer, A. R. PLoS Biol. 2007, 5, 
e73. 
(64) Hua, Y.; Sahashi, K.; Hung, G.; Rigo, F.; Passini, M. A.; Bennett, C. F.; Krainer, A. R. 
Genes Dev. 24, 1634. 
(65) Hua, Y.; Vickers, T. A.; Okunola, H. L.; Bennett, C. F.; Krainer, A. R. Am. J. Hum. 
Genet. 2008, 82, 834. 
(66) Garcia-Blanco, M. A. J. Clin. Invest. 2003, 112, 474. 
(67) Coady, T. H.; Shababi, M.; Tullis, G. E.; Lorson, C. L. Mol. Ther. 2007, 15, 1471. 
(68) Shababi, M.; Lorson, C. L. J. Mol. Neurosci. 2012, 46, 459. 
(69) Coady, T. H.; Baughan, T. D.; Shababi, M.; Passini, M. A.; Lorson, C. L. PLoS One 
2008, 3, e3468. 
(70) Shababi, M.; Glascock, J.; Lorson, C. L. Hum. Gene. Ther. 22, 135. 
(71) Coady, T. H.; Lorson, C. L. J. Neurosci. 2010, 30, 126. 
(72) Baughan, T.; Shababi, M.; Coady, T. H.; Dickson, A. M.; Tullis, G. E.; Lorson, C. L. 
Mol. Ther. 2006, 14, 54. 
(73) Marquis, J.; Meyer, K.; Angehrn, L.; Kampfer, S. S.; Rothen-Rutishauser, B.; 
Schumperli, D. Mol. Ther. 2007, 15, 1479. 
(74) Skordis, L. A.; Dunckley, M. G.; Yue, B.; Eperon, I. C.; Muntoni, F. Proc. Nat. Acad. 
Sci. U. S. A. 2003, 100, 4114. 
19 
 
CHAPTER 2 
DESIGN AND SYNTHESIS OF PEPTIDE SR PROTEIN MIMICS 
2.1 Introduction 
As the structure and function of proteins have been elucidated by the use of different 
biological and analytical techniques, it has become possible to determine which structures are 
important for activity and to develop molecules that are able to reconstitute the active site 
without the remaining protein structure.  Development of these novel protein mimics has 
produced molecules that are active in a number of different contexts, including but not limited to 
binding of activator sites to activate protein function, inhibition of protein-protein interactions, 
and reconstitution of protein activity using a peptide mimic.
1-5
  Thus, the development of novel 
molecules that are able to act as protein mimics is an important field that demands attention. 
2.1.1 SR Protein Mimic Design 
 
Our protein mimic design aims to recapitulate the activity of the SR protein SF2/ASF, a 
splicing factor involved in recognition of exon 7 in SMN2 pre-mRNA that has reduced affinity 
due to the change in the ESE sequence.  Taking inspiration from Krainer and co-workers,
5
 the 
designed protein mimics are peptide-oligonucleotide conjugates containing two regions: first, an 
antisense oligonucleotide that can replace the RBD by interacting with a sequence on the SMN2 
pre-mRNA; and second, a synthetic RS domain that will mimic the natural RS domain and 
interact with other proteins via electrostatic interactions (Figure 2.1).  The antisense 
oligonucleotide consists of a single-stranded DNA molecule, chosen because it should be 
relatively stable to nuclease degradation and is easily and cheaply synthesized.   
Figure 2.1: SR Protein Mimic Design 
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While the focus of the research was on the synthetic RS domain, there is a great deal of 
potential for study of the antisense oligonucleotide.  Work conducted by a number of research 
groups has shown that there is great potential for the use of antisense oligonucleotides to control 
alternative splicing outcomes (see Chapter 1).
6-10
 We chose to target nucleotides +7-18 on exon 
7, as they have been shown to be a good target for splicing enhancement and have been targeted 
by Krainer and co-workers in the development of their SR protein mimics.
5,7
   
2.1.2 RS Domain Mimics – α-Peptide 
 
 
The synthetic RS domain of the SR protein mimics consists of three motifs – α-peptide, 
β-peptide, or peptide dendrimer (Figure 2.2).  α-Peptides have been used previously as RS 
domain mimics.  We have chosen β-peptides as non-natural, linear α-peptide mimics that are 
protease resistant and able to form secondary structures.  Peptide dendrimers were chosen for 
their protease stability and globular arrangement of amino acid residues.  The goal of our 
research was to explore the effectiveness of these three motifs, determining which of the three 
has the best activity, as well as to compare different properties within these motifs.  By using 
short peptides, we would be able to systematically analyze a single property, such as charge, 
without the potential interference or interactions of a larger protein. 
2.1.2.1 Varying Dipeptide Repeats 
Previous work has shown that synthetic RS domains consisting of 10 RS, RD, and RE 
dipeptide repeats are effective at changing splicing patterns in BRCA1, SMN, and Bcl-x pre-
Figure 2.2: Synthetic RS Domain General Design. a) α-Peptide. b) β-Peptide. c) Peptide Dendrimer 
a) 
b) 
c) 
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mRNA.  We have chosen to use the RD dipeptide in order to mimic the hyperphosphorylated 
state of the RS domain that is thought to be important for mediating these interactions.  
Phosphorylation of the RS domain plays an important role in mediating protein-protein 
interactions, preventing non-specific binding, and facilitating nuclear transport.
11-13
  Although 
there may be some concern about mimicking the hyperphosphorylated state for nuclear transport, 
as dephosphorylation of the RS domain is necessary to transport the SR proteins out of the 
nucleus, the use of an in vitro splicing assay can avoid any potential issues associated with 
traversing the cellular membrane and nuclear transport.  The arginine present in the synthetic RS 
domain may also facilitate transport into the cell, should these molecules be tested under in vivo 
conditions.  Arginine-based cell-penetrating peptides (CPPs) have been used as carriers for 
antisense oligonucleotides to cross the cell membrane.
14
  Caputi and co-workers demonstrated 
some activity using synthetic SR protein mimics in HeLa cells.  Previous synthetic RS domains 
contained 8-10 dipeptide repeats, all of which had activity under in vitro conditions, but smaller 
iterations of the RS domain have not been explored.  We chose to analyze minimal activators of 
5, 8, and 10 dipeptide repeats to determine if they are sufficient to alter the splicing pattern of 
SMN2 pre-mRNA.   
2.1.2.2 Varying Charged Residues 
The RS domain of SR proteins is highly charged, with positively charged arginine 
residues and serine residues that are negatively charged when phosphorylated.  It has been shown 
that the highly charged nature of the RS domain is a necessary characteristic for facilitating 
protein-protein interactions.  Although the protein may still have activity in the absence of these 
highly charged residues, less is known about the effects of charge removal in peptide models.  
We hypothesized that removal of either arginine or aspartic acid from our peptide mimics would 
decrease splicing activation, and thus designed several peptides in which alanine is substituted 
for either member of the dipeptide.  In addition, peptides in which one or several of the 
dipeptides are replaced with alanine were designed in order to examine how removal of some, 
but not all, of the charged residues would affect splicing activation.  Examination of SR proteins 
indicates that the presence of RSRS tetrapeptides is important for activity, so substitution of 
alanine residues while still maintaining RDRD tetrapeptides on the periphery of the synthetic RS 
domain can address whether this property holds true in a peptide model. 
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2.1.2.3 Varying Charge Distribution 
To the best of our knowledge, the importance of sequence in the RS domain has not been 
explored extensively in peptide models.  In particular, little work has been done to examine 
whether the RS dipeptides need to be arranged in alternating order to maintain activity, or if 
other arrangements still produce active molecules.  We have designed several motifs in which 
the arrangement of arginine and aspartic acid residues is changed to an RRDD motif, with one or 
several repeats present on the peptide.  We hypothesize that the arrangement of these residues 
will not have a large effect on activity, as the electrostatic interactions of the charged residues 
play the biggest role in protein-protein interactions, and the RS domains of the SR proteins are 
intrinsically disordered.  These redistributed peptides will provide insight into how the charged 
residues interact with their protein targets, and whether or not the alternating charges are 
necessary for activity. 
2.1.3 RS Domain Mimics – β-Peptide 
Although the RS domains belong to a class of intrinsically disordered proteins, there is 
evidence based on characterization of small RD and RS repeat peptides that these sequences may 
be at least transiently structured.
15-17
  This observed sequence tolerance suggest that there may be 
other structural solutions to splicing activation.  With this in mind, we have designed a series of 
peptide-like molecules as substitutes for the α-peptide motif.  β-Peptides are a useful alternative 
due to their protease resistance and similarity to α-peptides in their linear arrangement of amino 
acid residues. 
 
 
β-Peptides are composed of β-amino acids, which are essentially α-amino acids 
containing an extra methylene carbon with side chain functionality at the α-position (β2-amino 
acids) or the β-position (β3-amino acids) (Figure 2.3).  This modification of the natural amino 
Figure 2.3: β-Amino Acids 
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acid structure confers protease resistance and conformational flexibility.  β-Peptides can fold into 
a variety of sequence-dependent secondary structures, such as 12- and 14-helices, in as few as 
four amino acids.
2
  β-peptides have been used in a variety of biological applications, most 
importantly in the disruption of protein-protein interactions.  In 2004, Schepartz and co-workers 
designed a series of 14-helices that were able to inhibit the formation of the hDM2-p53 complex, 
an interaction important in cancer proliferation.
1
  Helix formation was facilitated by hydrophobic 
and charged residues that would favorably interact only in a helical structure, even under 
aqueous conditions.
18
  β-peptide interaction with mRNA was demonstrated by Gellman and co-
workers, who designed a β-peptide mimic of the tat protein that interacted with TAR RNA, an 
important interaction for HIV disease progression.
19
  These studies demonstrated that β-peptides 
can be rationally designed to incorporate structure, and that they can interact with biologically 
relevant molecules.  
2.1.3.1 Varying Dipeptide Repeats 
The overall design of the β-peptides is similar to that of the α-peptides.  A synthetic RS 
domain is linked to an oligonucleotide that is complementary to the SMN2 pre-mRNA.  The first 
set of β-peptides contain the same sequences of 5, 8, and 10 dipeptide repeats as the α-peptides, 
so the molecules containing the same number of residues can be compared directly.  This can 
help to determine if a synthetic RS domain mimic with protease resistance has similar activity to 
molecules that have already been used in other studies.   
2.1.3.2 Effects of Carbon Backbone 
An interesting property of the β-peptides is the presence of the additional methylene 
carbon in the backbone of the β-amino acids, which increases protease resistance and 
conformational flexibility.  The presence of this additional carbon presents the possibility of 
exploring the importance of the carbon backbone on activity of synthetic RS domain mimics, a 
property that has not been explored previously.  We have designed a series of β-peptides that 
have a similar number of carbons as the backbones of α-peptides.  As each β-amino acid has an 
additional carbon in the backbone, these β-peptides use fewer amino acids than their α-peptide 
counterparts (Table 2.1).  Comparing these α- and β-peptides will suggest the effect the length of 
the backbone has on activity.   
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Table 2.1. Comparison of - and - peptides with similar backbone lengths 
Peptide 
Type 
# DR 
Repeats 
Carbon Chain 
Length 


5 
4 
34 
36 


8 
6 
57 
52 


10 
7 
63 
60 
 
2.1.3.3 Secondary Structure  
The β-peptides have a unique ability to form secondary structures in as few as four amino 
acids through favorable interactions of the β-amino acid side chains.  This allows for the 
possibility of “encoding” secondary structure into the β-peptide.  We have designed a series of 
molecules that have the ability to form secondary structures in order to probe the ability of these 
polymers to alter splicing patterns.  Helices will contain one to three faces with alternating R and 
D residues, which will serve the dual purpose of stabilizing the helix and providing the same 
array of positive and negative charges inherent to the RS domain.   
2.2 Results and Discussion  
2.2.1 Peptide RS Domain Synthesis 
Both α- and β-peptide were synthesized on 2-chlorotrityl resin functionalized with 
glycine using standard Fmoc/OtBu solid-phase peptide synthesis (SPPS) procedures.  This resin 
was chosen because the growing peptides could be cleaved under weakly acidic conditions using 
hexafluoroisopropanol (HFIP) without side-chain deprotection, allowing for monitoring via 
electrospray ionization (ESI) or matrix assisted laser desorption/ionization (MALDI) mass 
spectrometry (MS).  Peptide synthesis was also monitored by the ninhydrin test developed by 
Kaiser and co-workers that utilizes the color-changing properties of ninhydrin in the presence of 
free amines.  Purification of the peptides was done using reverse-phase high performance liquid 
chromatography (RP-HPLC) after cleavage from the resin using a TFA cleavage mix (see 
Materials and Methods).  The peptides were cleaved, deprotected, precipitated with diethyl ether, 
redissolved in a mixture 1:1 mixture of H2O:CH3CN containing 0.1% TFA, filtered, and 
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analyzed by RP-HPLC.  Purification of the peptides by RP-HPLC was not trivial, as all peptides 
had slightly different retention times due to changes in the charge profile (by substitution of 
charged residues for alanine) or size.  Peptides mass was verified by ESI-MS or MALDI-MS 
before being used in further manipulations. 
2.2.1.1 α-Peptide Synthesis 
Table 2 lists the different peptides synthesized by SPPS.  All α-peptides were synthesized 
with an N-terminal glycine residue (for flexibility at the peptide-oligonucleotide linkage) and a 
linker molecule. α-Peptides containing 5, 8, and 10 RD dipeptide repeats were synthesized, 
purified by RP-HPLC, and analyzed by MALDI-MS.  These peptides were designed to explore 
the minimal number of charges needed to produce an effective splicing activator.  In addition, α-
peptides containing 8 dipeptide repeats of either AD or RA were synthesized in order to analyze 
the importance of charged moieties.  These molecules were somewhat more difficult to purify, as 
the overall molecules were highly charged (as opposed to the RD dipeptides, which had a low 
overall charge due to cancellation of positive and negative charges), requiring careful 
examination of purification conditions to isolate them properly.  Peptides containing one or two 
DDRR repeats in between DR dipeptide repeats have also been synthesized and isolated as 
described above.   
Table 2.2. Synthesized - and -peptides 
α-Peptides β-Peptides 
(DR)5 (βD-βR)4 
(DR)8 (βD-βR)5 
(DR)10 (βD-βR)6 
(DA)8 (βD-βR)7 
(AR)8 (βD-βR)8 
(DR)3A(DR)3 (βD-βR)10 
(DR)3DDRR(DR)3  
(DR)3(DDRR)2(DR)3 
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2.2.1.2 β-Peptide Synthesis 
β-Peptide analogs of α-peptides containing 5, 8, and 10 RD dipeptide repeats have been 
synthesized.  Synthesis was conducted using commercially available β3-R and β3-D amino acids.  
β3-Alanine was substituted for glycine at the N-terminus, followed by the linker molecule.  In 
addition, β-peptides were synthesized containing different numbers of dipeptide repeats that were 
designed to contain similar backbone chain lengths to α-peptides while containing fewer charged 
residues (Table 2).  Products were analyzed by ESI-MS and MALDI-MS, and purified as 
described above.  Unfortunately, few of these peptides were conjugated and analyzed for 
alternative splicing modulation activity.  These peptides were synthesized well before we began 
our conjugation reactions, and had degraded before we could use them in our reactions.  The β-
peptides will not be mentioned in subsequent discussion of molecule activity (see Chapter 4). 
2.2.1.3 Peptide Synthesis Troubleshooting 
The synthesis of α- and β-peptides, while straightforward, was not without difficulties.  
Reagent purity was especially important.  PyBOP and HOBt coupling reagents, for example, 
both degrade over time at room temperature, decreasing coupling efficiency.  Both reagents have 
been stored at 4°C to prevent degradation.  Additional coupling reagents were utilized during 
peptide synthesis with varying degrees of success.  HBTU, a benzotriazole coupling reagent 
similar to PyBOP, showed similar levels of efficiency and could be used in the absence of HOBt, 
which has limited availability due to its recent classification as an explosive.  COMU, a coupling 
reagent based on ethyl (hydroxyimino)cyanoacetate (Oxyma) developed by Sigma Aldrich, was 
chosen as an alternative to PyBOP due to its reported high coupling efficiency and strong 
inhibition of racemization as a coupling additive.
20
  Like PyBOP and HBTU, this coupling 
reagent had reasonable efficiency when used on longer peptides, losing coupling activity after 
extended use.  The decreased efficiency of all coupling reagents over time highlighted the 
importance of maintaining fresh reagents for coupling reactions.  Like coupling reagents, the 
efficiency of the Fmoc-cleaving agent piperidine decreased over time, requiring regular 
replacement in order to make sure that the cleavage reaction remained quantitative.   
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Water can play an inhibitory role in amide bond formation, as it can act as a nucleophile 
and cause the activated ester to convert back to the free acid moiety.  To prevent water from 
interfering with the coupling reaction, reagents were extensively dried by azeotropic distillation 
with dry DMF, and dry DMF stored over activated molecular sieves was used in all coupling 
reagents.  It was found that the efficiency of the reaction decreased with the increasing number 
of amino acid residues, making the synthesis of 10 RD dipeptide repeat molecules particularly 
challenging.  This was due in part to the aggregation of peptides through backbone interactions 
while on the resin.  Pre-swelling of the resin using CH2Cl2, increasing reaction time, and 
conducting consecutive reactions with fresh coupling reagents helped to alleviate this problem.   
Isolation of the peptides following cleavage and purification was not trivial.  We were 
able to isolate the crude peptide with side-chain protecting groups removed, and precipitation 
with ethyl ether to remove additives from the TFA cleavage mix and cleaved side chains was 
moderately successful.  There remained some side-products in the peptide mixture that we 
attempted to remove by RP-HPLC.  Unfortunately, some product was lost during RP-HPLC 
purification, despite collection of the majority of the solvent producing a UV signal.  It is likely 
that issues with the HPLC pump, particularly for the CH3CN solvent, played a role in the signal 
broadening that prevented collection of the entire sample.  It was unknown if this was due to the 
viscosity of CH3CN or the pump itself, although it appeared to be functioning normally.  We 
attempted to address these issues by dissolving the peptide cleavage mixture in organic solvents 
and filtering off remaining solids, which had a somewhat beneficial effect.  Further 
experimentation with peptide cleavage mix solubility and solvent combinations would help with 
increasing the yield following RP-HPLC purification, improving the quality of the peptides 
being used for further manipulation. 
2.2.2 Peptide-Oligonucleotide Conjugation 
The conjugation of synthetic RS domains to antisense oligonucleotides is not trivial, and 
some thought must be put into deciding the conjugation method that will work most efficiently 
with the two fragments involved.  In their design, Krainer and co-workers used PNA as their 
antisense oligonucleotide, meaning that the entire SR protein mimic could be synthesized in an 
iterative fashion without the need for a conjugation reaction.  In our design, the antisense 
oligonucleotide and peptide are synthesized separately.  Thus, we needed to choose an 
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orthogonal reaction scheme that would allow for conjugation of the two fragments with little 
potential for side-product formation. 
The field of bioconjugation is extensive, and many strategies are available for connection 
of peptide and oligonucleotide fragments.  Our criteria for choosing a particular method included 
low cost to purchase or synthesize the conjugates, that the coupling reaction be orthogonal to 
other possible reactive groups, and that the reaction conditions be mild to ensure stability of the 
peptide and oligonucleotide fragments.  Commercially available linker molecules provide fairly 
straightforward synthesis and conjugation reactions, but the fairly high cost associated with their 
use drove us in a different direction.  A number of possible conjugation schemes that would 
utilize commercially available oligonucleotide modifiers.  Of those available, three were chosen: 
maleimide-thiol addition, Diels Alder cycloaddition, and copper-catalyzed alkyne azide 
cycloaddition (CuAAC or ‘click chemistry’) (Figure 2.4).   
 
 
2.2.2.1 Maleimide-Thiol Addition 
The maleimide-thiol addition has been used in a wide variety of contexts to produce 
conjugated molecules.  It has been used to produce peptide-oligonucleotide conjugates using a 
number of biologically relevant starting materials.  This reaction consists of two components – a 
maleimide ring containing an α,β-conjugated carbonyl system that acts as a Michael acceptor, 
and a free thiol that acts as a Michael donor.  Under buffered conditions, the free thiol will 
Figure 2.4. Possible Peptide-Oligonucleotide Conjugation Schemes 
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undergo nucleophilic attack of the alkene, forming an enol functionality.  Protonation of the enol 
produces the ketone and the substituted final product.  This reaction is advantageous in that it is 
orthogonal to the functionality of the peptide and oligonucleotide, can be run under mild, slightly 
basic buffer conditions, and the cost of starting materials is cheap.  The maleimide linker can be 
easily synthesized from commercially available reagents in large quantities, and it is able to 
withstand TFA mediated cleavage after addition to the synthetic peptide RS domains during 
solid phase peptide synthesis.  The thiol functionality on the oligonucleotide can be added at the 
3’-end by means of a commercially available modifier (Glen Research), and the only 
cumbersome step is reduction of the disulfide to free the thiol functionality prior to coupling.   
 
Synthesis of the maleimide linker is a straightforward preparation from glycine and 
maleic anhydride (Scheme 2.1).  In the first step, nucleophilic attack of the glycine nitrogen 
forms an amide bond, opening the electrophilic anhydride.  Addition of base and refluxing the 
reaction in toluene allows for a second attack of the free lone pair of nitrogen on the second acid 
moiety, closing the maleimide and releasing water from the reaction.  This series of reactions is 
straightforward and high yielding, producing a large quantity of the linker that can be used for 
coupling.  As the molecule is built off of glycine, it can be directly linked to the peptide at the N-
terminus as the last coupling step before the peptide is cleaved from the resin.  The molecule is 
stable to the TFA-mediated cleavage from the resin, leaving it available for coupling to the 
oligonucleotide.   
 
 
Scheme 2.1 
Scheme 2.2 
2.1 2.2 
2.3 
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The maleimide-thiol addition was examined under a number of conditions in order to 
determine what would be the most successful at producing peptide-oligonucleotide conjugates 
(Scheme 2.2).  In 1994, Ede et al. coupled peptides and oligonucleotides in a buffer of 20% 
0.1M triethylammonium acetate (TEAA) in CH3CN, and this method was initially chosen to 
produce our conjugates.
21
  The buffer system was chosen because it was the buffer system 
utilized in this report to purify the oligonucleotide and remove excess dithiothreitol (DTT) prior 
to conjugation.  We initially chose DTT as the disulfide reducing agent, as it is a common 
reagent for reducing disulfide bonds.  Initial attempts using these reaction conditions were 
moderately successful, producing a small amount of product relative to the starting reagents.  
Several factors were explored to improve the yield of these reactions.  It was first noted that the 
coupling buffer should be degassed to reduce the chance of oxidation of the thiol back to a 
disulfide.  Next, the amount of time needed to fully reduce the disulfide was explored, as the 
time of 1-2 hours listed in the protocol was insufficient.  Examination of the oligonucleotide at 
different time points revealed that overnight reduction with DTT was necessary for complete 
reduction, and conjugation with this fully reduced oligonucleotide produced a high yield of 
conjugate.  Reaction solvent was also of a concern.  The reaction needed to be slightly basic to 
promote thiol deprotonation, but not so basic so as to cause opening of the maleimide ring, which 
is sensitive to base.  Addition of potassium hydroxide to the previously established buffer 
conditions to increase pH was moderately successful, although it appeared to lead to more 
opening of the maleimide ring than the desired conjugate.  Examination of the pH of our buffers 
indicated that a reaction pH of around 7.5 was sufficient for this reaction to occur without too 
much breakdown of the malemide ring. 
It was noted that an issue with performing RP-HPLC purification of the oligonucleotide 
was the substantial loss of the oligonucleotide after purification, reducing the overall yield.  
Alternative methods were sought to remove the DTT reducing agent, including precipitation with 
silver nitrate and extraction with organic solvents such as ethyl acetate.  These methods, while 
moderately successful at removing DTT and ensuring that a majority of oligonucleotide 
remained available for coupling, were not 100% efficient at removing DTT.  This reducing agent 
also contains free thiols, and the presence of excess DTT meant that the free maleimide would 
often react preferentially with the DTT rather than the thiol on the oligonucleotide.  Thus, we 
explored alternatives to DTT as a reducing agent.   
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We determined that tris(2-carboxyethyl)phosphine (TCEP) would be a suitable 
alternative.  TCEP is a phosphine reducing agent that is advantageous over DTT for several 
reasons: it is a more powerful reducing agent, an irreversible reducing agent, less susceptible to 
oxidation in air, and less reactive with malemide functionality, although there is some evidence 
that it can react with maleimides under certain conditions.
22
  It can also be purchased on-resin, 
making it much easier to remove prior to conjugation.  We tested TCEP both as a 0.5M solution 
and on resin, with both providing very good reduction of the disulfide bond as indicated by 
MALDI-MS.  Importantly, reduction using TCEP could be completed in less than an hour, 
greatly improving the speed with which we could synthesize our conjugates.  On resin, the TCEP 
was removed by centrifugation, whereas in solution it was left in the reaction mixture.  In either 
case, we were able to obtain good yields of the maleimide-thiol conjugate, even in the presence 
of excess TCEP.  The experimental section contains a list of assembled conjugates. 
Purification of the maleimide-thiol conjugation utilized several methods, including 
purification by Amicon Ultra-0.5 mL Centrifugal Filters (Millipore) and RP-HPLC.  The 
Amicon columns contain a 3000 Da molecular weight cutoff membrane that would allow the 
starting materials to pass through the membrane while retaining the conjugate, which had an 
average molecular weight around 6000 Da.  This method was moderately successful, isolating 
primarily the desired product but occasionally retaining any excess oligonucleotide.  This was 
likely because the molecular weight of the oligonucleotides was just slightly larger than the 
membrane cutoff.  Although the manufacturer’s notes indicate that it should pass through the 
membrane (recommending that the molecule be at least twice the size of the membrane cutoff for 
good retention), some carryover still occurred.  Ideally this would not be an issue, as the peptide 
was present in excess during the reaction, but any excess unreacted oligonucleotide would be 
retained by the membrane.  Purification by RP-HPLC used the solvent system of 0.1M TEAA 
and CH3CN.  When purifying, we looked for differences in retention time between the 
oligonucleotide and the conjugate.  Purification was not trivial, and only a small amount of 
desired product was isolated by this method.  Spin column purification was the method of choice 
for quick purification before analysis using in vitro splicing assays.  Synthesized conjugates were 
diluted for analysis as described in Chapter 4. 
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2.2.2.2 Diels-Alder Conjugation  
The Diels Alder cycloaddition is a widely utilized conjugation reaction that consists of 
two pieces – a conjugated diene and a dienophile, which undergo a rearrangement to create two 
new carbon-carbon bonds and a stable linkage.  This reaction is advantageous in that it can 
proceed at room temperature or slightly elevated temperature under the right buffer conditions, 
forming a stable conjugate that is resistant to cleavage except under harsh conditions.  Of the 
possible diene-dienophile combinations, we chose to use a furan ring as the diene and maleimide 
as the dienophile (Scheme 2.3).  This combination has been utilized in the past for 
bioconjugation reactions with good result.
23
  As there is not a diene-modifier for oligonucleotide 
synthesis, we purchased a furan-containing acid that could be easily coupled to an antisense 
oligonucleotide via amide bond formation.  The maleimide had already been synthesized as 
described above.  The reaction could proceed at room temperature in buffer conditions described 
previously, yielding the desired product.  
 
 
For our furan diene, we chose 3(2-furyl)propionic acid, a small molecule that would 
provide some flexibility between the peptide and oligonucleotide and provide the diene 
necessary for Diels-Alder coupling.  The molecule was attached to an oligonucleotide containing 
a 3’-amino modifier via standard amide bond coupling using PyBOP as the coupling reagent.  
Attachment of the linker was moderately efficient, and an increase in temperature or reaction 
time at room temperature ensured that complete conversion would occur.  If complete conversion 
did occur, the product was used without purification.   
Scheme 2.3 
2.4 
2.5 
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The Diels-Alder reaction had been shown previously to occur at room temperature under 
aqueous conditions, and we attempted this reaction under these conditions using peptides that 
had been previously synthesized for the maleimide-thiol addition.
24,25
  Our results were not 
encouraging, as multiple reaction attempts did not produce a large quantity of product. Attempts 
to optimize the reaction focused on several areas.  Molecule solubility was explored, as both 
oligonucleotide and peptide may have suffered from some insolubility under aqueous conditions 
due to the presence of side products or coupling reagents.  Addition of CH3CN to the reaction 
mixture assisted in increasing solubility.  Reaction temperature was also explored, as it was 
postulated that the relatively large size of the two starting materials may have decreased coupling 
efficiency.  Increasing reaction temperature to 37°C appeared to increase the amount of product 
produced, but temperatures higher than this were not explored due to the possibility of 
breakdown of the Diels-Alder adduct at high temperatures.  Further improvements to the reaction 
may have involved using a size-exclusion agent such as polyvinyl alcohol (PVA) to increase 
effective concentration of the starting materials, or a chaotropic agent such as SDS or Triton-X 
that would have assisted in the breakdown of any aggregates of the two starting materials.  A 
small number of conjugates were synthesized by this method, but the reaction was abandoned 
because of the higher coupling efficiency of the maleimide-thiol reaction. 
2.2.2.3 Copper Catalyzed Azide-Alkyne Cycloaddition (‘Click Chemistry’) 
The development of ‘click chemistry’ goes back to the term coined by Sharpless in 2001, 
defining a set of characteristics for orthogonal reactions that undergo complete conversion under 
mild conditions.
26
  This definition was related to the simultaneous development by Sharpless and 
co-workers and Meldal and co-workers of the copper catalyzed azide-alkyne cycloaddition 
(CuAAC) that uses a copper catalyst to attach the two moieties together as a 1,2,3-triazole 
heterocycle.  This reaction, first described by Huisgen, has become widely utilized as a means of 
conjugating different biomolecules together, and variations of the reaction using other substrates 
such as strained cyclooctynes have seen use as in vivo conjugation substrates by researchers such 
as Bertozzi and co-workers.
27
  
Previous work done on this project using the click reaction for the synthesis of 
dendrimers (see Chapter 3) indicated that this reaction may be a viable alternative to the 
maleimide-thiol addition.  The first issue was the development of a linker that could be used in 
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solid-phase peptide synthesis.  Ideally, this linker would have a free carboxylic acid moiety for 
coupling to the N-terminus of the peptide.  We had previously synthesized a Boc-protected 2-
azidoethylamine for coupling to the C-terminus of our dendrons, but further manipulation of this 
molecule was necessary.  With the synthesis of the maleimide linker in mind, we envisioned a 
similar synthesis using this azide linker rather than glycine as one of the substrates (Scheme 2.4).  
While not as efficient as the addition of glycine to maleic anhydride, this reaction proceeded 
fairly well, providing a reasonable amount of azide linker without the need for purification.  This 
molecule could then be attached to the N-terminus of the peptide as the last step of SPPS.  
Cleavage from the resin and isolation of the product yielded the peptide containing the desired 
linker. 
 
Conjugation of the peptide and oligonucleotide was conducted under standard conditions 
for CuAAC (Scheme 2.5).  The oligonucleotide was decorated with a commercially available 3’-
alkyne moiety.  Standard reaction conditions contained catalytic amounts of copper sulfate and 
sodium ascorbate, a reducing agent to assist in the reduction of the copper ion from Cu
2+
 to Cu
+
, 
necessary for the reaction to occur.  Different buffer conditions containing some combination of 
H2O and a water-soluble organic solvent, such as DMF or t-BuOH, were used to increase the 
solubility of the starting materials and aid in the conjugation process.  Reactions run at room 
temperature for 12 hours showed a modest conversion of reactants to products, and a number of 
changes to the reaction conditions were sought to improve yield.  The relatively high boiling 
points of the solvents and stability of the starting materials to high temperatures suggested that 
an increased amount of heat would be useful in increasing reaction yield, and we utilized several 
methods to heat the reaction.  First, the use of a microwave reactor was employed to increase the 
energy available for reaction to occur, as well as to decrease reaction times.  Heating of the 
reactants in a microwave reactor or even a standard microwave for intermittent periods increased 
the yields substantially, with the only issue being loss of solvent in the standard microwave.  A 
Scheme 2.4 
2.6 
35 
 
second strategy utilized a thermal cycler, which has the benefit again of providing high 
temperatures for the coupling to occur.  Heating to near boiling point in H2O:DMF also increased 
yields, providing conjugates that could be analyzed in splicing assays. 
 
 
 
Purification of the CuAAC is not trivial.  Initial attempts to purify the molecule by RP-
HPLC were impeded by the fact that copper was not soluble in the HPLC solvents, leading to a 
buildup of excess copper on the HPLC guard column.  This problem was addressed in a number 
of ways.  Filtration of the solution through a 0.2 µm filter may have assisted in removing excess 
copper salts.  A different filtration method uses the Amicon Ultra-0.5 mL Centrifugal Filter 
columns.  An aqueous solution of the products and starting materials can be spun through the 
column, allowing the much smaller and water soluble copper sulfate and sodium ascorbate to 
pass through the membrane, leaving the desired product in the reservoir.  This would not only 
help to remove excess copper, but would also help to purify the compound by allowing some of 
the excess starting materials to pass through the membrane.  In doing so, HPLC purification was 
possible, yielding the desired conjugate for splicing assay analysis. 
2.3 Conclusions and Future Directions 
A series of synthetic RS domains have been designed and synthesized.  These molecules 
were designed to examine a number of properties of the RS domain, including overall charge, 
charge distribution, and structural presentation of charged residues.  Both α- and β-peptides have 
been synthesized and verified by ESI-MS and MALDI-MS, and a number of these molecules 
have been purified by RP-HPLC.  Although purification was not easy, optimization of 
purification conditions yielded several peptides for conjugation.  Several conjugation strategies 
were developed for connection of peptides and oligonucleotides, each having its own issues 
associated with synthesis and purification.  Each conjugation scheme yielded several peptide-
Scheme 2.5 
2.7 
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oligonucleotide conjugates that were analyzed via in vitro splicing assays as discussed in Chapter 
4.   
There are a number ways in which the synthesis and conjugation of these activators could 
be improved.  One issue is the synthesis of the peptide RS domains – as they are highly charged 
peptides, they are difficult to purify, and early attempts to purchase them from local sources were 
unsuccessful because they felt that the peptides could not be purified properly prior to 
conjugation.  Subsequent searching has identified several companies, such as Sigma Aldrich and 
New England Peptide, which appear to have much more success at synthesizing the peptides.  
Rather than spending a great deal of time on synthesis, ordering the peptides at the onset of the 
project would have saved time.  The bioconjugation reaction is another issue that should be 
addressed further.  While the reactions chosen were fairly simple in theory, a great deal of work 
was needed to optimize them for these particular substrates.  Use of a commercially available 
linker, while more expensive, may have solved this issue faster, as these reagents are usually 
optimized prior to being marketed as a coupling agent.  Further optimization of purification 
methods for both the starting materials and conjugation products would likely yield better means 
of purifying these compounds, assisting in the ease of synthesis and isolation of more products. 
Use of a different oligonucleotide could also be explored.  Several other possible sites for 
hybridization were envisioned after reviewing the work of Hua et al., including targeting the 
Htra2β1 site and the 3’ end of the exon (Figure 2.5).7  These sites differed from the original 
binding site of the first SR protein mimics, and would have provided an opportunity to see what 
effect the RS domain would have in opposition to the negative effects of antisense 
oligonucleotide binding.  Further studies on this project would benefit from analysis of these 
hybridization domains, and these molecules should be easily synthesized as the design of these 
molecules is modular. 
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In addition to DNA oligonucleotides, a number of antisense molecules could be chosen in 
future work.  The most commonly utilized molecules for antisense studies involve some sort of 
2’-OH protected RNA oligonucleotides, including 2’-OMe and 2’-OMOE (methoxy ethyl), 
which impart stability to proteases and help to increase affinity for the sense strand of the 
mRNA.  Other designs with varying properties could be explored, including morpholino 
oligonucleotides, locked nucleic acids, and peptide nucleic acids (PNA).  Krainer and co-workers 
and Caputi and co-workers utilized PNA for their SR protein mimics, as it could be synthesized 
using the same reagents as the peptide on a single resin.  Concerns with cost and availability of 
PNA deterred us from using it as the antisense nucleic acid in our initial designs, but further 
work on this project and exploration of alternatives to DNA would direct us to look again at 
whether or not PNA represents a possible alternative.  Re-examination of the market for PNA 
resources may provide commercial sources for PNA that would be more reasonable to purchase.  
This would increase the ease of synthesis, as the peptide could be built directly from the PNA 
without the need for a bioconjugation method.   
 
 
Figure 2.5: Potential Antisense Oligonucleotide Binding Sites 
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2.4 Materials and Methods 
General 
All reagents were purchased from commercial sources and used without further 
purification unless noted.  Air and moisture sensitive reactions were performed in flame-dried 
glassware under an inert atmosphere of dry nitrogen.  Dimethylformamide (DMF) was stored 
under nitrogen and over 4 Å molecular sieves.  Tetrahydrofuran (THF) was distilled from 
sodium benzophenone ketyl, and N-methylmorpholine and CH2Cl2 were distilled from calcium 
hydride before use.  All amino acids were dried by azeotropic distillation with dry DMF. 
Thin layer chromatography was performed on pre-coated silica gel plates (silica gel 60, 
F254) from EMD or Analtech, and eluting solvents are reported as volume ratios.  Compounds 
were visualized using short wave UV light, iodine vapor, ceric ammonium molybdate (CAM), 
KMnO4, or ninhydrin stains.  Azide containing compounds were visualized with ninhydrin after 
treating with a 1% solution of triphenyl phosphine in methanol.  Flash column chromatography 
was performed using Silica-P Flash Silica gel from Silicycle (40-63 µm particle size). 
1
H NMR spectra were obtained in CDCl3 or DMSO-d6 using Varian Unity 400 MHz or 
500 MHz spectrometers.  Chemical shifts (δ) are reported in ppm using residual solvent protons 
as a reference (7.26 ppm for CDCl3 and 2.50 ppm for DMSO-d6).  Mass spectra were obtained at 
the Mass Spectrometry Facility, University of Illinois.  Low resolution ESI mass spectra were 
obtained using Waters Quattro II instrument.  MALDI mass spectra were obtained using Applied 
Biosystems Voyager-DE STR and Bruker Daltonics UltrafleXtreme MALDI TOFTOF 
instruments.  Solid-phase peptide synthesis was performed manually in a specially made reaction 
vessel.  The loading of the resin used in all syntheses was 0.8 mmol amine/g resin.  All peptide 
coupling reactions were monitored using the Kaiser test, low-res ESI-MS, and low-res MADLI-
MS.  Peptides were cleaved and deprotected using trifluoroacetic acid cleavage mix (87.5:5:5:2.5 
TFA:DTT:H2O:TIPS).   
Peptide Synthesis General Procedure 
To a stirred solution of dried Fmoc-Asp(OtBu)-OH (50.0 mg, 0.12 mmol, 3 eq.) in dry 
DMF (1 mL) was added PyBOP (63.2 mg, 0.12 mmol, 3 eq.), HOBt-H2O (16.4 mg, 0.12 mmol, 
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3 eq.), and DIPEA (28.2 μL, 0.16 mmol, 4 eq.).  This solution was transferred to a solid phase 
peptide synthesis (SPPS) vessel contained pre-swelled 2-chlorotrityl resin loaded with glycine.  
The resin and peptide/coupling mixture were gently mixed with N2 gas bubbling through the 
vessel.  The reaction was monitored by ninhydrin test
28
 and mass spectrometry.  When the 
ninhydrin test indicated the reaction was complete, the vessel was drained by vacuum filtration, 
and beads rinsed with 2 mL DMF three times.  Fmoc deprotection was accomplished by the 
addition of 2 mL 20% piperidine in DMF and mixing with N2 gas three times, washing the beads 
with DMF between additions.  The ninhydrin test was also used to determine when reaction had 
gone to completion.  Subsequent amino acids were coupled in the same manner until the full 
peptide was synthesized. 
Peptide Product Characterization 
 For each completed peptide, a small sample of resin was transferred to a glass vial with 1 
mL 20% HFIP in CH2Cl2 and allowed to stand for 1 hr.  Samples were then filtered through a 
glass-wool plugged pipette into a second glass vial, concentrated in vacuo, and submitted for 
low-res ESI-MS or low-res MALDI-MS.  The following are completed peptides containing side-
chain protecting groups, with MS technique indicated. 
Linker:   Azide-Linker:  
Gly-(Asp-Arg)5-NH2 – LR-MS (ESI): calc. (M+H): 3195.9. Found (M+H): 3195.0. 
Gly-(Asp-Arg)5-linker – LR-MS (ESI): calc. (M+H): 3110.7. Found (M+H): 3110.2. 
Gly-(Asp-Arg)5-Gly-linker – LR-MS (MALDI): calc. (M+H): 3167.8. Found: (M+H): 3172.3. 
Gly-(Asp-Arg)5-Gly-azide-linker – LR-MS (MALDI): calc: (M+H): 3196.8. Found: (M+H): 
3193.8.  
Gly-(Asp-Arg)6-Gly-linker LR-MS (MALDI): calc: (M+H): 3747.5. Found: (M+H): 3757.7.  
Gly-(Asp-Arg)8-Gly-linker – LR-MS (MALDI): calc. (M+H): 4906.9. Found (M+H): 4906.5 
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Gly-(Asp-Arg)10-Gly-linker – LR-MS (MALDI): calc. (M+H): 6066.3. Found (M+H): 6066.7 
Gly-(Asp-Arg)3-Ala-(Asp-Arg)3-Gly-linker – LR-MS (MALDI): calc. (M+H): 3818.5. Found 
(M+H): 3818.0. 
Gly-(Asp-Arg)3-Asp2-Arg2-(Asp-Arg)3-Gly-linker – LR-MS (MALDI): calc. (M+H): 4906.9. 
Found (M+H): 4923.4. 
Gly-(Asp-Arg)2-Asp2-Arg2-Asp2-Arg2-(Asp-Arg)2-Gly-linker – LR-MS (MALDI): calc. (M+H): 
4906.9. Found (M+H): 4846.8. 
Gly-(Asp-Ala)6-Ala2-Asp-Ala-Gly-linker – LR-MS (ESI): calc. (M+H): 2107.3. Found (M+H): 
2107.2. 
Gly-(Asp-Ala)8-Gly-linker – LR-MS (MALDI): calc. (M+Na): 2229.0. Found (M+Na): 2229.0 
Gly-(Ala-Arg)8-Gly-linker – LR-MS (MALDI): calc. (M+H): 4105.9. Found (M+H): 4108.9. 
Gly-(βAsp-βArg)4-βAla-linker – LR-MS (MALDI): calc. (M+H): 2714.3. Found (M+H): 2715.9. 
Gly-(βAsp-βArg)5-NH2 – LR-MS (ESI): calc. (M+H): 3336.1. Found (M+H): 3336.7.   
Gly-(βAsp-βArg)5-linker – LR-MS (ESI): calc. (M+H): 3251.0. Found (M+H): 3251.0.   
Gly-(βAsp-βArg)5-βAla2-linker – LR-MS (MALDI): calc. (M+H): 3393.1. Found (M+H): 
3396.5. 
Gly-(βAsp-βArg)6-βAla-linker – LR-MS (MALDI): calc. (M+H): 4015.0. Found (M+H): 4015.3. 
Gly-(βAsp-βArg)7-βAla-linker – LR-MS (MALDI): calculated (M+H): 4537.6. Found (M+H): 
4537.9 
Gly-(βAsp-βArg)8-βAla-linker – LR-MS (MALDI): calculated (M+H): 5145.3. Found (M+H): 
5145.7. 
Gly-(βAsp-βArg)10-βAla-linker – LR-MS (MALDI): calculated (M+H): 6360.9. Found (M+H): 
6368.7. 
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Glycine-maleic acid 2.1 
To a stirred solution of maleic anhydride (981 mg, 10.0 mmol, 1 eq.) in acetic acid (5 
mL) was added glycine (826 mg, 11.0 mmol, 1.1 eq.) in acetic acid (5 mL).  After stirring for ~4 
hours, a white precipitate was isolated by vacuum filtration.  The solid was rinsed with three 5 
mL portions of ice-cold H2O, transferred to a round-bottomed flask, and dissolved in 90°C H2O.  
Re-crystallization yielded 1.31 g of the maleic acid as a white solid that was isolated by vacuum 
filtration and dried under vacuum (7.57 mmol, 75.5% yield).  
1H NMR (400 MHz, DMSO) δ 
9.19 (s, 1H, CH2NHC(O)), 6.39 (d, 1H, J = 12.5 Hz, C(O)CH=CHC(O)), 6.28 (d, 1H, J = 12.5 
Hz, C(O)CH=CHC(O)), 3.88 (d, 2H, J = 5.9 Hz, C(O)CH2N) 
 
Glycine-maleimide 2.2 
Maleic acid (1.0 g, 5.8 mmol, 1 eq.) was dissolved in toluene (25 mL), and to this 
solution was added triethylamine (1.3 mL, 9.2 mmol, 1.6 eq.).  Solution was heated to reflux 
under a Dean-Stark trap for one hour, and then cooled to room temperature.  Removal of the 
solvent by rotary evaporation yielded orange oil, which was stored under vacuum overnight.  9 
mL 1M HCl was added, and this solution was washed with three 15 mL portions of EtOAc.  The 
organic layer was dried with Na2SO4, filtered, and solvent was removed by rotary evaporation to 
yield the maleimide-functionalized glycine as a yellow solid (749 mg, 4.8 mmol, 83.2% yield).   
1
H NMR (400 MHz, CDCl3) δ 6.81 (s, 2H, CCH=CHC), 4.34 (s, 2H, C(O)CH2N) 
42 
 
 
Maleimide-Thiol Conjugation 2.3 
DTT Reduction: To a vial containing 400 µM SMN antisense oligonucleotide containing 
3’-thiol modifier (100 µL) was added 1M DTT (20 µL).  Solution was incubated at room 
temperature overnight.  Aqueous layer was extracted three times with 200 µL EtOAc to remove 
excess DTT.   
TCEP Reduction: To a vial containing 400 µM SMN antisense oligonucleotide 
containing 3’-thiol modifier (100 µL) was added 0.5M TCEP (20 µL).  Solution was incubated at 
room temperature for 2 hours.   
Conjugation: Aqueous layer containing oligonucleotide was transferred to a new vial 
containing 10 mM maleimide-containing peptide (200 µL) in 20% 0.1M triethylammonium 
acetate/CH3CN (800 µL).  Solution was incubated at 37°C overnight.  Analysis by MALDI-MS 
indicated that the desired product was synthesized.   
Maleimide-Thiol Product Characterization 
All malemide-thiol peptide-oligonucleotide products were characterized by MALDI-MS.  
Products are listed as peptide-oligonucleotide type. 
Gly-(Asp-Arg)5-Gly-linker-Bcl-x – LR-MS: calc. (M+H) 5523.3. Found (M+H): 5603.8 
Gly-(Asp-Arg)5-Gly-linker-SMN – LR-MS: calc. (M+H): 5412.1. Found (M+H): 5412.0 
Gly-(Asp-Arg)6-Gly-linker-SMN – LR-MS: calc. (M+H): 5683.3. Found (M+H): 5687.2 
Gly-(Asp-Arg)3-Ala-(Asp-Arg)3-Gly-linker-Bcl-x – LR-MS: calc. (M+H) 5470.8. Found (M+H): 
5379.5 
Gly-(βAsp-βArg)5-βAla2-linker-SMN – LR-MS: calc. (M+H): 5396.2. Found (M+H): 5394.0 
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Furan Containing Oligo 2.4 
To a stirred solution of 3(2-furyl)propionic acid (0.2 mg, 1.0 µmol, 5 eq.) in dry DMF (1 
mL) was added PyBOP (0.7 mg, 1.0 µmol, 5 eq.) and DIPEA (0.4 µL, 3.0 µmol, 10 eq.).  
Solution was stirred at room temperature for 1 hr.  Solution was transferred to a vial containing 
400 µM SMN antisense oligonucleotide containing 3’-amino modifier (500 µL, 0.25 µmol, 1 
eq.) and stirred at room temperature overnight.  Analysis by MALDI-MS indicated that the 
desired product had been synthesized.  MALDI-MS: calc. (M+H): 3981.5. Found (M+H): 
3981.7.   
 
Diels Alder Conjugation 2.5 
To a vial containing (DR)5 peptide in H2O (200 µL, 10 µmol, 100 eq.) was added 
antisense oligonucleotide in DMF (200 µL, 0.1 µmol, 1 eq.).  Solution was diluted to 500 µL 
with 0.1M phosphate buffer, pH 6.0 and incubated at 37°C overnight.  MALDI-MS analysis 
indicated a small amount of the desired product.  MALDI-MS: calc. (M+Na): 5630.1. Found 
(M+Na): 5639.1.   
 
Azide Peptide-Oligo Conjugation Linker 2.6 
44 
 
To a stirred solution of Boc-protected 2-azidoethylamine (100.0 mg, 0.5 mmol 1.1 eq.) in 
CH2Cl2 (3 mL) was added trifluoroacetic acid (3 mL).  Solution was stirred at room temperature 
under N2 for 1 hr.  Solvent was removed by azeotropic distillation and remaining solid was 
stored under vacuum overnight to remove excess TFA.  Solid was resuspended in acetic acid (5 
mL).  To this solution was added maleic anhydride (47.9 mg, 0.5 mmol, 1 eq.) in acetic acid (5 
mL) and solution was stirred at room temperature under N2 for 3 hr.  Following stirring, solvent 
was removed in vacuo and solid was resuspended in H2O and acidified to pH 1 with 1M HCl.  
Aqueous layer was transferred to a separatory funnel and extracted three times with EtOAc (20 
mL).  Combined organic layers were dried over Na2SO4, filtered into a tared round bottom flask, 
and concentrated by rotary evaporation to yield the product as an oil (20.0 mg, 20.2% yield).  
ESI-MS: calc. (M-H): 183.2. Found (M-H): 183.1. 
Azide linker was attached to (Asp-Arg)5 peptide using solid phase synthesis as described 
above.  Low-res MALDI-MS: calc. (M+H): 3194.47. Found (M+H): 3193.87. 
 
Azide Peptide-Oligo Conjugation 2.7 
To a stirred solution of peptide (400 µL, 0.4 µmol, 5 eq.) in 1:1 THF:H2O (2 mL) was 
added SMN antisense oligonucleotide containing 3’-alkyne modifier (200 µL, 0.08 µmol, 1 eq.).  
To this solution was added 1M sodium ascorbate (4 µL, 4 µmol, 50 eq.) and 1M CuSO4-5H2O (4 
µL, 4 µmol, 50 eq.).  Solution was heated in a microwave reactor at 50% power for ten 30 
second intervals then stirred overnight.  Analysis of the MALDI-MS indicated that the desired 
product had been synthesized.  MALDI-MS: calc. (M+H): 5621.1. Found (M+H): 5572.4 
 
 
 
 
45 
 
2.5 References 
(1) Kritzer, J. A.; Lear, J. D.; Hodsdon, M. E.; Schepartz, A. J.  Am. Chem. Soc. 2004, 126, 
9468. 
(2) Kritzer, J. A.; Stephens, O. M.; Guarracino, D. A.; Reznik, S. K.; Schepartz, A. Bioorg. 
Med. Chem. 2005, 13, 11. 
(3) Stephens, O. M.; Kim, S.; Welch, B. D.; Hodsdon, M. E.; Kay, M. S.; Schepartz, A. J. 
Am. Chem. Soc. 2005, 127, 13126. 
(4) Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; 
Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Science 2004, 305, 1466. 
(5) Cartegni, L.; Krainer, A. R. Nat. Struct. Biol. 2003, 10, 120. 
(6) Hua, Y.; Sahashi, K.; Hung, G.; Rigo, F.; Passini, M. A.; Bennett, C. F.; Krainer, A. R. 
Genes. Dev. 2010, 24, 1634. 
(7) Hua, Y.; Vickers, T. A.; Baker, B. F.; Bennett, C. F.; Krainer, A. R. PLoS Biol. 2007, 5, 
e73. 
(8) Hua, Y.; Vickers, T. A.; Okunola, H. L.; Bennett, C. F.; Krainer, A. R. Am. J. Hum. 
Genet. 2008, 82, 834. 
(9) Madocsai, C.; Lim, S. R.; Geib, T.; Lam, B. J.; Hertel, K. J. Mol. Ther. 2005, 12, 1013. 
(10) Porensky, P. N.; Mitrpant, C.; McGovern, V. L.; Bevan, A. K.; Foust, K. D.; Kaspar, B. 
K.; Wilton, S. D.; Burghes, A. H. Hum. Mol. Genet. 2012, 21, 1625. 
(11) Graveley, B. R. RNA 2000, 6, 1197. 
(12) Nikolakaki, E.; Drosou, V.; Sanidas, I.; Peidis, P.; Papamarcaki, T.; Iakoucheva, L. M.; 
Giannakouros, T. Biochim. Biophys. Acta 2008, 1780, 214. 
(13) Xiao, S. H.; Manley, J. L. EMBO J. 1998, 17, 6359. 
(14) Stewart, K. M.; Horton, K. L.; Kelley, S. O. Org. Biomol. Chem. 2008, 6, 2242. 
(15) Hamelberg, D.; Shen, T.; McCammon, J. A. Proc. Nat. Acad. Sci. U. S. A.  2007, 104, 
14947. 
(16) Pelsue, S.; Agris, P. F. J. Protein Chem. 1994, 13, 401. 
(17) Perutz, M. F. Pharm. Acta Helv. 1995, 69, 213. 
(18) Kritzer, J. A.; Tirado-Rives, J.; Hart, S. A.; Lear, J. D.; Jorgensen, W. L.; Schepartz, A. J. 
Am. Chem. Soc. 2005, 127, 167. 
46 
 
(19) Gelman, M. A.; Richter, S.; Cao, H.; Umezawa, N.; Gellman, S. H.; Rana, T. M. Org. 
Lett. 2003, 5, 3563. 
(20) El-Faham, A.; Subiros Funosas, R.; Prohens, R.; Albericio, F. Chemistry 2009, 15, 9404. 
(21) Ede, N. J.; Tregear, G. W.; Haralambidis, J. Bioconjug. Chem. 1994, 5, 373. 
(22) Shafer, D. E.; Inman, J. K.; Lees, A. Anal. Biochem. 2000, 282, 161. 
(23) Vieyres, A.; Lam, T.; Gillet, R.; Franc, G.; Castonguay, A.; Kakkar, A. Chem. Comm. 
2010, 46, 1875. 
(24) Marchan, V.; Grandas, A. Curr. Protoc. Nucleic Acid Chem. 2007, Chapter 4, Unit 4 32. 
(25) Marchan, V.; Ortega, S.; Pulido, D.; Pedroso, E.; Grandas, A. Nucleic Acids Res. 2006, 
34, e24. 
(26) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem. Int. Ed. 
Engl. 2002, 41, 2596. 
(27) Sletten, E. M.; Bertozzi, C. R. Acc. Chem. Res. 2011, 44, 666. 
(28) Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Anal. Biochem. 1970, 34, 595. 
 
 
 
 
 
 
 
 
 
 
 
47 
 
CHAPTER 3 
DESIGN AND SYNTHESIS OF DENDRIMER SR PROTEIN MIMICS 
3.1 Introduction 
The RS domain of SR proteins is intrinsically disordered, suggesting that a linear peptide 
mimic may be optimal for activation of alternative splicing.
1
  The amino acid residues associated 
with these domains tend to lack secondary structure, instead maintaining a more flexible form.  
This disorder is thought to be important for protein function, but exploration of this property has 
been limited.  Design of SR protein mimics containing a globular structure similar to proteins 
will help to assess whether a linear, disordered structure in a functional RS domain is an absolute 
requirement for activity.  Our goal is to examine whether the globular arrangement of amino 
acids on the periphery of the dendrimer can yield an effective splicing activator.   
Dendrimers are branched polymers of well-defined molecular weight that contain three 
essential components: a central core, repeating branching units, and peripheral functionality.  
These components influence the dendrimer architecture, solubility, and molecular interactions, 
leading to a globular, multivalent structure.
2,3
  Since their development in the 1980’s, dendrimers 
have been applied to many biological applications, most notably drug and gene delivery.
4
  A 
variety of dendrimer types have been developed that contain unique properties which are useful 
in a variety of contexts.  
Peptide dendrimers, constructed with amide bonds, are well known for their structural 
similarity to globular proteins, reflected in their development as protein mimics.
5,6
  The structural 
similarity of peptide dendrimers to proteins and protease resistance makes them ideal for use in a 
variety of biological applications and, like their linear counterparts, they can be easily 
synthesized using conventional SPPS methods. Although peptide dendrimers consist of a 
majority of our designs, several structural motifs were examined synthetically before our final 
design was analyzed by in vitro splicing, and a discussion of the evolution of our dendrimer 
motif is warranted.   
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3.2 Results and Discussion 
3.2.1 First Generation Dendrimer – Click Dendrimer 
The first-generation dendrimer RS domain mimic was designed based on the work of 
Sharpless and co-workers and utilized the Copper Catalyzed Alkyne-Azide Cycloaddition 
(CuAAC or ‘click chemistry’) to attach modified amino acids to a central aromatic core.  In their 
work, Sharpless and co-workers developed a poly-aromatic dendrimer molecule that contained 
branching aromatic groups that were iteratively coupled via click chemistry.
7
  These branching 
units could be modified to first be attached to the growing dendrimer then altered so that they 
can act as the branching unit to attach to a central core.  In our design, we took advantage of the 
iterative attachment  modification  attachment scheme to develop a series of branching 
aromatic units that could be attached to a central core to give a globular structure.   
 
 
The desired goal for the dendrimer was to place the RS dipeptides on the periphery, so 
that they could recruit the splicing machinery and induce splicing.  The initial design of the 
dendrimer structure is shown in Figure 3.1.  In order for the amino acids to be available for 
coupling to the aromatic core, a series of manipulations were required.  A priority during 
synthesis was keeping the amino acid side chain protected in order to prevent possible side 
reactions.  We envisioned a reaction scheme in which the free acid moiety of the amino acid 
Figure 3.1. First Dendrimer Design 
3.1 
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would be modified through a series of reactions to produce an amino azide for the CuAAC to the 
central core.  The aromatic core would be produced from a 3,5-dihydroxymethylbenzoate, as 
described by Sharpless and co-workers.  Manipulation of the methyl ester of the aromatic core 
could lead to several possible outcomes.  For example, reduction of the methyl ester would 
produce an alcohol moiety which could be used as a handle to produce an azide (Scheme 3.1).  
This handle could then be coupled to a second aromatic core via click chemistry, producing a full 
dendrimer.   
 
 
A second possible method would be reduction of the ester to an acid, followed by 
attachment to a central core via amide bond formation (Scheme 3.2).  Reduction of the other 
functionality followed by attachment of a second dendron would produce the dendrimer.  
Attachment of the dendrimer to the oligonucleotide would facilitated by a maleimide-thiol 
addition to the maleimide-containing branching unit attached to the core.  
Scheme 3.1 
3.2 3.3 
3.4 
3.5 
3.6 
3.7 
3.1 
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Synthesis of the modified amino acids required several manipulations to add an azide 
moiety for attachment to the aromatic core (Scheme 3.3).  First, the amino acid was converted to 
an activated mixed anhydride using ethyl chloroformate and N-methyl morpholine, which could 
then be reduced to amino alcohol 3.14 using sodium borohydride.  This reaction was 
cumbersome, requiring extremely dry conditions and solvents to ensure that the anhydride was 
not hydrolyzed by excess water.  Following isolation of the alcohol, several reactions were 
attempted to convert the molecule to an intermediate that could be used to make the azide.  Use 
of thionyl chloride or directly converting the alcohol to an azide using diphenyl phosphorazidate 
and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) were unsuccessful.
8
  Further analysis indicated 
that an iodide would be a suitable reactive intermediate for substitution with the azide.  Reaction 
of the alcohol with triphenylphosphine, imidazole, and iodine resulted in substitution of iodide 
3.15 in good yields.  Following this reaction, simple stirring of the molecule with sodium azide 
in DMF yielded amino azide 3.16 in good yield.  As a final step, the Fmoc protecting group of 
the amino azide was removed and substituted with an acetyl group (3.3), to prevent any non-
specific interactions during subsequent couplings.   
Scheme 3.2 
3.8 3.3 
3.9 
3.10 
3.11 
3.12 
3.13 
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Synthesis of the aromatic core was more straightforward (Scheme 3.3).  Reaction of the 
3,5-dihydroxymethylbenzoate with propargyl bromide and potassium carbonate produced the di-
alkyne 3.17 in high yields.  Several paths were envisioned with the methyl ester.  First, it was 
reduced to an alcohol using lithium aluminum hydride, in order to be converted to the azide via a 
chloride intermediate.  Synthesis of chloride 3.2 was not trivial, and only a small amount could 
be isolated.  Subsequent attempts to synthesize the iodide instead of the chloride were also only 
moderately successful, and the azide was never isolated.  A second pathway in which the methyl 
ester was reduced to acid 3.8 was more successful, and the acid was isolated in good yields. 
The next step in the synthesis was attachment of the modified amino azides to the central 
core via CuAAC.  A series of reaction conditions, varying the amounts of copper catalyst and 
solvents, were examined in order to determine the optimal reaction conditions for attachment.  
The products of the reaction were visualized by ESI-MS, and several produced good yields of the 
desired product that was purified by flash column chromatography.  Although we were able to 
synthesize the aspartic acid-containing dendron, we abandoned this reaction scheme because it 
was too cumbersome for synthesis of reasonable quantities of the desired dendrimer.   
There were a number of issues associated with the synthesis of this dendrimer.  First, the 
conversion of the amino acids to amino azides was not trivial, requiring multiple reaction steps 
Scheme 3.3 
3.14 3.15 
3.16 
3.3 
3.17 3.2 
3.8 
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that needed optimization and multiple attempts in order to be successful.  In fact, the entire 
reaction scheme was only successful with aspartic acid.  Repeated attempts with arginine were 
only moderately successful, and even then only the amino alcohol was isolated.  Use of lysine 
instead of arginine was somewhat more successful, but even then only the amino iodide could be 
isolated.  The attachment of the completed dendrons to the core was inherently challenging, as it 
required selective reduction of one side chain of the core while keeping the other in azide form.  
Different iterations of the core attempted to address this issue, but no design was settled upon 
that could simplify the attachment of two different components to the core.  In addition, 
attachment of the maleimide to the core was difficult, and if it were completed prior to the final 
coupling step there was a chance that the ring would reopen in the presence of base.  Finally, this 
design would only incorporate four charged residues on the periphery, and these would not even 
exist as dipeptides, making it extremely unlikely that we would see splicing activation.  Thus, a 
different reaction scheme was sought. 
3.2.2 Second Generation Dendrimer – Aromatic Polylysine Dendrimer 
After spending a great deal of time optimizing the synthesis of the dendrimer, it became 
clear that the number of cumbersome manipulations and relatively limited potential for modular 
construction made this design too difficult to develop further.  In particular, the difficulties with 
synthesizing and isolating both arginine and lysine amino azides indicated that this design would 
not be useful to pursue further.  We hoped to find a design that required fewer cumbersome 
manipulations, a relatively straightforward synthetic pathway, and the possibility for substitution 
of different amino acids on the periphery.   
After exploring a number of possible pathways, we settled upon a dendrimer design 
based on the work of Liskamp and co-workers.
9,10
  This group has designed a number of 
different dendrimer motifs incorporating many types of functionality, including peptides and 
sugar moieties, as well as different types of connectivity between the branching units and central 
core.  More importantly, these molecules have been used in a variety of biological contexts, from 
drug delivery to molecules that could be used to disrupt and block binding to cellular 
membranes.
11-14
  These designs would present a viable starting point for our second generation 
dendrimers. 
53 
 
 
 
We designed a series of dendrimers containing several components (Figure 3.2).  The 
core of the dendrimer contains a trivalent aromatic motif with two identical attachment points for 
addition of the branching units, and a third, orthogonal attachment point for addition of the 
antisense oligonucleotide.  This design uses the same aromatic core as the first generation 
dendrimer, but substitutes 2-bromoethylamine linkers for propargyl groups, to which can be 
attached the branching units via amide bond formation.  The third site on the core is a modified 
version of the branch point from the first generation dendrimer, but instead of directly converting 
the starting methyl ester into an azide group, the ester can be reduced to an acid and then reacted 
with a linker molecule that attaches to the antisense oligo. 
The dendrimer branches were redesigned to incorporate a polylysine branching dendron 
decorated on the periphery with the charged amino acids.
2
  This design was advantageous over 
the previous design for several reasons.  First, the dendron branches can be synthesized using 
solid phase peptide synthesis (SPPS) in a manner similar to the peptides, making them much 
simpler synthetically than the previously designed amino azides.  Second, the number of residues 
on the periphery can be increased significantly compared to the previous dendrimer, from 2-4 
amino acids to at least 8 dipeptide repeats on a full dendrimer.  Third, the design is now modular, 
so that different combinations of amino acids can be added to the periphery from a single, 
Figure 3.2. Second Dendrimer Design 
3.18 
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branching lysine dendron.  Synthesis of the lysine dendrons is straightforward, using the same 
SPPS methods that were utilized for peptide synthesis (Scheme 3.4).  Reaction times and 
equivalents of starting materials were increased as peripheral amino acids were added in order to 
ensure complete conversion. Terminal amino groups were acetylated upon completion of the 
synthesis to prevent undesired side reactions during attachment to the aromatic core.  These 
dendrons were cleaved from the resin using HFIP to retain the side-chain protecting groups, 
again to prevent possible side reactions during attachment to the core.  
 
In order to test the ability of the dendrimers to act as 
SR protein mimics, we synthesized series of peptide 
dendrons containing different numbers and arrangements of 
charged amino acids (Table 3.1).  These include dipeptides 
containing aspartic acid, arginine, and alanine in different 
combinations.  With this design, full dendrimers contain 8 
dipeptide repeat motifs on the periphery.  These dendrimers 
can be used to determine if molecules containing the DR 
dipeptide motif will be effective splicing activators, despite 
the non-linear presentation of amino acid residues.  We 
have also designed and synthesized several peptide 
dendrons containing tetrapeptide motifs on the periphery, with the potential to contain 16 
dipeptide repeats on the periphery of a single dendrimer.  These molecules should be better 
splicing activators than the dendrimers containing dipeptide repeats, as the tetrapeptide motif has 
been shown to be effective at activating splicing in protein models.
15
  Synthesis of these 
Peptide Dendrons 
DR 
DA 
AR 
AA 
DRDR 
DDRR 
Scheme 3.4 
Table 3.1. Synthesized Peptide Dendrons 
3.19 3.20 3.21 
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molecules required a large excess of reagents, as it was difficult to access multiple coupling sites 
with such large molecules. 
 
The design and synthesis of the aromatic core went through several iterations as we 
determined the most effective dendrimer-oligonucleotide conjugation scheme.  Our first design 
began the 3,5-dihydroxymethylbenzoate (Scheme 3.5).  To synthesize the branching connection 
points, 2-bromoethylamine was first protected using di-tert-butyl dicarbonate and then attached 
to the free hydroxyl groups of the core to produce 3.23.  These reactions proceeded in good 
yields, with some impurities due to the unreacted di-tert-butyl dicarbonate.  Subsequent 
saponification of the methyl ester and coupling of an Fmoc-protected ethylene diamine to give 
the aromatic core proceeded in moderate yields.  The next steps included removal of the Fmoc 
group using piperidine and attachment of the maleimide linker discussed in Chapter 2, but this 
reaction proved cumbersome and isolation of the product was not completed (although the 
product was identified by ESI-MS).  We attempted to circumvent this step by first attaching the 
maleimide linker to the Fmoc-protected ethylene diamine, which produced molecule 3.26 in 
moderate yields (Scheme 3.6), but this design was inherently flawed as the maleimide is 
sensitive to basic conditions.  The Fmoc group must be removed by piperidine, and attempts to 
do so and couple with the aromatic core in situ were unsuccessful.  An additional redesign was 
necessary.  
Scheme 3.5 
3.22 3.23 
3.24 
3.25 
3.18 
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With our experience using CuAAC, as well as the many examples utilizing CuAAC as a 
bioconjugtion method, we explored using it as a method for attaching the dendrimer core to the 
oligonucleotide.  To develop a handle for attachment, we substituted azide linker 3.27 for the 
Fmoc-ethylene diamine (Scheme 3.7).  This would prevent unwanted problems with the 
maleimide linker and provide a point for attachment of the oligonucleotide.  The azide linker was 
synthesized from the Boc-protected 2-bromoethylamine by nucleophilic substitution using 
sodium azide in DMF, in a similar fashion to our previous amino azide synthesis.  This synthesis 
was straightforward and provided good yields of the product without the need for purification, as 
aqueous workup removed the excess sodium azide and sodium bromide salts.  Removal of the 
Boc-protecting group using TFA and subsequent attachment to the core via amide bond 
formation provided aromatic core 3.28 in good yield. 
 
Attachment of the polylysine dendrons to the aromatic core was not trivial, and several 
attempts at redesigning the molecules to improve efficiency of coupling were moderate 
successful.  To attach the dendrons to the core, the core was first deprotected with TFA to 
remove the Boc-protecting groups.  Pre-activation of the dendrons using PyBOP and HOBt in 
the presence of diisopropylethylamine (DIPEA) was thought to be important to ensure that the 
coupling would occur in high yields.  Upon mixing, the formation of a single-armed dendrimer 
Scheme 3.7 
Scheme 3.6 3.26 
3.22 3.23 
3.27 
3.28 
3.29 
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seemed to be straightforward and proceeded in good yields.  Unfortunately, little to none of the 
desired full-sized dendrimer was isolated in our initial reaction attempts.   
We speculated that there were a number of possible reasons for this lack of attachment.  
Running the reaction at room temperature was likely to not be energetically favorable and did 
not provide enough energy for the second attachment to occur.  However, subsequent attempts 
using higher temperatures did not produce much more of the desired product.  A more important 
issue was probably the large amount of steric bulk on the dendrons.  The side-chains of the 
amino acids on the periphery remained protected to prevent unwanted side reactions, increasing 
the steric bulk substantially and likely preventing the second dendron piece from being able to 
access the core after the first had attached.  We attempted to address this issue using several 
approaches (Figure 3.3).   
 
 
The first was to increase the length between the core and the dendrons while keeping the 
same attachment scheme for coupling the pieces together.  Several methods were utilized to 
extend the branching units from the core, including attaching Boc-protected glycine (3.30) and 
using CuAAC to attach the Boc-protected 2-azidoethylamine (3.31).  In addition, we began 
synthesis of dendrons containing 2-3 glycine residues instead of starting directly with lysine, 
again increasing the distance between the branching moieties and the core attachment.  In both 
Figure 3.3. Extended Dendrimer Monomers 
3.30 
3.31 
3.21 
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cases, increasing the length did not seem to produce a more favorable result.  A third possible 
issue was that the dendrons may have been undergoing aggregation due to the hydrophobic 
nature of the branching lysine residues.  Use of a chaotropic agent such as SDS was employed to 
address this problem, but again there was no improvement in the yield of the desired product.   
3.2.3 Third Generation Dendrimer – Polylysine Dendrimer 
One of the difficulties associated with the synthesis of the full dendrimer as described in 
design 2 is that the peptide dendrons contain a great deal of steric bulk.  As amide coupling was 
chosen to attach the dendrons to the central core, it was necessary to keep the side chains of the 
peripheral residues protected, increasing the steric bulk significantly.  As a result, only a small 
amount of the full dendrimer could be synthesized, with a majority of product being a single-
armed dendrimer.  We addressed the issue producing a set of different molecules that increased 
the length between the central core and the branches, both on the branching dendron and on the 
core itself.  Unfortunately, attempts to couple these pieces proved no more successful than with 
the original core.  Redesign to incorporate the click reaction into the attachment rather than 
amide coupling (as utilized by Liskamp and co-workers in a number of papers) also did not 
prove successful (see Materials and Methods).  Attempts to increase the yield of the full-sized 
product by using chaotropic agents such as sodium dodecyl sulfate (SDS) were also 
unsuccessful.  Therefore, we sought a new strategy that still took advantage of the branching 
lysine dendrons without the issues associated with attaching the dendrons to the central core. 
Examining the dendrimer design, we determined that the main issue appeared to be 
coupling of the dendrons to the core, and that there was potential for redesign at the point of 
attachment between the core and the branches.  By simply repurposing the 2-azidoethylamine 
linker an attachment point on the branching dendron, the dendron itself could then be attached to 
the antisense oligonucleotide via CuAAC (Scheme 3.8).  While this design decreased the 
number of charged residues, as well as the fully globular shape of the dendrimer in design 2, it 
would still be an interesting molecule series to examine, as the branching dendrons would 
provide a different arrangement of charged residues with which the spliceosome can interact.   
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Synthesis of the branching dendrons was conducted as described above.  Following 
synthesis, the dendrons were cleaved from the resin and isolated.  We then coupled the dendrons 
with the 2-azidoethylamine that had been synthesized as the linker from the aromatic core to the 
oligonucleotide.  This synthesis was straightforward, and produced a moderate yield of desired 
product 3.32 for coupling to the oligonucleotide.  The only issues associated with this synthesis 
involved the aqueous workup of dendrons that contained alanine substitutions.  Loss of product 
was occasionally an issue, and a modified aqueous workup that did not use strong acid or base 
ensured that the desired product was isolated.  These dendron pieces were simple and 
straightforward to synthesize and isolate, making them much easier to work with than those 
molecules that had been designed previously. 
3.2.4 Dendrimer-Oligonucleotide Coupling 
Coupling of the dendrimer to the antisense oligonucleotide was developed in parallel with 
the coupling of peptides and oligonucleotides discussed in Chapter 2, and a more thorough 
discussion of the coupling methods can be found there.  Our initial dendrimers were designed to 
incorporate the maleimide ring onto the core for attachment of the oligonucleotide via 
maleimide-thiol addition.  Unfortunately, these molecules were never synthesized, and no 
attempts were made to couple the molecules in this fashion. 
3.2.4.1 Copper-Catalyzed Alkyne-Azide Cycloaddition 
The next strategy using our second generation dendrimers was to utilize the CuAAC to 
attach the dendrimer core to the antisense oligonucleotide.  Synthesis of the dendrimer core is 
described above, producing the azide-containing moiety for attachment.  We were able to obtain 
Scheme 3.8 
3.22 3.27 
3.21 3.32 
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antisense oligonucleotides containing a commercially available 3’-alkyne modifier.  As we were 
only able to obtain a single-armed dendrimer from our synthesis, the click reaction was 
attempted using that molecule.  Unfortunately, no products were obtained from this reaction.  
Due to the relatively small amount of material, this dendrimer conjugation was not pursued 
further. 
 
 
Conjugation of the third generation dendrimer to the antisense oligonucleotide was much 
more successful than other iterations.  As described previously, we utilized the same antisense 
oligonucleotide containing the 3’-alkyne moiety to conjugate to our azide-containing dendrons 
under the conditions for CuAAC described by Sharpless and co-workers and further developed 
by others (Scheme 3.9).  The first attempts at this conjugation used catalytic copper sulfate and 
sodium ascorbate at room temperature, yielding a modest amount of the desired product and a 
good deal of starting material.  Attempts to optimize the reaction examined reaction solvent, 
switching from H2O:t-BuOH mixtures to H2O:DMF mixtures to increase solubility of the starting 
materials.  Different amounts of copper were also examined, which indicated that a larger than 
catalytic amount would be necessary to increase yields.  Reaction temperature was varied as 
well, with use of microwave reactors, standard microwave ovens, and thermal cyclers all being 
used to increase the energy available for the reaction to occur.  Optimization of these conditions 
yielded a number of molecules that could be used for splicing. 
Purification of the dendrimers was not trivial.  As described in Chapter 2, the biggest 
issue associated with purification was buildup of excess copper on the guard column when using 
RP-HPLC.  Removal of this copper using filtration devices alleviated the load of copper on the 
Scheme 3.9 
3.32 3.33 
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column, making it easier to purify the molecules by HPLC.  Several other methods were 
attempted to purify these conjugates further, including membrane dialysis and filtration using the 
Amicon Ultra-0.5 mL Centrifugal filtration devices.  Purification by dialysis led to precipitation 
of the reaction mixture into the dialysis membrane, and the products isolated by dialysis 
contained primarily the antisense oligonucleotide.  Filtration through Amicon columns was much 
more successful, yielding a reasonable amount of the products for analysis.  Further work using 
the CuAAC would benefit from additional purification methods.  In particular, size exclusion 
chromatography would be the ideal choice for separating out the products from starting 
materials.  Removal of the copper before purification would ensure that issues with column-
clogging would be eliminated. 
3.2.4.2 Alkyne-Cyclooctyne Conjugation 
A recently emerging area in the field of bioconjugation is the use of strained cyclooctynes 
as the alkyne moieties for coupling to azides.  Developed in great part by Bertozzi and co-
workers, these molecules have been used in a number of systems both in vitro and, more 
importantly, in vivo, to synthesize biologically relevant molecules.
16-18
  Some examples include 
the conjugation of fluorescent markers to cellular surfaces for visualization of cells, as well as 
18
F-labeling of cancer imaging agents for analysis and testing of chemotherapeutics.
19
  This 
reaction has been dubbed “strain-promoted click chemistry” because the strain of the 
cyclooctyne ring provides the energy necessary for the reaction to occur, and also “copper-free 
click chemistry” because, in the presence of this strain, a copper catalyst is not necessary for the 
reaction to occur.  Our issues associated with the synthesis and purification of the CuAAC led us 
to investigate whether dendrimer-oligonucleotide conjugation using this method would be a 
viable option for synthesizing our molecules. 
The field of strain-promoted click chemistry is relatively new, meaning that only a small 
number of commercial sources were available for the synthesis of our conjugates.  Although 
recent advances have led to the development of nucleotide-based cyclooctynes that can be 
incorporated into DNA synthesis procedures such as PCR, few are available that can be used in 
conventional DNA synthesis machines.
20
  More importantly, there are few commercially 
available 3’-modifiers containing the desired cyclooctyne moiety.  A search of possible sources 
led us to a company called Click Chemistry Tools, which had a number of possible options.  As 
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stated, no 3’-modifiers were available, although there exist cyclooctyne phosphoramidites that 
can be incorporated during 3’-5’ DNA synthesis at the 5’-end.  Unfortunately, our chosen 
oligonucleotide source (Yale) could not include these molecules in their synthesis, so a 
phosphoramidite was not the proper choice for our molecules.  Instead, we were able to obtain a 
strained cyclooctyne linker with an activated NHS-ester for coupling to a free amino group.  The 
3’-amino modifier is readily available, and we obtained both the modified oligonucleotide and 
the cyclooctyne linker for coupling. 
 
 
Attachment of the activated NHS-ester cyclooctyne to the antisense oligonucleotide 
required optimization to produce desired product 3.34 (Scheme 3.10).  Initial attempts to couple 
the starting materials used 1X phosphate buffered saline, pH 7.4, which was used in the protocol 
accompanying the molecule to couple the NHS-ester to a protein target.  This reaction produced 
only a small amount of the desired product after reacting overnight, suggesting that the 
conditions needed to be improved.  The pH of the reaction may not have been sufficiently high to 
make the amine nucleophilic, so the buffer was changed to 0.1M phosphate buffer, pH 8.0.  
Continued stirring at room temperature only increased the yield slightly.  Taking our previous 
experience with coupling reactions into account, it was decided that the temperature of the 
reaction was to blame for our lack of success.  By increasing the reaction temperature to 37°C 
using an incubator, and in later reaction to 94°C using a thermal cycler, we were able to get 
complete conversion of the antisense oligonucleotide to contain the strained cyclooctyne linker.  
One difficulty with using phosphate buffer for our reaction, however, was that the phosphate 
made analysis by MALDI-MS much more difficult.  Removal of phosphate buffer salts by 
standard desalting methods such as Zip Tip is an alternative possibility for analysis, if phosphate 
must be used.  Knowing that a base was necessary to drive the reaction, a different strategy was 
used in which a slight excess of diisopropylethylamine (DIPEA) was added to the reaction 
mixture in DMF.  Mixing of this reaction using the thermal cycler led to complete conversion to 
the product, with the added benefit that the reaction could be easily monitored.   
Scheme 3.10 
3.34 
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Synthesis of the dendrimer-oligonucleotide conjugate using the strained cyclooctyne was 
conducted under several sets of conditions (Scheme 3.11).  The conditions suggested by the 
manufacturer were to use a buffer in which the azide-containing molecule is soluble and then add 
the strained cyclooctyne, so we first used an H2O:CH3CN buffer, as it was used for previous 
syntheses.  These reactions were moderately successful, producing only a small amount of the 
desired product.  With our experience using the thermal cycler to attach the strained cyclooctyne 
linker, we attempted the reaction under the same conditions using DMF as the buffer because of 
its increased boiling temperature.  Gratifyingly, this strategy was successful, producing desired 
product 3.35 with complete conversion of the oligonucleotide starting material.  These molecules 
could be purified as described previously, yielding the desired product for splicing. 
3.3 Conclusions and Future Work 
The design and synthesis of dendrimer RS domains was accomplished after going 
through several iterations of design.  An initial design using modified amino acids and CuAAC 
or ‘click chemistry’ produced several molecules, but proved too cumbersome a synthesis to 
pursue for production of the dendrimers.  A second design based on the work of Liskamp and co-
workers substituted the modified amino acids for polylysine dendrons, as well as modifying the 
central core for conjugation of the dendrimer to the antisense oligonucleotide via click chemistry.  
This design was much more successful and straightforward to synthesize, but suffered from 
issues with steric bulk associated with the final synthetic step.  Repeated attempts yielded only a 
single-armed dendrimer.  Further redesign that removed the aromatic core and directly attached 
the dendron to the antisense oligonucleotide via click chemistry proved to be the most 
straightforward, generating several molecules that could be purified and examined by in vitro 
Scheme 3.11 
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splicing assay.  Purification of these molecules was not trivial, requiring several alternative 
methods to remove the copper from the reaction mixture prior to other purification strategies.  
Finally, an alternative method for conjugation utilizing strained cyclooctyne rings provided a 
second method for attachment of the dendrimer and antisense oligonucleotide that could be more 
easily purified and used in splicing assays, as discussed in Chapter 4. 
Future synthesis and analysis of the dendrimer-oligonucleotide conjugates could benefit 
from the analysis of alternative conjugation methods.  For example, different synthetic 
procedures for polypeptides attached to a central aromatic core via CuAAC or amide bond 
formation may provide additional methods for synthesizing the full dendrimer.  Optimization of 
reaction temperature, solvent, and use of chaotropic agents could also improve the dendrimer 
synthesis.  If the branching lysine dendron is utilized as the sole dendrimer piece, use of 
additional conjugation methods such as commercially available linkers may be useful in ensuring 
that the coupling occurs with high efficiency and that the final product can be easily purified.  
Alternative methods for purification of these molecules would also be beneficial, so that issues 
associated with methods such as RP-HPLC can be avoided.  With some optimization, these 
molecules could be more easily synthesized, purified, and analyzed for splicing modulation 
activity. 
3.4 Materials and Methods 
 
Amino Alcohol 3.14 
 To a cooled (0°C) solution of dry Fmoc-protected aspartic acid (2.0 g, 4.9 mmol, 1 eq.) in 
dry THF (5 mL) in a flame-dried Schlenk flask under argon was added N-methylmorpholine 
(641 μL, 5.8 mmol, 1.2 eq.) and ethylchloroformate (558 μL, 5.8 mmol, 1.2 eq.).  The solution 
was stirred for 45 min at 0°C under argon and monitored by TLC (4:1 Hexane:EtOAc).   
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 After stirring, the N-methylmorpholonium salts were filtered off through an oven-dried, 
cotton-plugged Pasteur pipette into a flame-dried Schlenk flask under argon using an oven-dried 
Pasteur pipette.  The precipitate was washed with dry THF (10 mL) into the Schlenk flask.  The 
combined filtrates were cooled to 0°C with an ice bath.  To the solution was added a solution of 
NaBH4 (276 mg, 7.3 mmol, 1.5 eq.) in H2O (2.8 mL).  The reaction was stirred at 0°C until H2 
evolution ceased (45 min), when TLC indicated that the reaction was complete.  Excess NaBH4 
was quenched by the addition of 10 mL H2O.  The organic layer was washed with 20 mL sat. 
NaHCO3.  The aqueous layer was washed with three 20 mL portions of EtOAc, and the 
combined organic layers were dried over Na2SO4.  The solution was filtered and concentrated in 
vacuo, followed by flash column chromatography (1:1 EtOAc:Hexane), to yield 1.41 g (3.6 
mmol, 73.2% yield) of pure solid.  
1
H NMR (400 MHz, CDCl3) δ 7.76 (d, 2H, J = 7 Hz, Fmoc 
ar), 7.59 (d, 2H, J = 7 Hz, Fmoc ar), 7.40 (t, 2H, J = 7 Hz, Fmoc ar), 7.31 (t, 2H, J = 7 Hz, Fmoc 
ar), 5.50 (d, 1H, J = 8 Hz, NH), 4.40 (d, 2H, J = 6.8 Hz, Fmoc CH2), 4.21 (t, 1H, J = 6.8 Hz, 
Fmoc CH), 4.11 (m, 1H, CHCH2OH), 3.73 (t, 2H, J = 5 Hz, CH2OH), 2.57 (m, 2H, J = 6 Hz, 
CH2(O)OtBu), 2.46 (t, 1H, J = 5.5 Hz, CH2OH), 1.45 (s, 9H, -OtBu) 
 
Amino Iodide 3.15 
 To a stirred solution of triphenylphosphine (396 mg, 1.5 mmol, 3 eq.) in dry CH2Cl2 (4 
mL) was added solid I2 (639 mg, 2.5 mmol, 5 eq.).  After allowing I2 to dissolve, imidazole (171 
mg, 2.5 mmol, 5 eq.) was added, followed by the amino alcohol (200.0 mg, 0.5 mmol, 1 eq.).  
The solution was stirred for 3 h, when starting material was consumed as confirmed by TLC (5:1 
EtOAc:Hexane).  Solvent was removed in vacuo using a secondary trap, and flash column 
chromatography (5:1 EtOAc:Hexane) yielded 186.3 mg (0.37 mmol, 73% yield) of the iodide as 
a pure white solid.  
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, 2H, J = 7.6 Hz, Fmoc ar), 7.60 (dd, 
2H, J = 7,1 Hz, Fmoc ar), 7.40 (t, 2H, J = 7,1 Hz, Fmoc ar), 7.32 (t, 2H, J = 7 Hz, Fmoc ar), 5.36 
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(d, 1H, J = 9 Hz, NH), 4.39 (2H, Fmoc CH2), 4.23 (t, 1H, J = 7 Hz, Fmoc CH), 3.96 (m, 1H, 
CHCH2I), 3.42 (m, 2H, CH2I), 2.61 (ddd, 2H, J = 16,6 Hz, CH2(O)OtBu), 1.54 (s, 9H, -OtBu) 
 
Amino Azide 3.16 
 To a stirred solution of iodide (500 mg, 0.99 mmol, 1 eq.) in dry DMF (5 mL) was added 
NaN3 (320 mg, 4.9 mmol, 5 eq.).  The solution was stirred at room temperature for 5 h, when 
starting material was consumed as confirmed by TLC (2:1 Hexane:EtOAc).  Solvent was 
removed in vacuo using a secondary trap, and flash column chromatography (2:1 
Hexane:EtOAc) yielded 358 mg (0.85 mmol, 86.0% yield) of the azide as a pure white solid.  
1
H 
NMR (400 MHz, CDCl3) δ 7.77 (d, 2H, J = 7 Hz, Fmoc ar), 7.59 (d, 2H, J = 7,1 Hz, Fmoc ar), 
7.41 (t, 2H, J = 7 Hz, Fmoc ar), 7.31 (t, 2H, J = 7,1 Hz, Fmoc ar), 5.43 (d, 1H, J = 9 Hz, NH), 
4.41 (2H, J = 17,10,7 Hz, Fmoc CH2), 4.22 (t, 1H, J = 7 Hz, Fmoc CH), 4.14 (m, 1H, 
CHCH2N3), 3.51 (2H, J = 20,12,5 Hz, CH2N3), 2.53 (d, 2H, J = 6 Hz, CH2(O)OtBu), 1.46 (s, 9H, 
-OtBu) 
 
Acyl-protected Amino Azide 3.3 
 To a stirred solution of the Fmoc-protected azide (358 mg, 0.85 mmol, 1 eq.) in dry DMF 
(3 mL) was added 1 mL of a solution of 20% piperidine in DMF (200 μL, 2.0 mmol).  The 
solution was stirred for 35 min, when starting material was consumed as confirmed by TLC (4:1 
EtOAc:Hexane).  Excess acetic anhydride (400 μL, 4.2 mmol, 5 eq.) was added, and the solution 
was stirred for 16 h.  The solution was concentrated in vacuo using a secondary trap and 
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remaining solvent was acidified to pH 2 using 1 M HCl as indicated by pH paper.  The aqueous 
layer was washed with three portions of 20 mL EtOAc, and the combined organic layers were 
washed with 1 x 10 mL H2O and brine.  Combined organics were dried over Na2SO4, filtered, 
and concentrated in vacuo.  Flash column chromatography (4:1 EtOAc:Hexane) yielded 170 mg 
(0.70 mmol, 83.0% yield) as a colorless oil.  
1
H NMR (400 MHz, CDCl3) δ 6.27 (d, 1H, J = 8 
Hz, NH), 4.37 (m, 1H, CHCH2N3), 3.48 (m, 2H, CH2N3), 2.50 (m, 2H, CH2(O)OtBu), 2.00 (s, 
3H, CH3(O)NH), 1.46 (s, 9H, -OtBu).   
 
Methyl ester 3.17 
 To a stirred solution of methyl-3,5-dihydroxybenzoate (5.00 g, 29.7 mmol, 1 eq.) and 
propargyl bromide (7.32 mL, 65.4 mmol, 2.2 eq.) in acetone (90 mL) was added K2CO3 (4.52 g, 
32.7 mmol, 1.1 eq.) and 18-crown-6 (31.4 mg, 0.12 mmol, 0.004 eq.).  The solution was heated 
to reflux and stirred for 18 h.  The reaction mixture was filtered, and then evaporated to dryness.  
The solid residue was re-suspended in methanol and cooled to 0°C, yielding a yellow solid.  The 
solid was filtered, washed with methanol, and dried under reduced pressure to yield 5.624 g 
yellow solid (23.0 mmol, 77.4% yield). 
1
H NMR (400 MHz, CDCl3) δ 7.30 (d, 2H, J = 2.4 Hz, 
aromatic), 6.81 (t, 1H, J = 2.4 Hz, aromatic), 4.72 (d, 4H, J = 2.5 Hz, CH2C≡CH), 3.91 (s, 3H, 
OCH3), 2.55 (t, 2H, J = 2.5 Hz, CH2C≡CH) 
 
Benzoic Acid 3.8 
 To a stirred solution of methyl ester 21 (500 mg, 2.1 mmol, 1 eq.) in DMF (2 mL) was 
added aqueous 4M NaOH (2.6 mL, 10 mmol, 5 eq.).  The solution was heated to 70°C and 
stirred until the starting material was consumed as indicated by TLC (3:2 EtOAc:Hexane).  The 
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solution was cooled to room temperature and acidified with 1 M HCl to pH 2, as indicated by pH 
paper.  A yellow solid precipitated from the solution that was collected by vacuum filtration and 
used without further purification: 424.8 mg, 2.1 mmol, 90.1% yield.  
1
H NMR (400 MHz, 
CDCl3) δ 7.35 (d, 2H, J = 2.4 Hz, aromatic), 6.85 (t, 1H, J = 2.4 Hz, aromatic), 4.73 (d, 4H, J = 
2.4 Hz, CH2C≡CH), 2.56 (t, 2H, J = 2.5 Hz, CH2C≡CH) 
 
Benzyl Alcohol  
 To a stirred suspension of methyl ester 21 (500 mg, 2.0 mmol, 1 eq.) in dry THF (10 mL) 
was added excess LiAlH4 (715.7 mg, 20.5 mmol, 10 eq.).  After stirring at room temperature for 
2 h, the solution was cooled to 0°C.  Excess LiAlH4 was quenched by subsequent addition of 
H2O (720 µL), 3M NaOH (720 µL), and an additional portion of H2O (2.2 mL).  The mixture 
was stirred at room temperature for 20 min, followed by addition of Na2SO4 and stirring for an 
additional 15 min.  The solid was filtered under vacuum and washed with CH2Cl2.  The filtrate 
was concentrated under reduced pressure to yield 408 mg solid (1.9 mmol, 94.4% yield).  
1
H 
NMR (400 MHz, CDCl3) δ 6.64 (d, 2H, J = 2.4 Hz, aromatic), 6.55 (t, 1H, J = 2.4 Hz, aromatic), 
4.68 (d, 4H, J = 2.4 Hz, CH2C≡CH), 4.67 (d, 2H, J = 6 Hz, CH2OH), 2.53 (t, 2H, J = 2.4 Hz, 
CH2C≡CH), 1.66 (t, 1H, J = 6 Hz, CH2OH) 
 
Benzyl Chloride 3.2 
 To a cooled (0°C) solution of benzyl alcohol 22 (500 mg, 2.3 mmol, 1 eq.) and dry 
pyridine (374 µL, 4.6 mmol, 2 eq.) in dry CH2Cl2 (5 mL) was added SOCl2 (252 µL, 3.5 mmol, 
1.5 eq.) slowly.  The solution was allowed to warm to room temperature and was stirred 
overnight.  The reaction was quenched with water (10 mL) and aqueous and organic layers were 
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separated.  The organic layer was washed with 3 portions of 20 mL H2O.  The aqueous layer was 
washed with two portions of 20 mL CH2Cl2.  Combined organic layers were dried over Na2SO4.  
The solution was filtered and concentrated in vacuo followed by flash column chromatography 
(2:1 CH2Cl2:hexane) to yield 116.8 mg (0.50 mmol, 21.5% yield).  
1
H NMR (400 MHz, CDCl3) 
δ 6.65 (d, 2H, J = 2.4 Hz, aromatic), 6.58 (t, 1H, J = 2.3 Hz, aromatic), 4.69 (d, 4H, J = 2.4 Hz, 
CH2C≡CH), 4.53 (s, 2H, CH2Cl), 2.54 (t, 2H, J = 2.4 Hz, CH2C≡CH) 
 
Click Dendron 
 To a stirred solution of azide (573 mg, 1.4 mmol, 2 eq.) in 1:1:1 t-BuOH/H2O/CH2Cl2 (6 
mL) was added alkyne (166 mg, 0.7 mmol, 1 eq.).  To this solution was added Na ascorbate 
(13.4 mg, 0.07 mmol, 0.1 eq.) and CuSO4-5H2O (16.9 mg, 0.07 mmol, 0.1 eq.).  The reaction 
was stirred at room temperature under N2 overnight.  The solution was diluted with 10 mL H2O 
and 1 mL concentrated NH4OH and stirred for ten minutes.  It was then transferred to a 
separatory funnel and extracted with three 20 mL portions of EtOAc.  The combined organic 
layers were washed with one 10 mL portion of saturated NaCl, dried over Na2SO4, and 
concentrated in vacuo.  Flash column chromatography (3:1 EtOAc:Hexane) yielded the desired 
product as a white solid (452 mg, 0.4 mmol, 61% yield).  
1
H NMR (400 MHz, CDCl3) δ 7.72 (d, 
4H, J = 7.5 Hz, Fmoc ar H), 7.56 (s, 2H, triazole C=CHN), 7.54 (t, 4H, J = 3.6 Hz, Fmoc ar H), 
7.37 (t, 4H, J = 7.5 Hz, Fmoc ar H), 7.29 (t, 4H, J = 7.5 Hz, Fmoc ar H), 7.27 (s, 2H, central ar 
H), 6.77 (s, 1H, central ar H), 5.65 (d, 2H, J = 8 Hz, CHNHC(O)), 5.13 (s, 4H, OCH2C(N)=C), 
4.60 (m, 4H, J = 7.2 Hz, Fmoc CH2), 4.39 (m, 6H, NHCHCH2N [peak overlap]), 4.17 (t, 2p, J = 
6.7 Hz, Fmoc CH), 3.88 (s, 3H, C(O)OCH3), 2.47 (d, 4H, J = 5.7 Hz, CHCH2C(O)), 1.44 (s, 
18H, OC(CH3)3). LR-MS (ESI): calc. (M+H): 1089.2. Found (M+H): 1089.9. 
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Boc-protected 2-bromoethylamine 3.22 
 To a stirred solution of 2-bromoethylamine (3.0 g, 14.6 mmol, 1 eq.) in dry CH2Cl2 (20 
mL) was added Boc2O (3.2 g, 14.6 mmol, 1 eq.), and solution was cooled to 0°C with an ice 
bath.  Triethylamine (2.5 mL, 17.6 mmol, 1.2 eq.) was added to the solution dropwise over 20 
min.  The solution was stirred at 0°C for 30 min, warmed to room temperature, and stirred for 24 
hr.  Reaction mixture was diluted with CH2Cl2 (10 mL), transferred to a separatory funnel, and 
washed with 20 mL portions of 1M KHSO4, H2O, and brine.  The organic layer was dried over 
Na2SO4, filtered, and concentrated by rotary evaporation to yield the Boc-protected 2-
bromoethylamine as a clear oil (2.7 g, 11.2 mmol, 83% yield).  
1
H NMR (400 MHz, CDCl3) δ 
4.95 (bs, 1H, CH2NHC(O)), 3.53 (t, 2H, J = 5.5 Hz, CH2CH2NH), 3.45 (t, 2H, J = 5.5 Hz, 
BrCH2CH2), 1.45 (s, 9H, OC(CH3)3) 
 
Boc-protected 2-azidoethylamine 3.27 
To a stirred solution of Boc-protected 2-bromoethylamine (500.0 mg, 2.2 mmol, 1 eq.) in 
dry DMF (10 mL) was added NaN3 (725.2 mg, 11.2 mmol, 5 eq.).  Solution was stirred at room 
temperature under N2 overnight.  Following stirring, solvent was removed in vacuo and 
resuspended in EtOAc (30 mL).  Solution was transferred to a separatory funnel and washed 
twice with H2O (20 mL) and once with brine (20 mL).  The organic layer was dried over 
Na2SO4, filtered into a tared round bottom flask, and concentrated by rotary evaporation to yield 
the product as a yellow oil (373.3 mg, 89.9% yield).  
1
H NMR (500 MHz, CDCl3) δ 4.81 (bs, 1H, 
CH2NHC(O)), 3.42 (t, 2H, J = 5.5 Hz, CH2CH2NH), 3.31 (t, 2H, J = 5.5 Hz, N3CH2CH2), 1.45 
(s, 9H, OC(CH3)3).  ESI-MS calc. (M+H): 187.2. Found (M+H): 187.3. 
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Fmoc-Protected Maleimide Linker 3.26 
To a stirred solution of glycine-maleimide (84.2 mg, 0.5 mmol, 1.5 eq.) in dry DMF (5 
mL) was added PyBOP (368.6 mg, 0.7 mmol, 2 eq.), HOBt-H2O (108.5 mg, 0.7 mmol, 2 eq.), 
and DIPEA (184.8 µL, 1.1 mmol, 3 eq.).  Solution was stirred at room temperature for 10 
minutes.  To this solution was added Fmoc-protected ethylene diamine (100.0 mg, 0.4 mmol, 1 
eq.).  Solution was stirred at room temperature overnight.  Following stirred, solvent was 
removed in vacuo and solid was resuspended in 30 mL EtOAc.  Solution was transferred to a 
separatory funnel and washed with H2O (20 mL), 1M KHSO4 (20 mL), saturated NaHCO3 (20 
mL), and brine (20 mL).   The organic layer was dried over Na2SO4 and concentrated under 
reduced pressure.  Purification using flash column chromatography (95:5 CH2Cl2:MeOH) 
yielded the product as a clear oil (17.4 mg, 11.7% yield). 
1
H NMR (400 MHz, CDCl3) δ 7.77 (d, 
2H, J = 7.6 Hz, Fmoc ar), 7.59 (2, 2H, J = 7.2 Hz, Fmoc ar), 7.41 (t, 2H, J = 7.6 Hz, Fmoc ar), 
7.32 (t, 2H, J = 7.6 Hz, Fmoc ar), 6.75 (s, 2H, CCH=CHC), 6.41 (bs, 1H, NH), 5.24 (bs, 1H, 
NH), 4.39 (d, 2H, J = 6.8 Hz, Fmoc CH2), 4.21 (t, 1H, J = 6.8 Hz, Fmoc CH), 4.16 (s, 2H, 
C(O)CH2N), 3.37 (t, 2H, J = 6 Hz, FmocNHCH2CH2), 3.32 (t, 2H, J = 6 Hz, FmocNHCH2CH2). 
ESI-MS calc. (M+H): 420.4. Found (M+H): 420.2. 
 
Boc-Protected Methyl ester 3.23 
 To a stirred solution of Boc-protected (2-bromoethyl) amine (1.5 g, 6.7 mmol, 2.5 eq.) in 
dry DMF (10 mL) was added 3,5-dihydroxymethyl benzoate (0.45 g, 2.7 mmol, 1 eq.).  To this 
solution was added K2CO3 (1.7 g, 12.0 mmol, 4.5 eq.) and 18-crown-6 (2.8 mg, 0.01 mmol, 
0.004 eq.).  Solution was heated to 40°C and stirred under nitrogen gas for 16 hr.  Solution was 
filtered through a medium frit Buchner funnel to remove a brown solid, and concentrated in 
vacuo.  The residue was redissolved in EtOAc (30 mL), transferred to a separatory funnel and 
washed with two 20 mL portions of H2O and 20 mL brine.  Organic layer was dried over 
Na2SO4, filtered, and concentrated in vacuo, yielding the desired product as a clear oil (970 mg, 
80% yield).  
1
H NMR (400 MHz, CDCl3) δ 7.17 (d, 2H, J = 2 Hz, ar H), 6.63 (t, 1H, J = 2 Hz, ar 
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H), 4.98 (bs, 2H, CH2NHC(O)), 4.03 (t, 4H, J = 5 Hz, OCH2CH2NH), 3.89 (s, 3H, C(O)OCH3), 
3.53 (q, 4H, J = 5 Hz, OCH2CH2NH), 1.45 (s, 18H, OC(CH3)3) 
 
Boc-Protected Acid  
To a stirred solution of Boc-protected methyl ester (478.5 mg, 1.1 mmol, 1 eq.) in 14:5 
dioxane:MeOH (19 mL) was added NaOH (210.6 mg, 5.3 mmol, 5 eq.).  Solution was stirred at 
room temperature overnight.  Following stirring, the reaction was acidified to pH 2 using 1M 
HCl.  Solvent was removed in vacuo and solid was resuspended in 30 mL EtOAc and transferred 
to a separatory funnel.  Solvent was washed twice with 20 mL 1M HCl, twice with 20 mL 1M 
KHSO4, and twice with 20 mL brine.  Organic layer was dried over Na2SO4, filtered, and 
concentrated in vacuo, yielding the desired product as a clear oil (388.5 mg, 83.8%).  
1
H NMR 
(400 MHz, CDCl3) δ 7.19 (d, 2H, J = 4 Hz, ar H), 6.64 (t, 1H, J = 4 Hz, ar H), 5.06 (bs, 2H, 
CH2NHC(O)), 4.03 (t, 4H, J = 5 Hz, OCH2CH2NH), 3.54 (q, 4H, J = 5 Hz, OCH2CH2NH), 1.45 
(s, 18H, OC(CH3)3).  ESI-MS (M+H): calc.: 441.2. Found (M+H): 441.2. 
 
Boc-Protected Fmoc-Amine Core 3.24 
To a stirred solution of Boc-protected acid (400.9 mg, 0.9 mmol, 1 eq.) in dry DMF (5 
mL) was added PyBOP (710.8 mg, 1.4 mmol, 1.5 eq.), HOBt-H2O (209.2 mg, 1.4 mmol, 1.5 
eq.), and DIPEA (475.2 µL, 2.7 mmol, 3 eq.).  Solution was allowed to stir at room temperature 
for 10 minutes.  To this solution was added Fmoc-protected ethylene diamine (385.6 mg, 1.4 
mmol, 1.5 eq.).  Solution was allowed to stir at room temperature overnight.  Following stirring, 
solvent was removed in vacuo and solid was resuspended in 30 mL EtOAc and transferred to a 
separatory funnel.  The organic layer was washed with 20 mL H2O, 20 mL 6M HCl, 20 mL H2O, 
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20 mL 4M NaOH, 20 mL H2O, and 20 mL brine.  Solution was dried over Na2SO4, filtered, and 
concentrated by rotary evaporation.  Purification by flash column chromatography (2:1 
EtOAc:Hexane) yielded the product as a white solid (193.8 mg, 30% yield).  
1
H NMR (400 
MHz, CDCl3) δ 7.74 (d, 2H, J = 7.6 Hz, Fmoc ar), 7.55 (2, 2H, J = 7.2 Hz, Fmoc ar), 7.38 (t, 2H, 
J = 7.2 Hz, Fmoc ar), 7.27 (t, 2H, J = 7.2 Hz, Fmoc ar), 7.03 (bs, 1H, FmocNH) 6.94 (d, 2H, J = 
4 Hz, ar H), 6.50 (t, 1H, J = 4 Hz, ar H), 5.39 (bs, 1H, ArC(O)NH) 4.97 (bs, 2H, CH2NHC(O)), 
4.40 (d, 2H, J = 6.8 Hz, Fmoc CH2), 4.17 (t, 1H, J = 6 Hz, Fmoc CH) 3.96 (t, 4H, J = 5 Hz, 
OCH2CH2NH), 3.58 (m, 2H, FmocNHCH2CH2), 3.47 (m, 5H, OCH2CH2NH and FmocNHCH2), 
1.44 (s, 18H, OC(CH3)3). ESI-MS (M+H) calc.: 705.8. Found (M+H): 705.3. Elemental Analysis 
calc. CHN: 64.7:6.9:8.0. Found CHN: 63.1:6.7:7.4.   
 
Boc-Protected Azide Core 3.28 
To a stirred solution of Boc-protected 2-azidoethylamine (85.9 mg, 0.5 mmol, 1.5 eq.) in 
dry CH2Cl2 (5 mL) was added TFA (5 mL).  Solution was stirred at room temperature for 1 hr.  
After stirring, solvent was removed in vacuo and stored under vacuum overnight.  In a second 
vial, to a stirred solution of Boc-protected acid (135.4 mg, 0.3 mmol, 1 eq.) was added PyBOP 
(240.0 mg, 0.5 mmol, 1.5 eq.), HOBt-H2O (70.6 mg, 0.5 mmol, 1.5 eq.), and DIPEA (160.5 µL, 
0.9 mmol, 3 eq.).  Solution was stirred at room temperature for 10 minutes.  Solution was 
transferred to vial containing 2-azidoethylamine and stirred at room temperature overnight.  
Following stirring, solvent was removed by azeotropic distillation and solid was resuspended in 
30 mL EtOAc and transferred to a separatory funnel.  The organic layer was washed with 20 mL 
H2O, 20 mL 6M HCl, 20 mL H2O, 20 mL 4M NaOH, 20 mL H2O, and 20 mL brine.  Solution 
was dried over Na2SO4, filtered, and concentrated by rotary evaporation.  Purification by flash 
column chromatography (3:1 EtOAc:Hexane) yielded the product as a white solid (83.1 mg, 
53.2% yield). 
1
H NMR (400 MHz, CDCl3) δ 6.97 (bs, 1H, N3CH2CH2NH), 6.93 (d, 2H, J = 1.2 
Hz, ar H), 6.48 (t, 1H, J = 2.4 Hz, ar H), 5.15 (bs, 2H, CH2NHC(O)), 3.97 (t, 4H, J = 5.2 Hz,  
OCH2CH2NH), 3.60 (m, 2H, N3CH2CH2), 3.54 (m, 2H, N3CH2CH2), 3.48 (m, 4H, 
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OCH2CH2NH), 1.44 (s, 18H, OC(CH3)3).  ESI-MS (M+H) calc.: 509.3. Found (M+H): 509.4. 
Elemental Analysis calc. CHN: 54.32:7.13:16.52. Found CHN: 54.24:7.01:15.32.   
 
Extended Boc-Protected Azide Core 3.30 
To a stirred solution of Boc-protected azide core (180.8 mg, 0.4 mmol, 1 eq.) in CH2Cl2 
(3 mL) was added TFA.  Solution was stirred at room temperature for 1 hr.  Following stirring, 
solvent was removed in vacuo and remaining solid was stored under vacuum.  In a separate flask, 
to a stirred solution of Boc-protected glycine (187.0 mg, 1.1 mmol, 3 eq.) was added PyBOP 
(555.2 mg, 1.1 mmol, 3 eq.), HOBt-H2O (163.4 mg, 1.1 mmol, 3 eq.), and DIPEA (371.2 µL, 2.1 
mmol, 6 eq.).  Solution was stirred at room temperature for 10 minutes, then transferred to flask 
containing the azide core and stirred at room temperature overnight.  Following stirring, solvent 
was removed by azeotropic distillation and solid was resuspended in 30 mL EtOAc and 
transferred to a separatory funnel.  The organic layer was washed with 20 mL H2O, 20 mL 6M 
HCl, 20 mL H2O, 20 mL 4M NaOH, 20 mL H2O, and 20 mL brine.  Solution was dried over 
Na2SO4, filtered, and concentrated by rotary evaporation.  Product was identified by ESI-MS 
(M+H) calc.: 623.7. Found (M+H): 623.4. 
 
Click Core Acid 
To a stirred solution of Boc-protected 2-azidoethylamine (250.0 mg, 1.3 mmol, 2.1 eq.) 
in 1:1 THF:H2O (6 mL) was added benzoic acid (147.2 mg, 0.6 mmol, 1 eq.).  To this solution 
was added sodium ascorbate (63.3 mg, 0.3 mmol, 0.5 eq.) and CuSO4-5H2O (79.8 mg, 0.3 mmol, 
0.5 eq.).  Solution was stirred at room temperature overnight.  Following stirring, solvent was 
removed in vacuo and solid was resuspended in 30 mL saturated NaHCO3.  Aqueous layer was 
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extracted with three portions of 20 mL CH2Cl2.  A white solid crashed out from extraction 
solution that was collected by vacuum filtration.  Organic layer was dried over Na2SO4, filtered, 
and concentrated in vacuo to yield a small amount of product.  Collected white solid was 
identified by ESI-MS as desired product (384.3 mg, 99.8% yield).  LR-MS (ESI): calc. (M+Na): 
625.6. Found (M+Na): 625.4.   
 
Click Core Azide 3.31 
To a stirred solution of Boc-protected 2-azidoethylamine (149.4 mg, 0.8 mmol, 1.5 eq.) 
in CH2Cl2 (3 mL) was added TFA (3 mL).  Solution was stirred at room temperature for 1 hr.  
Following stirring, solvent was removed in vacuo and solid was stored under vacuum overnight.  
In a separate flask, to a stirred solution of click core acid (322.2 mg, 0.5 mmol, 1 eq.) in dry 
DMF (5 mL) was added PyBOP (417.5 mg, 0.8 mmol, 1.5 eq.) and DIPEA (279.1 µL, 1.6 mmol, 
3 eq.).  Solution was stirred at room temperature for 1 hr.  Solution was then transferred to flask 
containing 2-azidoethylamine and stirred at room temperature overnight.  Following stirring, 
solvent was removed by azeotropic distillation and solid resuspended in 30 mL saturated 
NaHCO3.  Aqueous layer was extracted with three portions of 20 mL CH2Cl2.  Combined 
organic layers were dried over Na2SO4, filtered, and concentrated by rotary evaporation.  
Purification by flash column chromatography (95:5 CH2Cl2:MeOH) yielded the desired product 
as identified by ESI-MS.  LR-MS (ESI): calc. (M+H): 671.7. Found (M+H): 671.3.   
 
Fmoc-protected Lysine 
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 Lysine-HCl (1.0 g, 5.5 mmol, 1 eq.) was dissolved in H2O (200 mL) and 1,4-dioxane (80 
mL).  To this stirred solution was added NaHCO3 (965.9 mg, 11.5 mmol, 2.1 eq.), followed by 
Fmoc-OSuc (3.7 g, 11.0 mmol, 2 eq.) as a solution in 1,4-dioxane dropwise.  The solution was 
stirred overnight under air at room temperature.  Addition of H2O (400 mL) and acidification to 
pH 1 with 1M HCl yielded a white solid.  The solid was filtered through a 150 mL course frit 
filter and dried under vacuum over Dryerite overnight, yielding the protected lysine as a white 
solid (2.8 g, 4.7 mmol, 86% yield).  
1
H NMR (400 MHz, CDCl3) δ 7.74 (d, 4H, J = 7 Hz, Fmoc 
ar H), 7.56 (t, 4H, J = 6.3 Hz, Fmoc ar H), 7.37 (t, 4H, J = 7.2 Hz, Fmoc ar H), 7.28 (t, 4H, J = 
7.4 Hz, Fmoc ar H), 5.60 (m, 2H, OC(O)NH), 4.87 (m, 1H, NHCHC(O)), 4.38 (m, 4H, Fmoc 
CH2), 4.17 (t, 2H, J = 6.2 Hz), 3.19 (m, 2H, J = 7 Hz, CHCH2CH2CH2CH2NHC(O)), 1.77 (m, 
2H, CHCH2CH2CH2CH2NHC(O)), 1.52 (m, 2H, CHCH2CH2CH2CH2NHC(O)), 1.40 (m, 2H, 
CHCH2CH2CH2CH2NHC(O)).  LR-MS (ESI): calc. (M+H): 591.7.  Found (M+H): 591.5. 
 
Lysine Dendron 3.19 – Standard Synthesis  
To a stirred solution of dried Fmoc-Lys(Fmoc)-OH (42.5 mg, 0.07 mmol, 3 eq.) in dry 
DMF (1 mL) was added PyBOP (37.5 mg, 0.07 mmol, 3 eq.), HOBt-H2O (11.0 mg, 0.07 mmol, 
3 eq.), and DIPEA (16.7 μL, 0.1 mmol, 4 eq.).  This solution was transferred to a solid phase 
peptide synthesis (SPPS) vessel containing pre-swelled 2-chlorotrityl resin loaded with glycine 
(30.0 mg, 0.02 mmol, 1 eq.).  The resin and peptide/coupling mixture were gently mixed with N2 
gas bubbling through the vessel.  The reaction was monitored by ninhydrin test
21
 and MALDI-
MS.  The vessel was drained by vacuum filtration, and beads rinsed with 2 mL DMF three times.  
Fmoc deprotection was accomplished by the addition of 2 mL 20% piperidine in DMF and 
mixing with N2 gas three times, washing the beads with DMF between additions.  The coupling 
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and deprotection steps were repeated with twice the equivalents of coupling reagents, yielding 
the lysine dendron which was used without further purification.  LR-MS containing Fmoc-
protected amines (MALDI): calc. (M+H) 1348.5. Found (M+H): 1348.8. 
 
 
Lysine-Asp-NH2 Dendron 3.20 – Standard Synthesis  
To a stirred solution of dried Fmoc-Asp(OtBu)-OH (118.5 mg, 0.3 mmol, 12 eq.) in dry 
DMF (2 mL) was added PyBOP (149.9 mg, 0.3 mmol, 12 eq.), HOBt-H2O (44.1 mg, 0.3 mmol, 
12 eq.), and DIPEA (66.8 μL, 0.4 mmol, 16 eq.).  This solution was transferred to a solid phase 
peptide synthesis (SPPS) vessel containing pre-swelled 2-chlorotrityl resin loaded with the Lys-
NH2 dendron (30.0 mg, 0.02 mmol, 1 eq.).  The resin and peptide/coupling mixture were gently 
mixed with N2 gas bubbling through the vessel overnight.  The reaction was monitored by 
MALDI-MS.  The vessel was drained by vacuum filtration, and beads rinsed with 2 mL DMF 
three times.  Fmoc deprotection was accomplished by the addition of 2 mL 20% piperidine in 
DMF and mixing with N2 gas three times, washing the beads with DMF between additions, 
which yielded the dendron without further purification. LR-MS containing Fmoc-protected 
amines (MALDI): calc. (M+H) 2033.3. Found (M+H): 2035.2. 
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Lysine-Asp-Arg-Ac Dendron 3.21 – Standard Synthesis  
To a stirred solution of dried Fmoc-Arg(Pbf)-OH (186.9 mg, 0.3 mmol, 12 eq.) in dry 
DMF (2 mL) was added PyBOP (149.9 mg, 0.3 mmol, 12 eq.), HOBt-H2O (44.1 mg, 0.3 mmol, 
12 eq.), and DIPEA (66.8 μL, 0.4 mmol, 16 eq.).  This solution was transferred to a solid phase 
peptide synthesis (SPPS) vessel containing pre-swelled 2-chlorotrityl resin loaded with the Lys-
Asp-NH2 dendron (30.0 mg, 0.02 mmol, 1 eq.).  The resin and peptide/coupling mixture were 
gently mixed with N2 gas bubbling through the vessel overnight.  The reaction was monitored by 
MALDI-MS.  The vessel was drained by vacuum filtration, and beads rinsed with 2 mL DMF 
three times.  Fmoc deprotection was accomplished by the addition of 2 mL 20% piperidine in 
DMF and mixing with N2 gas three times, washing the beads with DMF between additions.  
After deprotection, added 2 mL acetic anhydride and mixed with N2 gas bubbling through the 
vessel overnight.  The vessel was drained and rinsed as described above, yielding the acyl-
protected dendron.  LR-MS containing Fmoc-protected amines (MALDI): calc. (M+H) 3667.4. 
Found (M+H): 3671.3.  LR-MS containing Acyl-protected amines (MALDI): calc. (M+H) 
2946.6. Found (M+H): 2950.1. 
Dendron Derivative Characterization 
For each completed dendron, a small sample of resin was transferred to a glass vial with 
1 mL 20% HFIP in CH2Cl2 and allowed to stand for 1 hr.  Samples were then filtered through a 
glass-wool plugged pipette into a second glass vial, concentrated in vacuo, and submitted for 
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low-res MALDI-MS.  The following are completed dendrons containing side-chain protecting 
groups, with peripheral dipeptides and N-terminal protecting group indicated. 
Gly-DR-acetyl: LR-MS: calc. (M+H): 2947.6, Found (M+H): 2947.3 
Gly2-DR-acetyl: LR-MS: calc. (M+H): 3004.6, Found (M+H): 3004.5 
Gly3-DR-acetyl: LR-MS: calc. (M+H): 3061.7, Found (M+H): 3061.8 
Gly3-(DR)2-acetyl: LR-MS: calc. (M+H minus Pbf protecting group): 5128.2, Found (M+H 
minus Pbf protecting group): 5129.6 
Gly3-D2R2-acetyl: LR-MS: calc. (M+H): 5380.5, Found (M+H): 5380.3 
Gly3-DA-acetyl: LR-MS: calc. (M+Na): 1733.9, Found (M+Na): 1732.5 
Gly3-AR-acetyl: LR-MS: calc. (M+H): 2659.3, Found (M+H): 2659.3 
Gly3-AA-Fmoc: LR-MS: calc. (M+Na): 2052.9, Found (M+Na): 2052.8 
 
 
Full Dendrimer Synthesis – Boc-Protected Aromatic Core + Peptide Dendron (3.29) 
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To a stirred solution of Boc-protected aromatic core containing azide linker (17.2 mg, 
0.03 mmol, 1 eq.) in CH2Cl2 (3 mL) was added TFA (3 mL).  Solution was stirred at room 
temperature for 1 hr.  Following stirring, solvent was removed in vacuo and stored under 
vacuum.  In a separate flask, to a stirred solution of peptide dendron (398.2 mg, 0.1 mmol, 4 eq.) 
in dry DMF (3 mL) was added PyBOP (140.6 mg, 0.3 mmol, 8 eq.), HOBt-H2O (41.4 mg, 0.3 
mmol, 8 eq.), and DIPEA (47.0 µL, 0.3 mmol, 8 eq.).  Solution was stirred at room temperature 
for 10 minutes, then transferred to flask containing aromatic core and stirred at room temperature 
under N2 overnight.  Following stirring, solvent was removed by azeotropic distillation and solid 
was resuspended in 30 mL EtOAc and transferred to a separatory funnel.  Organic layer was 
washed with 20 mL H2O, 20 mL 6M HCl, 20 mL H2O, 20 mL 4M NaOH, 20 mL H2O, and 20 
mL brine.  Organic layer was dried over Na2SO4, filtered, and concentrated by rotary 
evaporation.  A small amount of desired product was identified by MALDI-MS, with a majority 
being the single-addition product.   
Full Dendrimer Characterization 
Products listed describe composition of peptide dendron side chain.  Single-armed and 
full dendrimers are listed when found. 
Gly-DR-acetyl – single-arm: LR-MS: calc. (M+H): 3237.9, Found (M+H): 3238.0 
Gly-DR-acetyl – full: LR-MS: calc. (M+H): 6166.4, Found (M+H): 6166.5 
Gly2-DR-acetyl – single-arm: LR-MS: calc. (M+H): 3294.9, Found (M+H): 3295.5 
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Dendron + 2-azidoethylamine 3.32 
To a stirred solution of Boc-protected 2-azidoethylamine (33.3 mg, 0.2 mmol, 5 eq.) in 
CH2Cl2 (2 mL) was added trifluoroacetic acid (2 mL).  Solution was stirred at room temperature 
under N2 for 1 hr.  Solvent was removed in vacuo and remaining solid was stored under vacuum 
overnight to remove excess TFA.  In a separate vial, to a stirred solution of dendron (109.4 mg, 
0.04 mmol, 1 eq.) in dry DMF (3 mL) was added PyBOP (93.0 mg, 0.2 mmol, 5 eq.), HOBt-H2O 
(27.4 mg, 0.2 mmol, 5 eq.), and DIPEA (31.1 µL, 0.2 mmol, 5 eq.).  Solution was stirred at room 
temperature for 1 hr.  Solution was then transferred to flask containing 2-azidoethylamine and 
stirred at room temperature under N2 overnight.  Solvent was removed by azeotropic distillation, 
and solid was resuspended in 30 mL EtOAc and transferred to a separatory funnel.  The organic 
layer was washed with 20 mL H2O, 20 mL 1M HCl, 20 mL H2O, 20 mL 4M NaOH, 20 mL H2O, 
and 20 mL brine.  The organic layer was dried over Na2SO4, filtered into a tared round bottom 
flask, and concentrated by rotary evaporation to yield the product as an off-white solid (31.5 mg, 
28.2% yield). 
Dendron-Azide Linker Derivative Characterization 
Products were characterized by MALDI-MS.  The following are completed dendrons 
containing azide linker and side-chain protecting groups, with peripheral dipeptides and N-
terminal protecting group indicated. 
Gly2-DR-acetyl: LR-MS: calc. (M+H): 3071.7, Found (M+H): 3071.4 
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Gly3-DR-acetyl: LR-MS: calc. (M+H): 3128.8, Found (M+H): 3128.9 
Gly3-(DR)2-acetyl: LR-MS: calc. (M+H): 5447.6, Found (M+H): 5447.6 
Gly3-AR-acetyl: LR-MS: calc. (M+H minus Pbf protecting group): 2476.0, Found (M+H minus 
Pbf protecting group): 2476.0 
Gly3-AA-acetyl: LR-MS: calc. (M+H): 1378.5, Found (M+H): 1387.8 
 
Full Dendrimer – Copper Catalyzed Click Reaction with Acid Core 
 To a stirred solution of peptide dendron containing azide linker (53.4 mg, 0.02 mmol, 2 
eq.) in 1:1 THF:H2O (2 mL) was added aromatic core (2.0 mg, 0.01 mmol, 1 eq.), sodium 
ascorbate (0.9 mg, 0.004 mmol, 0.5 eq.), and CuSO4-5H2O (0.1 mg, 0.004 mmol, 0.05 eq.).  
Solution was heated to 100°C for 10 minutes in a microwave reactor.  A solid crashed out of 
solution, which was washed with three portions of 1 mL MeOH.  MALDI-MS indicated that the 
single-armed product was isolated.   
Full Dendrimer Characterization 
Products listed describe composition of peptide dendron side chain.  Single-armed and 
full dendrimers are listed when found. 
Gly2-DR-acetyl – single-arm, protected side-chains: LR-MS: calc. (M+H): 3301.9, Found 
(M+H): 3308.6 
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Gly2-DR-acetyl – single-arm: LR-MS: calc. (M+H): 2068.2, Found (M+H): 2069.3 
Gly3-DR-acetyl – single-arm, protected side-chains: LR-MS: calc. (M+H): 3358.5, Found 
(M+H): 3361.5 
 
 
Copper Catalyzed Click Dendrimer Conjugation 3.33 
To a solution of peptide dendron Gly3-DR-acetyl containing azide linker (1.9 mg, 1.0 
µmol, 10 eq.) in CH2Cl2 (2 mL) was added TFA (2 mL) and solution was stirred at room 
temperature for 1 hr.  Solvent was removed in vacuo and solid was stored under vacuum.  Solid 
was resuspended in 200 µL DMF.  To this solution was added SMN antisense oligonucleotide 
containing 3’-alkyne modifier (250 µL, 0.1 µmol, 1 eq.), 1M sodium ascorbate (4 µL, 4 µmol, 40 
eq.), and 1M CuSO4-5H2O (4 µL, 4 µmol, 40 eq.).  Solution was heated in a thermal cycler at 
94°C for 30 minutes, then 72°C for 30 minutes.  Product was analyzed by MALDI-MS, 
indicating that desired product had been synthesized.  LR-MS: calc. (M-H): 5860.5, Found (M-
H): 5860.7 
 
Dibenzocyclooctyne-Modified Oligonucleotide 3.34 
To a vial containing 400 µM SMN antisense oligonucleotide containing 3’-amino 
modifier in nuclease-free H2O (100 µL, 0.04 µmol, 1 eq.) was added 10 mM 
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dibenzocyclooctyne-NHS ester in DMF (50 µL, 0.5 µmol, 13 eq.).  To this solution was added 
20 µL DIPEA, then diluted to 250 µL with DMF.  Solution was heated in a thermal cycler to 
94°C for 30 minutes, then 72°C for 30 minutes.  Analysis by MALDI-MS indicated that desired 
product was synthesized.  LR-MS: calc. (M+H): 4231.9. Found (M+H): 4231.1.  
 
Dibenzocyclooctyne Click Reaction 3.35 
To a vial containing DBCO-antisense oligonucleotide in DMF (200 µL, 0.04 µmol, 1 eq.) 
was added peptide dendron Gly3-DR-acetyl containing azide linker (3.8 mg, 2.0 µmol, 50 eq.) in 
100 µL DMF.  Solution was heated in a thermal cycler to 94°C for 30 minutes, then 72°C for 30 
minutes.  Analysis by MALDI-MS indicated that desired product was synthesized.  LR-MS: calc. 
(M+H): 6126.9. Found (M+H): 6108.5.  
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CHAPTER 4 
ANALYSIS OF SYNTHETIC SR PROTEINS BY IN VITRO SPLICING ASSAY 
4.1 Introduction 
4.1.1 Analysis of pre-mRNA Splicing 
Analysis of the alternative splicing reaction is an important part of determining the 
effects of splicing modulators.  By determining the differences associated with certain molecules, 
it is possible to identify effective splicing modulators that could lead to potential therapeutic 
treatments.  The products of the splicing reaction, including intermediates and fully spliced final 
products, can be analyzed by a number of methods that will isolate and visualize the mRNA.  
The classic method for analysis of mRNA is Northern blotting, in which the mRNA is separated 
by gel electrophoresis and then transferred to a second membrane where it can interact with 
antibodies to produce a signal that can be read, either via fluorescence or radioactivity.
1
  Newer 
and more efficient methods of mRNA detection, including quantitative RT-PCR, have made it 
easier to analyze mRNA splicing products.
2-5
 The effects of splicing modulators could initially 
only be determined by isolating the mRNA from cells or harvested tissues, time-consuming tasks 
that first require delivery of the molecules to the cells and then isolation of the mRNA.  This 
method creates limitations to the possible molecules that can be analyzed – splicing modulators 
need to cross the cellular membrane (using a transfection reagent or passive cellular uptake), and 
then cells or tissues need to be destroyed to harvest the mRNA.  Thus, other methods for analysis 
of splicing modulators would be helpful.   
The study of mRNA alternative splicing yielded an assay that could be utilized for 
analysis of splicing products and the effects of splicing modulators without needing to isolate the 
mRNA from cells.  In the 1980’s, Krainer and co-workers began systematically analyzing the 
products of alternative splicing in order to determine what factors are necessary for the splicing 
reaction to occur.
6-10
  In doing so, they determined what factors could be used to reconstitute the 
splicing reaction outside of the cell, developing an in vitro splicing assay that contained the most 
important components – ATP and creatine phosphate as the energetic phosphate donor; 
magnesium ions to help facilitate the proteins that assisted in splicing; a buffer to keep the pH at 
a consistent value; a size-exclusion polymer such as polyvinylalcohol to increase the effective 
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concentration of the proteins; and nuclear extracts containing the correct splicing proteins, often 
isolated from HeLa cells.
11
  By adding these components in the proper ratios, one can 
reconstitute the environment necessary for pre-mRNA splicing to occur in vitro, without the need 
for the cellular conditions.   
There are several advantages to using the in vitro splicing assay over cellular assays.  
First and most importantly, splicing modulators can be used without the need for transfection 
across the cellular membrane.  While small molecules may be able to diffuse across the cell 
membrane, larger molecules with properties that are unfavorable for cellular conditions are more 
difficult to analyze.  These molecules can be analyzed more easily using an in vitro assay.  The 
mRNA and proteins necessary for splicing to occur are readily available in vitro without needing 
to cross a cellular membrane.  Second, visualization of the mRNA can be much more easily 
accomplished than with cellular assays, as the mRNA can be transcribed from DNA using a 
radiolabeled NTP, incorporating a radiolabel that can be visualized after gel electrophoresis by 
autoradiography or phosphorimaging.  This reduces the number of required steps for analysis, 
compared to cellular mRNA, which must be isolated, converted to cDNA, then amplified by RT-
PCR and visualized by some other method.  Third, the in vitro splicing assay can be easily 
modified to accommodate a variety of mRNA transcripts.   
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4.1.2 Development of In Vitro Splicing Assay 
 
 
The in vitro splicing assay is the final step in a series of reactions that produces mRNA 
transcripts for the splicing reaction (Figure 4.1).  First, a DNA plasmid containing the gene of 
interest must be amplified, either by a miniprep procedure to produce more plasmid or by 
utilizing polymerase chain reaction (PCR) to amplify the minigene.  The plasmid must be further 
processed by restriction enzyme digestion to linearize the DNA and gel purified to ensure that 
any remaining proteins or enzymes are removed prior to later applications.  Following 
purification, an in vitro transcription reaction incorporating a 
32
P radiolabeled rUTP produces the 
pre-mRNA transcript that is universally labeled with a radioactive marker, so that all mRNA 
products can be visualized by phosphorimaging or autoradiography.  Following isolation of the 
pre-mRNA transcript, the product can be spliced in the presence of our molecules and separated 
by polyacrylamide gel to visualize the products.   
 
Figure 4.1. In Vitro Splicing Assay Project Design 
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4.2 Results and Discussion 
4.2.1 Miniprep 
The DNA plasmids containing the SMN1 and SMN2 minigenes were graciously donated 
by Adrian Krainer of Cold Spring Harbor Laboratory.  The plasmids contained modified SMN 
gene sequences in which the introns had been significantly shortened to ease in vitro synthesis of 
pre-mRNA.
12,13
  In addition, following the first 75 nucleotides of exon 8 a consensus 5’ sequence 
(GTAAGTACTT) was added to improve splicing efficiency of the minigene.  The minigene 
insertion site was surrounded by restriction enzyme digestion sites as part of the ligation 
insertion procedure, which could be utilized to linearize the plasmid prior to in vitro 
transcription.  The miniprep procedure was utilized to increase DNA plasmid concentrations for 
further manipulations.  In this procedure, the plasmid is transformed into an E. coli cell (XL-1B) 
that is able to produce more plasmid copies.  The cells are incubated on LB media supplemented 
with ampicillin, and only cells containing the desired plasmid and expressing the ampicillin 
resistance gene are able to survive.  Colonies are picked and further amplified by incubation in 
LB broth.  Isolation of the DNA gives a high yield of the plasmid for further manipulations.  
Plasmids were treated with Proteinase K and gel purified prior to further manipulation to remove 
any potential RNase contamination and eliminate any side products (Figure 4.2). 
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Sequencing of the plasmids using pCI Forward and pCI Reverse primers targeted to the 
minigene region of the plasmid revealed some discrepancies between the published sequence and 
that of our plasmids.  In particular, the 5’ splice sequence was not included in the plasmids that 
we were sent.  Instead, the plasmids continued on with exon 8 for an extended number of 
nucleotides, following with the NotI enzyme digestion site.  Our initial attempts to utilize this 
plasmid for transcription after linearizing with the NotI enzyme were unsuccessful.  Thus, we 
sought several alternatives to solve issues associated with sequence and lack of the correct 
sequence.   
In the latter stages of this project, we were able to obtain synthetic minigenes from 
Genscript.  This company offers customized plasmids containing minigenes of interest for 
molecular biology manipulations.  These plasmids were custom designed to contain the corrected 
minigene sequence as described in the initial work by Krainer and co-workers,
13
 including the 
consensus 5’ splice site sequence.  Work with these plasmids was not without its issues.  For 
Figure 4.2. DNA plasmids isolated during project. 1) 100 bp ladder (NEB), 2) SMN1 (Krainer), 3) SMN2 
(Krainer), 4) SMN6-7-8 (IDT), 5) SMN6-8 (IDT), 6) 100 bp ladder (NEB), 7) 1 kb ladder (NEB), 8) SMN1 
(Genscript), 9) SMN2 (Genscript), 10) Bcl-x (Caputi), 11) Bcl-x (Caputi), 12) 1 kb ladder (NEB) 
1         2        3         4         5                6          7         8          9             10         11         12 
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example, the plasmid vector used for the custom minigenes did not contain a polymerase 
promoter, so it was necessary to include the promoter in the custom minigene.  The T7 promoter 
sequence utilized was based off of the sequence contained in the pCI vector (available from 
Promega), on which our first plasmids were based.  Initial work with this plasmid was 
problematic, as the pCI vector contains a proprietary nucleotide change in the T7 sequence that 
alters the 3’ end of the T7 promoter.  Conversations with Promega technical service indicated 
that this change should not affect transcription of the minigene, but did suggest that a normal T7 
promoter primer for sequencing could not be used, clarifying why we were having difficulties 
obtaining the plasmid sequences.
14
  Therefore, special primers targeted to the pUC57 plasmid 
(the plasmid in which the minigene is synthesized) were required.  The sequences that were 
obtained matched those included in the design.  These plasmids were linearized using the NotI 
enzyme as described above (Figure 4.2).   
Several additional plasmids were prepared by miniprep to be utilized in different ways 
during the course of our molecule analyses.  One issue associated with transcription and splicing 
of the SMN1 and SMN2 mRNA was determining the exact location of the desired splicing 
products on our gels.  Labeling of molecular weight markers was one option, but an additional 
option was the synthesis of plasmids with minigenes containing the desired correctly and 
incorrectly spliced sequences, in absence of intervening introns.  Transcription of these plasmids 
provided additional molecular weight markers corresponding to our desired products, making it 
easier for analysis.  In addition, these plasmids could be important for alternate methods of 
splicing detection.
15
  The SMN6-7-8 and SMN6-8 plasmids were purchased from IDT.  These 
plasmids incorporated a T7 polymerase promoter sequence and NotI enzyme digestion site, 
making it possible to linearize and transcribe the plasmid as described (Figure 4.2). 
To examine the effects of our molecules on alternative splicing in a different system, we 
also used a Bcl-x minigene system developed by Caputi and co-workers.  This minigene was 
used for the analysis of synthetic SR proteins for modulating its splicing.
16
  The Bcl-x gene is 
spliced into long (Bcl-xL) and short (Bcl-xS) forms, with the different forms playing an 
important role in cancer cell proliferation.  We began using these plasmids in the hopes of 
showing the effectiveness of our SR protein mimics in a different system, highlighting that these 
molecules are modular and can work in a variety of contexts.  Efforts have been made to switch 
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the splicing from the anti-apoptotic Bcl-xL form to the pro-apoptotic Bcl-xS form.  We isolated 
the plasmid as described above and linearized it using NotI for in vitro transcription and splicing 
(Figure 4.2).  
4.2.2 PCR 
To further amplify the minigene for transcription and to incorporate the desired 5’-
consensus sequence into the DNA template, we utilized the polymerase chain reaction (PCR).  
Our initial attempts to utilize PCR focused primarily on amplifying the minigene site.  We used 
two primers, pCI Fwd and pCR Rev, which were targeted to regions outside of the minigene and 
incorporated the minigene, enzyme digestion sites, and T7 promoter site (see Materials and 
Methods).  We chose to use the Pfu Turbo enzyme rather than another enzyme such as Taq 
polymerase because it was a highly efficient, high fidelity enzyme that was reported to have few 
errors during replication.  A screen of different conditions, primarily focusing on magnesium ion 
concentration, provided a set of conditions from which a high amount of DNA could be 
synthesized.   
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As described above, one issue with the plasmid was the lack of a 5’ splice site sequence 
at the 3’-end of the minigene.  We determined that we could utilize PCR to incorporate this 
sequence by directly adding it via a primer.  This would not only produce PCR product for 
transcription, but would provide a substrate for ligation into a new plasmid, should that route be 
followed.  Two primers were developed for PCR, a forward primer that contained the same 
target as the pCI Fwd but was longer to match the length of the reverse primer, and a reverse 
primer targeted just downstream of the first 75 nucleotides of exon 7 containing the 5’ splice site 
sequence and two enzyme digestion sites, NotI and SalI (see Materials and Methods).  
Amplification using these primers and the Pfu Turbo enzyme required additional modifications, 
most notably the use of 5% v/v DMSO in the reaction mixture to prevent secondary structure of 
the primers due to large size and high GC content.  Switching the enzyme to several different 
master mixes, including the EconoTaq Green 2X (Invitrogen) and, more recently, OneTaq (New 
England Biolabs), provided high yields of the desired PCR products (Figure 4.3). 
Figure 4.3. PCR products isolated using OneTaq 1) 1 kb ladder 
(NEB), 2) 100 bp ladder, 3) SMN1, 4) SMN1, 5) SMN2, 6) 
SMN2  
          1           2           3            4           5            6 
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4.2.3 In Vitro Transcription 
In vitro transcription is a technique that can be utilized to produce large quantities of long 
pre-mRNA transcripts for analysis by the in vitro splicing assay.  In this reaction, a bacterial 
RNA polymerase enzyme is activated by an enzyme promoter region on the DNA in the 
presence of buffer and the necessary rNTPs as starting materials for the polymerase reaction.  An 
[α-32P] radiolabeled rUTP can be included in the reaction mixture for universal labeling of the 
transcript, which can then be visualized by phosphorimaging or autoradiography.  In addition, 
the incorporation of a Ribo m7G cap analog – similar to the cap attached to the 5’-end of 
endogenous RNA transcripts – can help to improve pre-mRNA stability and splicing, as well as 
translation should it be further studied.   
The development of our in vitro transcription reaction required optimization of a number 
of factors, including reaction conditions and reagents utilized in the reaction.  All plasmids 
contained a T7 promoter region for transcription.  The initial reaction conditions were based on 
the protocol provided by Promega with their T7 RNA polymerase, which was focused on the 
synthesis of short, high activity probes.  Attempts to use this protocol were unsuccessful, and 
analysis of the protocol helped us to identify several points for optimization.  First, reaction time 
was modified, as the long (~1000 base) pre-mRNA transcript was much longer than the short 
probes described in the protocol.  Analysis of the reaction time from 2 to 8 hours indicated that a 
reaction time of longer than 4 hours was necessary for sufficient transcript to be produced.  Next, 
the concentrations of the rNTP starting materials were modified so that more nucleotides were 
available for transcription.  10 mM stocks were used for all rNTPs except rUTP, which was kept 
at a lower concentration (500 µM) so that radiolabeled rUTP nucleotide could be incorporated 
into the transcript.  Addition of a cap analog as described above further increased the yield and 
stability of the transcript (Figure 4.4). 
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Despite optimization of the reaction yielding better results, further work was necessary to 
increase the amount of desired transcript and decrease side products.  A consistent feature of the 
in vitro transcription reaction was the presence of faint bands whose length appeared to 
correspond to aborted transcription reactions or degradation of full length transcript.  Analysis of 
all reagents for RNase activity indicated that this was not the issue. Purification of the transcripts 
would be necessary.   
Several methods were utilized to assist in transcript purification.  The first used Amicon 
Ultra-0.5 mL Centrifugal filters (Millipore) containing 100 kDa molecular weight cutoff 
membranes.  This strategy would purify the transcripts by allowing smaller side products 
(smaller than 100 kDa) to pass through the membrane, with the remaining solution containing all 
products greater than 100 kDa.  The estimated number of bases that correspond to 100 kDa is 
approximately 300 bases, meaning that any products corresponding to the fully spliced minigene 
Figure 4.4. In Vitro Transcription of DNA templates. 1) SMN1 (Krainer), 2) SMN2 (Krainer), 3) SMN2 
(Krainer), 4) SMN6-7-8 (IDT), 5) SMN6-8 (IDT), 6) SMN1 (Genscript), 7) SMN2 (Genscript), 8) Bcl-x (Caputi), 
9) Bcl-x (Caputi) 
   1         2           3       4         5                         6          7                              8           9              
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(both exon 7 inclusion and exclusion products are less than 300 bases) would no longer be in the 
transcript sample.  Purification by this method was moderately successful, as smaller products 
were indeed removed from the mixture as indicated by gel electrophoresis, and the yield from the 
purification was very good.  Not all side products were removed, however, and further analysis 
during splicing was still somewhat marred by the presence of side products.  A more thorough 
method for purification was still needed. 
A standard method for purification of transcripts is to use gel purification to remove and 
isolate the desired bands.
17,18
  There are a number of methods available for isolation of RNA 
from polyacrylamide gel, which use buffers ranging from pure water to sodium acetate buffers 
containing SDS, and incubate samples at 4°C, room temperature, 37°C, or even higher 
temperatures.  A number of methods were used to purify the SMN transcripts, which were only 
moderately successful and generally only produced a small amount of product that could not be 
used in splicing assays.  The most successful protocol utilized a freeze-thaw method to rapidly 
crystallize the gel and break it apart to elute the RNA.
18
  In this method, the gel pieces are 
suspended in the elution buffer and rapidly frozen to -80°C using a dry ice bath.  The solution is 
then rapidly heated to 90°C in order to heat shock the gel piece, allowing the transcript to be 
eluted into the elution buffer.  Filtration through a 0.2 µm filter is used to remove the gel pieces 
remaining in solution, and the RNA is then precipitated from the buffer.  As mentioned, this 
method was moderately successful, and produced the most transcript of all gel purification 
methods.  Unfortunately, use of the transcript in subsequent in vitro splicing assays was not 
successful, and subsequent in vitro splicing assays used spin column-purified transcript.   
It is interesting to note that the transcription of the SMN6-7-8, SMN6-8, and Bcl-x 
plasmids appeared to occur with few of the problems associated with SMN1 and SMN2 (Figure 
4.4).  Analysis of the plasmids by polyacrylamide gel generally produced a single desired band 
for each of these plasmids, without the same patterns of shortened bands associated with the 
SMN1 and SMN2 transcripts.  It is possible that the complexity and length of the SMN1 and 
SMN2 minigenes may have caused inefficient transcription.  This is in contrast with the SMN6-7-
8 and SMN6-8 plasmids, which both contained no introns.  The relatively simple splicing pattern 
and shorter sequence of the Bcl-x plasmid may have made it more stable to degradation.  We also 
speculated that the donated plasmids may have been of lower quality than commercially 
97 
 
available counterparts.  However, SMN1 and SMN2 plasmids derived from the pUC57 vector and 
obtained from a commercial source had similar problems to the original SMN plasmids.  The 
sequence used for these newer minigenes matched the genomic sequence, making it unlikely that 
some inherent issue associated with the donated SMN1 and SMN2 plasmids was transferred to 
the new plasmids.  Therefore, it is possible that the sequences of SMN1 and SMN2 themselves 
may have played some detrimental role in transcription analysis.   
4.2.4 In Vitro Splicing Assay 
The use of the in vitro splicing assay to analyze the effects of different molecules is well 
documented, and we used this method to analyze our synthetic SR protein mimics.
11,19-21
  The 
initial design of the assay was based on the work of Mayeda and Krainer, who first developed a 
standard splicing assay protocol.
11
  This general assay reconstitutes the conditions of the nucleus 
of HeLa cells in order to splice the pre-mRNA.  Our initial attempts to use the splicing assay for 
analysis of SMN1 and SMN2 splicing using this method were moderately successful, producing 
some changes in the arrangement of bands on the gel but few discernible differences between the 
mRNA splicing products.  We initially examined the splicing of unlabeled SMN1 and SMN2 pre-
mRNA transcripts, with the hope that we would be able to easily identify the desired products 
without need for a radiolabel.  Unfortunately, tRNA in the splicing stop solution (see Materials 
and Methods) appeared to block the region of interest (200-400 nucleotides) on the agarose gels.  
Use of a Proteinase K stop solution in substitution for the splicing stop solution did not resolve 
the issue, so it was decided that a radiolabel must be incorporated into the transcripts in order to 
ensure that we could more easily visualize the products.  Subsequent assays utilized the [α-32P] 
radiolabeled rUTP nucleotide during transcription, to ensure that the gel could be visualized by 
phosphorimager analysis after splicing occurred. 
A number of steps were taken to optimize the assay prior to the analysis of our synthetic 
SR protein mimics.  The concentrations of several key components in the splicing assay were 
altered to better match the conditions necessary for splicing of SMN minigenes.  For example, 
the MgCl2 concentration in the standard protocol was 3.2 mM, whereas for SMN genes it was 1.6 
mM according to later protocols.
21
  Preparation of fresh reagents was also important, as the 
activity of certain reagents (especially MgCl2 and ATP/creatine phosphate mix) decreased over 
time, inhibiting the ability of the nuclear extract proteins to fully activate splicing.  The HeLa 
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nuclear extracts themselves may have been one of the primary reasons for lack of activity.  Even 
when prepared fresh in the lab, these extracts do not display consistent splicing activity, 
indicating that multiple reactions must be run under the same conditions in order to determine 
level of splicing activity and obtain consistent results.  A survey of different commercially 
available extracts was conducted to determine which would provide the most consistent activity, 
and those from Promega appeared to be the most consistent.  Previously, Promega had actually 
produced and sold splicing-grade nuclear extracts, but unfortunately these extracts are no longer 
available.   
 
 
Analysis of radiolabeled SMN1, SMN2, and Bcl-x transcripts was conducted in the 
absence of the peptide-oligonucleotide conjugates to determine how the different transcripts 
would be spliced under our assay conditions (Figure 4.5).  Qualitative analysis of the SMN1 and 
SMN2 plasmids showed that some of the desired bands were associated with splicing patterns in 
previously published work, as indicated by proximity to radiolabeled DNA markers.  In spite of 
our efforts, we were unable to identify bands corresponding to the desired splicing pattern 
differences between SMN1 and SMN2 mRNA.  It appeared as though the splicing reaction did 
not fully complete, producing only bands corresponding to the intermediates.  On the other hand, 
analysis of the Bcl-x transcripts appeared to be more successful, producing bands that 
Figure 4.5. In Vitro Splicing Assay in the absence of molecules.  Possible arrangement of splicing products, as 
suggested by molecular weight markers, is indicated next to gel.  US = unspliced.   
 SMN1 SMN2 
Bcl-x 
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corresponded to the Bcl-xL isoform of the mRNA.  Very little of the Bcl-xS product was 
synthesized, as expected.  Although the Bcl-x plasmid appeared to be much better for analysis, 
we did not perform many additional assays with it.   
Despite difficulties with the 
production of consistent splicing assay 
results, we continued forward and 
began analyzing the effects of 
different molecules on SMN2 pre-
mRNA splicing.  We hoped to 
determine the effects of several 
different molecules on alternative 
splicing – first, the separate antisense 
oligonucleotide and peptide or 
dendrimer components, and then the 
full conjugates containing both pieces.  
We hypothesized that the peptide or 
Dendron components separately would 
have no effect on splicing, as they 
should not bind directly to the mRNA.  
The antisense oligonucleotide was 
likely to show some activity, as it was 
shown previously by Krainer and co-
workers to have an effect on splicing 
in several studies.
19,21
  We had hoped, 
however, that the addition of the synthetic RS domain would have an additional beneficial effect 
on alternative splicing of SMN2, producing the most full-length SMN2 mRNA following the 
splicing reaction.  Analysis of the peptide-oligonucleotide conjugate containing 5 DR dipeptides, 
along with the separate components of the conjugate, revealed that the conjugate had the most 
dramatic effect on alternative splicing, producing primarily an mRNA band corresponding to the 
SMN6-7-8 molecular weight marker (Figure 4.6).  Interestingly, there did not appear to be a 
      1    2    3   4     5   6    7   8         9   10 
Figure 4.6. Analysis of peptide-oligonucleotide conjugate 
components on splicing of SMN1 (lanes 1-4) and SMN2 
mRNA (lanes 5-8).  Bands corresponding to correctly and 
incorrectly spliced SMN2 are marked. 1) H2O, 2) SMN 
antisense oligonucleotide, 3) (DR)5 peptide, 4) (DR)5 peptide-
oligonucleotide conjugate, 5) H2O, 6) SMN antisense 
oligonucleotide, 7) (DR)5 peptide, 8) (DR)5 peptide-
oligonucleotide conjugate, 9) SMN6-7-8, 10) SMN6-8 
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band corresponding to the SMN6-8 molecular weight marker in the lanes containing the antisense 
oligonucleotide or peptide-oligonucleotide conjugate.   
The results from this first analysis highlighted one important issue that we spent a great 
deal of time attempting to resolve – the lack of a band corresponding to incorrectly spliced 
SMN2.  Analysis of a number of gels showed essentially no band corresponding to the proposed 
SMN2 band location, as indicated by both SMN6-8 transcript and a radiolabeled RNA marker 
(Figure 4.6).  A common feature of our gel analysis was the presence of two bands, one 
corresponding to the SMN6-7-8 band and one not far below it, still above the SMN6-8 band, 
indicating that some reaction had occurred but not any that corresponded to the molecular weight 
markers.  Sequencing of the SMN6-7-8 and SMN6-8 plasmids indicated that our proposed 
number of nucleotides should have corresponded correctly, and they appeared to match well with 
bands located in the radiolabeled RNA marker.  As a further determination of our splicing 
products, we ran unlabeled splicing assays using SMN2 and submitted the final products for 
MALDI-MS.  Analysis of the splicing products produced a peak that corresponded with the 
calculated incorrectly spliced SMN2 molecular weight, suggesting that this product was forming, 
although the amount of product being formed was not discerned by this method.  Therefore, for 
subsequent analysis of the splicing assays, the two bands corresponding to SMN6-7-8 and the 
band below it were used to determine if the molecules had activity.  Although imperfect, this 
method served as a means of determining molecule effects while alternative methods of analysis 
were explored. 
We next examined the peptide-oligonucleotide conjugates at decreased concentrations to 
determine the dose response of the molecules.  In previous studies, both antisense 
oligonucleotides and peptide-oligonucleotide conjugates were analyzed at nanomolar 
concentration, so we examined our molecules at the same concentration in order to be able to 
compare their effects more directly to previously described molecules.
19,21,22
  The concentration 
of the molecules that were tested was measured using UV spectroscopy, based on the UV signal 
of the oligonucleotide.  Samples were then diluted to a series of concentrations ranging from 400 
nM to 1 nM.  We hypothesized that decreasing the concentration would decrease the ability of 
the molecules to modulate splicing.   
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Qualitative analysis of the molecules revealed that several of the molecules were active at 
400 nM concentration, with that activity disappearing as the concentration decreased.  In each 
case, a band approximately the same size as the SMN6-7-8 marker (corresponding to the 
correctly spliced SMN2 mRNA) formed at the highest concentration, with the signal for that 
band fading at lower concentrations (Figure 4.7).  Attempts to quantify these changes using the 
equation for determining SMN exon 7 inclusion (see Materials and Methods) indicated that the 
(DR)5 peptide-oligonucleotide conjugate had the best activity, increasing exon 7 inclusion to 
nearly 80% as opposed to a background level of around 50%.  The DR dendron, containing four 
sets of DR dipeptide repeats, could only activate splicing to around 70% inclusion.  This 
suggests one of two possible reasons for the change.  Either the additional DR dipeptide of the 
peptide-oligonucleotide conjugate helped to further increase activation, or the arrangement of the 
charged residues on the periphery, while somewhat effective, does not have as large of an effect 
when displayed in a nonlinear fashion.  Interestingly, analysis of the antisense oligonucleotide 
appeared to have little effect on SMN2 splicing at lower concentrations, suggesting further that 
the presence of both the antisense oligonucleotide and the synthetic RS domain is necessary to 
create a strong splicing activator when targeted to this sequence on SMN2.   
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The major issue associated with analysis of our conjugates was the large amount of 
inconclusive data that could be obtained from splicing assay gels.  In spite of our efforts to 
optimize both assay and analysis conditions, there was never a clear result from which we could 
Figure 4.7. Splicing assay gel results.  Assays were run as described, using SMN2 pre-mRNA transcript and 
serial dilution of 400 nM  1 nM molecule. Unmarked lanes contain H2O as a control instead of conjugate 
molecule. Desired band corresponding to SMN6-7-8 is highlighted with an arrow. a) Antisense oligonucleotide. 
b) (DR)5 peptide-oligonucleotide conjugate. c) (DR)6 peptide-oligonucleotide conjugate. d) DR peptide 
dendrimer-oligonucleotide conjugate. 
a) b) 
c) d) 
 400  200 100    50     25    10     5      1   400   200  100   50     25    10     5      1 
  400 200  100    50     25    10     5      1    
  400       200 100 50   25   10    5    1    
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definitively state that our molecules were having an effect on splicing.  Even when using 
plasmids that had been redesigned to contain the correct sequence elements, we were not able to 
consistently obtain conclusive results.  Use of the Bcl-x plasmid was the logical first step in 
determining what effect the molecules have, as the number of splicing products is significantly 
smaller and less complex than for SMN plasmids, and the unspliced transcript has fewer side 
products that can disrupt splicing analysis.  Lack of time and focus on making the SMN plasmids 
successful prevented further analysis of Bcl-x.  A second way to improve analysis was to use 
other alternative splicing analysis methods in order to determine if the desired products are even 
being formed.  It was possible that the analysis by polyacrylamide gel electrophoresis was 
suboptimal and the biggest cause of our problem, so verification by an alternative method would 
be helpful. 
An alternative detection method for the analysis of splicing assay products uses a set of 
molecules called ‘junction probes’.  Developed by Sintim and co-workers in 2008, this technique 
uses a tripartite array of three molecules – two antisense oligonucleotides targeted to the desired 
DNA or RNA target and to each other, and the third DNA or RNA target.
15
  Upon formation, 
these molecules bind to the target oligonucleotide and to each other, creating an enzyme 
digestion sequence that is only available in the presence of the desired target.  Enzymatic 
cleavage of the newly formed sequence releases a quencher on the 5’ end of one of the two 
antisense oligonucleotides, allowing a fluorophore on the other antisense oligonucleotide to 
fluoresce.  Analysis of the fluorescence signal can then be quantified, allowing for the 
determination of the amount of correct target available in a reaction.  These molecules are 
advantageous in that they are sequence specific and have been developed to contain structure 
elements to prevent non-specific binding and fluorescence in the absence of a target.
23
   
Our work with the Sintim group in development of these molecules for targeting SMN 
splicing products involved synthesizing the SMN transcripts while they developed their detection 
molecules.  Initial analysis using the SMN6-7-8 and SMN6-8 transcripts showed that they could 
obtain a strong reading above the background for the SMN6-7-8 transcript, but not for the SMN6-
8 transcript.  Further analysis using DNA templates of the same sequence indicated that they 
could be targeted to those sequence elements, but not to the RNA.  They hypothesized that 
possible RNA secondary structure may have been interfering with their analysis.  It is interesting 
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to note that they too had issues with identifying the incorrectly spliced SMN2 mRNA, further 
suggesting that there may have been issues with the SMN2 sequence or plasmids.  Unfortunately, 
further work into this matter was not conducted during the latter stages of this project. 
4.3 Conclusions and Future Directions 
The in vitro splicing assay is an important technique that can be used to analyze the 
effects of splicing modulators under acellular conditions using HeLa cell nuclear extracts.  This 
is advantageous over cellular assays in that the molecules do not need to traverse the cell 
membrane, and that the products can be analyzed directly on polyacrylamide gels if they 
incorporate a radiolabeled nucleotide.  Plasmids containing SMN1, SMN2, SMN6-7-8, SMN6-8, 
and Bcl-x minigenes were amplified by Miniprep and either linearized using restriction enzymes 
or further amplified using PCR.  These plasmids were then transcribed into pre-mRNA using an 
in vitro transcription reaction.  Depending on the starting material, the products of the reaction 
either consisted of a single band or multiple bands that required purification by spin column 
filtration or elution from the gel.  Alternative splicing of these transcripts was analyzed using the 
in vitro splicing assay.  Using this assay, qualitative differences were observed in the SMN1 and 
SMN2 mRNA following splicing in the presence of our conjugates.  A number of conjugates 
were tested, but many remain to be tested.  Despite numerous attempts at optimization, the assay 
was not conclusive, although trends did appear that make us hopeful that the molecules have 
activity. 
There are a number of ways in which this project could be improved so that a clearer 
picture of how these molecules affect splicing could be produced.  The most obvious would be to 
use the Bcl-x plasmid as the primary target for splicing activation.  Splicing of the Bcl-x 
minigene is simpler, containing only two splicing products, and the sequence of the minigene 
appears to be amenable to transcription and splicing.  Use of the SMN minigenes, while clinically 
relevant and able to provide very interesting data if successful, was riddled with problems even 
when resynthesized using commercially available sources.  Further improvements to the splicing 
analysis would be the isolation and analysis of HeLa cell nuclear extracts in the laboratory, rather 
than relying on commercial sources.  Extract batches could be tested for splicing activity and 
discarded if not up to desired standards.  The facilities for growing and maintaining HeLa cells 
are generally available.  A third way to improve the outcome of the assay, should the SMN 
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minigenes be pursued, would be to determine the necessary sequences for minigene splicing and 
then to purchase these minigenes from a commercially available source, such as Genscript.  
Although we had hoped that following this strategy would be useful to us, we based the sequence 
on the already established minigene provided by Krainer and co-workers. This may have been 
problematic and one of the causes of our lack of successful results.  Re-synthesis of a new set of 
plasmids that contained the verified correct sequence may have assisted in improving 
transcription and splicing assay results.   
Additional improvements to the project could be made through the use of alternative 
techniques to examine splicing.  A number of different methods are available, and each could be 
utilized to verify the effects of our molecules.  As mentioned above, junction probes were an 
experimental method for analysis of DNA and RNA, and more work using this technique could 
provide a quantitative measure of different splicing products.  RT-PCR and qPCR are a second 
set of techniques that could be used to determine the differences in amount of splicing product.  
The spliced RNA products would first be converted to cDNA molecules using reverse 
transcriptase, and primers specific to the different spliced products could be amplified and 
quantitatively measured using fluorescence to determine the different amounts of each product.  
Attempts were made near the end of this project to use this technique, but the results were not 
successful, indicating that much more optimization would be necessary to make it a viable 
technique.  Campus facilities for RT-PCR and qPCR would be able to assist with assay 
development, although early attempts to plan a possible analysis with them were less than 
encouraging.  Development of the primers for qPCR would be the first important hurdle, 
following which optimization of the assay would lead to the desired products.  A third possible 
assay is the RNase protection assay.
24
  Antisense molecules targeted to specific regions of the 
splicing products, such as the exon-exon junctions, would first be bound to the RNA.  Digestion 
of the remaining splicing products would be completed using an RNase enzyme, following 
which visualization of the products would reveal the relative amounts of correctly and 
incorrectly spliced RNA.  Generally, this technique uses a radiolabeled antisense 
oligonucleotide, but it could also be conducted with the radiolabeled RNA transcripts, which 
have already been synthesized.   
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4.4 Materials and Methods 
General 
All buffers for biological experiments were prepared with autoclaved Millipore or 
Nuclease-free (BioRad) water, pipette tips, and microfuge tubes.  T7 RNA polymerase was 
purchased from Promega.  HeLa nuclear extracts were purchased from Promega, Millipore, 
AnaSpec, and Calbiochem.  Pfu Turbo was purchased from Stratagene.  EconoTaq Plus GREEN 
2X Master Mix was purchased from Lucigen.  OneTaq 2X Master Mix was purchased from New 
England Biolabs.  Plasmid DNA concentration was measured using a UV spectrometer.  Plasmid 
DNA was sequenced at the Core Sequencing Facility, Keck Institute, University of Illinois.  
Antisense oligonucleotides were purchased from Yale Keck Oligonucleotide Synthesis Facility 
using modifiers purchased from Glen Research.  Agarose was purchased from Fischer Scientific.  
Denaturing acrylamide gel solutions were purchased from National Diagnostics.  Acrylamide 
gels were visualized on phosphorimaging screens (Molecular Dynamics) and were scanned using 
a Molecular Dynamics Storm 240 Scanner.  Gel bands were quantified using ImageQuant 
software (Molecular Dynamics).   
Plasmid Transformation and Miniprep 
5 μL of the desired plasmid in buffer EB was mixed with 50 µL competent XL-1B cells 
and incubated on ice for 30 minutes.  Cells were heat shocked for 90 sec at 42°C and 
immediately put on ice.  200 μL SOC buffer was added, and cells were incubated at 37°C with 
shaking for 60 min.  35 μL cells were plated onto LB media containing Ampicillin and incubated 
at 37°C for 16 hours.  Single bacterial colonies were transferred to 5 mL LB media containing 5 
µL Ampicillin (1000x) and incubated with shaking at 37°C for 16 hours.  Plasmid DNA was then 
isolated using a Qiagen Miniprep Kit (Qiagen, CA).  Plasmid DNA samples were gel purified on 
1% agarose gels using 0.5X TBE buffer containing 0.5 mg/mL ethidum bromide.  Desired bands 
were removed and isolated using a Qiagen Gel Extraction Kit (Qiagen, CA).  Gels were 
visualized on a BioRad Gel Imager.  Isolated plasmid DNA from each sample was stored in 1.5 
mL Eppindorf tubes at -20°C.   
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Plasmid Sequences 
 Plasmids containing SMN1 and SMN2 minigenes were graciously donated by Dr. 
Adrian Krainer, Cold Spring Harbor Laboratory or purchased from Genscript.
13
 Plasmid 
containing Bcl-x minigene was graciously donated by Dr. Massimo Caputi, Florida Atlantic 
University.
16
 Plasmids containing SMN6-7-8 and SMN6-8 minigenes were purchased from IDT.  
SMN6-7-8 
CCCGAGATTCCCCCACCACCTCCCATATGTCCAGATTCTCTTGATGATGCTGATGCTT
TGGGAAGTATGTTAATTTCATGGTACATGAGTGGCTATCATACTGGCTATTATATGG
GTTTTAGACAAAATCAAAAAGAAGGAAGGTGCTCACATTCCTTAAATTAAGGAGAA
ATGCTGGCATAGAGCAGCACTAAATGACACCACTAAAGAAACGATCAGACAGATCT
GGAATGTGAAGCGTTATAGGAATGTGAAGCGTTATAGACGATAACTGGCCT 
SMN6-8 
CCCGAGATTCCCCCACCACCTCCCATATGTCCAGATTCTCTTGATGATGCTGATGCTT
TGGGAAGTATGTTAATTTCATGGTACATGAGTGGCTATCATACTGGCTATTATATGG
AAATGCTGGCATAGAGCAGCACTAAATGACACCACTAAAGAAACGATCAGACAGAT
CTGGAATGTGAAGCGTTATAGGAATGTGAAGCGTTATAGACGATAACTGGCCT 
Restriction Enzyme Digestion 
 Restriction enzyme digestion was performed using NotI and XhoI restriction enzymes 
using a modified version of the manufacturer’s protocol (New England Biolabs).  Briefly, each 
reaction contained 10 µL nuclease-free H2O, 2 µL Buffer 3 (NEB), 1 µL bovine serum albumin, 
8 µL DNA template, and 2 µL restriction enzyme.  Samples were incubated at 37°C overnight.  
Following incubation, digested plasmids were separated by 1% agarose gels and purified using 
Qiagen Qiaquick PCR Purification Kit (Qiagen, CA) or IBI Gel/PCR DNA Fragment Extraction 
Kit (IBI Scientific, IA).  Products were gel purified and stored as described previously.   
PCR  
 PCR was performed using a MJ Research, Inc. PTC-100 Programmable Thermal 
Controller or a Techne TC-3000 Thermal Cycler using gel purified SMN plasmids, according to 
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manufacturer’s protocols (primer sequences, cycling times and temperatures are given below), 
except 5% (v/v) DMSO was added to each reaction.  PCR products were purified using a Qiagen 
Qiaquick PCR Purification Kit (Qiagen, CA) or IBI Gel/PCR DNA Fragment Extraction Kit (IBI 
Scientific, IA).  Products were gel purified and stored as described previously.   
In vitro Transcription 
 In vitro transcription was performed using T7 RNA polymerase using a modified version 
of the manufacturer’s protocol for high activity probes (Promega).  Briefly, each reaction 
contained 4 µL Transcription-optimized 5x buffer, 2 µL 100 mM DTT, 1 µL RNase inhibitor 
(Promega), 4 µL 10 mM rNTP-rUTP mix, 2 µL 500 µM rUTP, 1.0 µL 40 mM Ribo m
7
G cap 
analog (Promega), 4 µL DNA template, 2 µL [α-32P]-labeled rUTP, and 2 µL T7 RNA 
polymerase.  Samples were incubated for 2 hr at 37°C.  To each reaction was then added 4 µL 10 
mM CaCl2 and 2 µL RNase-free DNase (New England Biolabs), and reactions were incubated at 
37°C for 30 min.  To each reaction was then added 2 µL EDTA, pH 8.0, 6 µL 5M NaCl, and 150 
µL TE buffer, pH 8.0.  200 µL 25:24:1 Phenol:CHCl3:isoamyl alcohol was added, and tubes 
were vortexed briefly and centrifuged at 13,000 rpm for 1 min.  The organic layer was removed, 
and the extraction repeated with 200 µL 24:1 CHCl3:isoamyl alcohol.  To the remaining aqueous 
layer was added 500 µL EtOH, and tubes were stored at -20°C overnight.  Samples were then 
centrifuged at 13,000 rpm for 20 min, the supernatant was removed, and samples were dried 
using a speed vacuum.  Samples were then resuspended in 40 µL TE buffer, pH 8.0 for further 
use.  All RNA samples were denatured prior to analysis on 8% denaturing acrylamide gels by the 
addition of a formaldehyde-formamide loading buffer followed by heating to 85°C for 2 minutes.  
Spin Column Purification: RNA transcripts were diluted to 500 µL and transferred to an Amicon 
Ultra 0.5 mL Centrifugal Filter with 100 kDa molecular weight cutoff membrane (EMD 
Millipore, MA).  Samples were centrifuged for 20 minutes.  Remaining solvent in upper chamber 
was collected in new vials and analyzed by gel electrophoresis.  Gel Purification: Gel pieces 
containing desired transcripts were removed and suspended in gel extraction buffer.  Samples 
were frozen to -80°C using a dry ice bath, then rapidly heated to 90°C with a hot water bath.   
Samples were then incubated overnight with shaking at 37°C.  Following incubation, samples 
were passed through 0.2 µm filters to remove gel pieces. Buffer was extracted and EtOH 
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precipitated as described previously, and transcripts were stored in TE buffer as described 
previously.   
In Vitro Splicing Assay 
 In vitro splicing assays using SMN plasmids were performed using a modified version of 
a protocol outlined by Krainer and co-workers.  Briefly, each reaction contained 0.5 µL 25x 
ATP/CP mix, 0.26 µL 80 mM MgCl2, 0.64 µL 0.4 M HEPES-KOH, pH 7.3, 0.5 µL RNase 
inhibitor (Promega), 2.6 µL nuclease-free H2O, 2.5 µL 13% polyvinyl alcohol (PVA), 4.0 µL 
HeLa nuclear extract, and 3.0 µL transcribed RNA.  In vitro splicing assays using Bcl-x plasmids 
were performed using a protocol outlined by Caputi and co-workers.  Briefly, each reaction 
contained 4.8 µL 13% PVA, 1.0 µL 100 mM MgCl2, 1.0 µL 100 mM ATP, 1.0 µL 125 mM CP, 
0.5 µL RNase inhibitor, 7.5 µL HeLa nuclear extract, 7.5 µL nuclease-free H2O, and 3.0 µL 
transcribed RNA.  For assays analyzing molecules, 0.5 µL molecule diluted in nuclease-free H2O 
was added to reaction mixture prior to incubation. 0.5 µL nuclease-free H2O was added for 
control reactions.  Concentrations are given with gel analysis.  Samples were incubated for 4 hr 
at 37°C.   At that time, 200 µL Splicing Stop Solution or Proteinase K (see SI) buffer was added 
to each sample.  Samples were then extracted as described above, except Tris-buffer saturated 
phenol (Invitrogen) was substituted for 25:24:1 Phenol:CHCl3:isoamyl alcohol.  Samples were 
EtOH precipitated and resuspended in 5 µL RNA dye and 5 µL TE buffer, denatured by heating 
to 85°C for 2 minutes, then analyzed on 8% denaturing acrylamide gels as described above.  
Exon7 inclusion was calculated as a percentage of the total amount of fully spliced mRNA, i.e. 
included mRNA X 100/(included mRNA + skipped mRNA).   
Buffers 
10 X TBE Buffer (1 L): 
- 108 g Tris Base 
- 55 g Boric Acid 
- 9.3 g Disodium EDTA 
- Stored at 4°C 
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Formaldehyde-Formamide RNA Buffer: 
- 2 mL Formamide 
- 700 µL 37 % Formaldehyde 
- 400 µL MOPS buffer 
- Distributed in aliquots of 20 µL and stored at -20°C 
MOPS Buffer: 
- 0.2 M MOPS, pH 7 
- 50 mM NaOAc 
- 5 mM EDTA, pH 8 
RNA dye 
- 90% (v/v) formamide 
- 50 mM Tris-HCl, pH 7.5 
- 1 mM EDTA 
- 0.1% bromophenol blue 
- 0.1%  xylene cyanol FF 
- Stored at 4°C 
Acrylamide Gel Extraction Buffer 
- 10 mM Tris, pH 7.5 
- 1 mM EDTA 
- 0.5 M Ammonium Acetate, pH 5.6 
- 0.1% (w/v) SDS 
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- Stored at 4°C 
Splicing Stop Solution 
- 0.3 M Sodium Acetate, pH 5.2 
- 0.1% (w/v) SDS 
- 62.5 µg/mL tRNA 
- Stored at 4°C 
Proteinase K Buffer 
- 10 mM Tris 
- 1% (w/v) SDS 
- 0.15 mM NaCl 
- 10 mM EDTA 
- 0.25 mg/mL glycogen 
- 0.25 mg/mL Proteinase K 
- Stored at 4°C 
Buffer D 
- 20 mM HEPES-KOH, pH 8.0 
- 100 mM KCl 
- 0.2 mM EDTA 
- 20% (v/v) glycerol 
- 1 mM DTT 
- Stored at 4°C 
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PCR Primers 
Forward: 5’-
GCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGAA-3’ 
 
Reverse: 5’-GAAGCGGCCGCGTCGACAAGTACTTACCTGTAACGCTCCACATTCCAG-3’ 
PCR Cycling Times and Temperatures 
94°C- 2 minutes 
94°C- 30 s (denaturation) 
55°C- 30 s (annealing) 
72°C- 2 min (extension) 
72°C- 10 min (finishing) 
 
4.5 References 
(1) Kevil, C. G.; Walsh, L.; Laroux, F. S.; Kalogeris, T.; Grisham, M. B.; Alexander, J. S. 
Biochem. Biophys. Res. Commun. 1997, 238, 277. 
(2) Coady, T. H.; Baughan, T. D.; Shababi, M.; Passini, M. A.; Lorson, C. L. PLoS One 
2008, 3, e3468. 
(3) Gomez-Curet, I.; Robinson, K. G.; Funanage, V. L.; Crawford, T. O.; Scavina, M.; 
Wang, W. Neurogenetics 2007, 8, 271. 
(4) Hua, Y.; Sahashi, K.; Hung, G.; Rigo, F.; Passini, M. A.; Bennett, C. F.; Krainer, A. R. 
Genes Dev., 2010, 24, 1634. 
(5) Madocsai, C.; Lim, S. R.; Geib, T.; Lam, B. J.; Hertel, K. J. Mol. Ther. 2005, 12, 1013. 
(6) Krainer, A. R.; Conway, G. C.; Kozak, D. Genes Dev 1990, 4, 1158. 
(7) Krainer, A. R.; Conway, G. C.; Kozak, D. Cell 1990, 62, 35. 
(8) Krainer, A. R.; Maniatis, T. Cell 1985, 42, 725. 
(9) Krainer, A. R.; Maniatis, T.; Ruskin, B.; Green, M. R. Cell 1984, 36, 993. 
(10) Ruskin, B.; Krainer, A. R.; Maniatis, T.; Green, M. R. Cell 1984, 38, 317. 
30 cycles 
113 
 
(11) Mayeda, A.; Krainer, A. R. Methods Mol. Biol. 1999, 118, 315. 
(12) Cartegni, L.; Hastings, M. L.; Calarco, J. A.; de Stanchina, E.; Krainer, A. R. Am. J. 
Hum. Genet. 2006, 78, 63. 
(13) Cartegni, L.; Krainer, A. R. Nat. Genet. 2002, 30, 377. 
(14) Milligan, J. F.; Groebe, D. R.; Witherell, G. W.; Uhlenbeck, O. C. Nucleic Acids Res. 
1987, 15, 8783. 
(15) Nakayama, S.; Yan, L.; Sintim, H. O. J. Am. Chem. Soc. 2008, 130, 12560. 
(16) Wilusz, J. E.; Devanney, S. C.; Caputi, M. Nucleic Acids Res. 2005, 33, 6547. 
(17) Clarke, P. A. Methods Mol. Biol. 1999, 118, 1. 
(18) Ellington, A.; Pollard, J. D., Jr. Curr. Protoc. Mol. Biol. 2001, Chapter 2, Unit 2 12. 
(19) Cartegni, L.; Krainer, A. R. Nat. Struct. Biol. 2003, 10, 120. 
(20) Hicks, M. J.; Lam, B. J.; Hertel, K. J. Methods 2005, 37, 306. 
(21) Hua, Y.; Vickers, T. A.; Baker, B. F.; Bennett, C. F.; Krainer, A. R. PLoS Biol. 2007, 5, 
e73. 
(22) Hua, Y.; Vickers, T. A.; Okunola, H. L.; Bennett, C. F.; Krainer, A. R. Am. J. Hum. 
Genet. 2008, 82, 834. 
(23) Yan, L.; Nakayama, S.; Yitbarek, S.; Greenfield, I.; Sintim, H. O. Chem. Comm. 2011, 
47, 200. 
(24) Kim, M. S.; Ha, C. M.; Lee, B. J. Brain Res. Brain Res. Protoc. 2001, 7, 277. 
 
 
 
 
 
